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Abstract
IDENTIFICATION OF RBPMS AS A SMOOTH MUSCLE MASTER SPLICING
REGULATOR VIA ASSOCIATION OF ITS GENE WITH SUPER-ENHANCERS
Erick Eidy Nakagaki Silva
Alternative splicing (AS) is primarily regulated by regulatory RNA-binding proteins
(RBPs). It has been suggested that a small number of master splicing regulators might
control cell-specific programs and these regulators could be identified via the association
of their genes with transcriptional super-enhancers. Using this approach, RNA Binding
Protein with Multiple Splicing (RBPMS) was identified as a critical splicing regulator
in vascular smooth-muscle cells (SMCs). RBPMS is strongly downregulated during
SMC dedifferentiation and is responsible for nearly 20% of the AS changes during this
transition as indicated by mRNA-Seq of rat PAC1 cells with RBPMS-manipulated
levels. RBPMS overexpression also promoted splicing events that are usually only
observed in tissue SMCs. RBPMS targeted a network of proteins involved in the
cytoskeleton and cell-adhesions, machineries remodeled during the transition from
contractile to motile-dedifferentiated SMCs. RBPMS directly regulated target exons
with a positional bias depending upon whether acting as an activator or repressor, as
indicated by RBPMS-maps, in vivo transfections with minigene reporters, RBPMS
RNA binding mutant, MS2 artificial tethering and lastly in vitro binding assays.
RBPMS controlled splicing and activity of other splicing and post-transcriptional
regulators (MBNL1, MBNL2 and LSM14B) as well as the key SMC transcription factor
Myocardin. Structure-function analyses revealed that the two major RBPMS isoforms
(RBPMS-A and B) have differential activity, and that dimerization and RBPMS C-
terminus are essential to RBPMS splicing activity. Yet, RBPMS RRM was insufficient
for splicing. In fact, a core section of the C-terminus of RBPMS-B antagonized its
repressor-splicing activity. Additionally, two threonine residues of RBPMS could be
phosphorylated differentially modulating RBPMS isoforms activity. Therefore, this
study provides the strongest evidence to date for a molecular function of RBPMS as a
splicing-regulator, matching many of the expected criteria of a master regulator of AS
in differentiated VSMCs.
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Chapter 1
Introduction
1.1 Gene expression control in eukaryotes
“I have also tried to relate the problem to the other central problems of molecular
biology - those of gene action and nucleic acid synthesis”
– Francis Crick, On protein synthesis, 1957
The quote above was stated by Francis Crick in 1957 when addressing the protein
synthesis problem which led to the postulation of the Central Dogma of molecular
biology (Crick, 1958). The dogma remarkably proposed the flow of genetic information
within a cell to be from DNA to RNA to finally protein (Crick, 1970). In other words,
DNA is able to auto-replicate and to be decoded into RNA during transcription which
then can be translated into a polypeptide sequence. Even though a few years later,
multi-directionality of the flow by reverse information of RNA to DNA in virus was
reported, the initially proposed transfer of genetic information, perhaps rather simple,
still stands at the center of gene expression as the principal route.
During the genetic information flow, RNA molecules intermediate the translation
of the genetic code into proteins, yet their synthesis is coordinated by the signals
embedded in the DNA template. The cis-elements in the DNA mediate recruitment
of trans-acting components that comprise a plethora of transcription factors. The
cis-elements include enhancers, promoters, transcription terminators and others. These
signals play a major role in the recruitment and release of the RNA polymerase II (pol
II), the main enzyme of the transcription apparatus. Pol II catalyzes the production
of protein coding mRNAs and a number of non-coding RNAs (ncRNA) in eukaryotic
cells. In addition, chromatin remodeling factors play a critical role in the control of
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transcription by regulating the physical accessibility to the regulatory sequences found
in the DNA. Thus, specific cell states can be produced by the establishment of gene
expression programs through control of the first step in decoding the DNA sequence by
transcription factors, cofactors, and chromatin regulators. In that way, misregulation
of this process is associated with a broad range of disease (reviewed in Lee and Young
(2013)).
In addition to transcriptional control, gene expression can also be regulated at the
post-transcriptional and translational level. Moreover, even the final protein is subjected
to post-translational control. This regulates the protein’s turn-over and activity by
deactivation, activation or modifications. Together these processes determine the final
array of proteins expressed in a cell-type.
1.2 Post-transcriptional processes as regulators of
gene expression
In prokaryotes, little or no mRNA processing is observed, with ribosomes being
able to assemble on the transcript and promote translation before completion of
transcription. This is mainly due to the fact that these processes do not take place in
separated compartments within the prokaryotic cells and also because bacterial genes
are continuous, encoding genetic messages for functional proteins in an uninterrupted
manner. On the other hand, in most eukaryotic cells, prior to cytoplasm export
for translation, pre-mRNAs in the nucleus undergo maturation which consists of a
three-step process: 5′ capping, splicing, and 3′ cleavage together with polyadenylation
(Figure 1.2). Briefly, this involves the attachment of a 7-methylguanosine cap to the
5′ end, after which intronic sequences are removed and exons ligated upon splicing.
Finally, a poly(A) tail is added after the 3′ end cleavage. Although commonly called
post-transcriptional, the pre-mRNA processing occurs at the gene in concert with
transcription. Thereby, coupling of mRNA processing with transcription has been
suggested to exist with the Pol II carboxy-terminal domain (CTD) playing a critical
role in the functional connection of these processes (Bentley, 2014).
Therefore, post-transcriptional processing provides another layer of gene expression
regulation in eukaryotic cells. In the post-transcriptional gene control, RNA-binding
proteins (RBPs) and ribonucleoproteins are the key players coordinating a range
of processes including maturation, transport and stability of messenger as well as
non-coding RNAs (mRNA and ncRNA) (Gerstberger et al., 2014). So, although
transcriptional programs have long been studied as the main driving forces of cell
1.2 Post-transcriptional processes as regulators of gene expression 3
Translational
control
AAAAAA
Translation
Factor
TF
Chr remodeling
Transcriptional
control
Post-transcriptional
control
AAAAAA
SF
PAP
CP
Post-translational
control
Fig. 1.1 Layers of gene expression regulation. Gene expression can be con-
trolled at different levels. Transcriptional control regulates the transcription of the
genes. Post-transcriptional control acts on pre-mRNA processing, transport and decay.
Translational control determines the translation of mRNAs. Post-translational control
involves the regulation of the proteins by for example activation and degradation. (TF)
transcription factor, Chromatin (Chr) remodeling proteins, (CP) Cap binding proteins,
(SF) Splicing factor, (PAP) Poly-A binding proteins. 5′ cap is shown in blue.
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Fig. 1.2 pre-mRNA processing. pre-mRNAs while transcribed in the nucleus un-
dergo three main modifications 5′ end capping, splicing and 3′ cleavage and polyadeny-
lation to produce mature mRNAs. These are then exported to the cytoplasm. DNA is
represented by gray lines and RNA by black lines. RNA-polymerase II and associated
factors forming the transcription elongation complex is shown in dark purple, yellow,
green and orange. Spliceosome is highlighted in pink, blue and green. 5′ cap is repre-
sented in light purple. Cleavage and polyadenylation is represented by red and gray.
RBPs bound to the poly-A tail are shown in dark blue.
specific transcriptomes, recent lines of evidence have brought post-transcriptional
regulation at the forefront of the processes contributing to the reshaping of tissue
transcriptomes.
1.3 pre-mRNA splicing
1.3.1 Chemistry of the pre-mRNA splicing
Over forty-years after the discovery of pre-mRNA splicing, its fundamental role in RNA
maturation as well as its importance in gene expression are indisputable. The progress
in structural and global approaches have paved the way for the current understanding
of splicing. First described for the adenovirus 2 (Ad2) mRNAs in 1977 (Berget et al.,
1977; Chow et al., 1977), splicing is now known to exist as a conserved mechanism of
pre-mRNA processing in the majority of eukaryotic organisms (Ast, 2004). This critical
step in the maturation of mRNAs involves the recognition and excision of non-coding
regions of the gene, called introns, from the pre-mRNA transcripts and subsequent
ligation of the flanking coding regions, known as exons (Figure 1.3). The intronic
regions of a transcript are determined by three main conserved sequence features
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consisting of the 5′ splice site (5′SS), the branch point, and the 3′ splice site (3′SS). In
higher eukaryotes the branch point is followed by a pyrimidine rich sequence known as
the polypyrimidine tract (Figure 1.3). The 5′SS and the 3′SS define the exon-intron
and intron-exon junctions, the polypyrimidine tract assists the 3′SS recognition and
the branch point sequence is critical for the first step of the splicing reaction (reviewed
in Plaschka et al. (2019)).
The splicing reaction relies on two consecutive phosphoryl transfer reactions. The
first reaction is achieved by the nucleophilic attack of the phosphate at the 5′SS by the
branch point adenosine 2′-hydroxyl group. This reaction then produces a free 5′ exon
and also an intermediate product corresponding to the intron lariat still linked to the
downstream 3′ exon. The second reaction involves the attack of the 3′-hydroxyl group
from the free 5′ exon at the phosphate in the 3′SS, resulting in the ligated exons and a
free intron lariat (Plaschka et al., 2019). Thus the pre-mRNA splicing consists of a
simple two-step chemical reaction, yet it is orchestrated by a very complex machinery,
the spliceosome.
YNYURAY AGYN
GURAGN
GUNNNN
NN
AG
Exon 1 Exon 2Intron
5’ splice site 3’ splice siteBranchpoint
Polypyrimidine
tract
5'SS 3'SSBP
p pA
2’-OH
3’OH pA
ASTEP 1 STEP 2
Fig. 1.3 Schematic of the splicing reaction. Top, cis-elements involved in pre-
mRNA splicing of humans are highlighted. Conserved sequences at the 5SS and 3SS
and the internal branch point (BP) sequence are also shown. Bottom, intron removal
from pre-mRNAs is catalyzed in a two-step reaction involving phosphoryl transfers.
The first step leads to the intron branching and the second one results in the exon
ligation. Figure modified from (Plaschka et al., 2019)
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1.3.2 The spliceosome
The spliceosome complex is a large ribonucleoprotein which comprises over 100 proteins
in humans and is assembled upon the coordinated recognition of the intronic sequences
by five major small nuclear ribonucleoproteins (snRNPs): U1, U2, U4, U5 and U6
(Plaschka et al., 2019). These snRNPs, mainly U1 and U2, are important in the initial
steps of splicing (pre-spliceosome formation) recognizing and interacting with the RNA
elements in the intron defining the sequences to be spliced (Figure 1.4). In fact, the
recognition of the splice sites certainly represents a daunting problem, given that
the splicing machinery must identify short sequences embedded in very long introns.
Therefore, multiple relatively weak interactions and their crosstalk are required to
ensure proper recognition of the splice sites before splicing commitment. Formation of
this network of interactions across exons and/or introns are termed as exon definition
(ED) and intron definition (ID) respectively (Hollander et al., 2016) (Figure 1.4). For
instance, binding of the SR proteins (see below) influence binding of U1 snRNP to
the downstream 5′ splice site and of U2AF to the upstream polypyrimidine tract
establishing a "cross-exon" recognition complex (ED) (Mayeda and Krainer, 1992; Reed,
1996) (Figure 1.4). Nevertheless, intron definition can also be formed by recognition of
the pair of splice sites flanking the same intron (Figure 1.4). This mechanism is known
to exist in lower eukaryotes, for example in yeast, whose introns are typically shorter
than mammalian ones (Hollander et al., 2016).
Recent structural work by cryo-EM (cryogenic electron microscopy) focusing on
the yeast spliceosome, due to its simpler splicing machinery, have provided insights
into the key steps of the splicing reaction (reviewed in Plaschka et al. (2019)). The
splicing cycle involves a series of concerted critical steps that lead to the spliceosome
assembly, activation, catalysis of the first reaction with lariat formation, remodeling,
catalysis of the second reaction culminating on exon ligation, and final disassembly
and recycling (Figure 1.5). Moreover, several states of the spliceosome have been
isolated, namely E, A, pre-B, B, Bact, B*, C, C*, P, and intron lariat spliceosome
(ILS) complexes. The assembly and transitions between the distinct states occur as
follows: firstly, a E complex is formed upon the recognition of the 5′ splice site and
the branch point by U1 snRNP and the branchpoint bridging protein. Interaction
of U2 snRNP at the 3′ splice site forms the A complex, which associates with the
pre-assembled tri-snRNP U4/U6.U5 to result in a pre-B complex. The next state of the
spliceosome, the pre-catalytic B complex, is achieved upon U1 dissociation via Prp28
helicase activity. Subsequent release of the U4 snRNPs from the complex together
with Lsm proteins is carried out by the helicase Brr2. A Bact containing the stabilized
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Fig. 1.4 Schematic of the recognition of splicing regulatory sequences. In-
teractions between RNA elements and snRNPs occurring in the prespliceosome stage.
Cross-intron and exon interactions establishing intron definition and exon definition
are illustrated at the bottom.
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RNA structure of the active site is mediated by the association of the nineteen complex
(NTC) and nineteen-related (NTR) proteins. Next, the Prp2 helicase activity drives
the dissociation of the SF3a and SF3b from the complex with U2 snRNP and of the
retention and splicing (RES) complex. These events lead to the binding of the Prp16
helicase and of the branching factors, Yju2, Isy1, and Cwc25, which bring the branch
helix into the active site for the step 1 reaction. Then the nucleophilic attack of the
5′SS by the branch point adenosine 2′-hydroxyl group takes place in the B* spliceosome
stage. As a result of the reaction, a lariat intron intermediate and a 5′ exon are
produced with following formation of the C complex. Step 1 factors dissociate together
with Prp16 helicase in response to its ATPase activity, further allowing the binding
of another helicase, Prp22, as well as the step 2 factors, Prp18 and Slu7. The second
reaction is catalyzed in the resulting C* spliceosome complex. The 3′SS is docked into
the active site where the 3′-hydroxyl group of the 5′ exon attacks the 3′SS, generating
the lariat intron and the ligated exons. Eventually, the mRNA with the ligated exons
is released from the post-splicing P complex by the action of the Prp22 helicase. The
remaining ILS complex is disassembled upon Prp43 helicase activity and the recycled
snRNPs are then available for a next round of splicing (reviewed in Plaschka et al.
(2019)) (Figure 1.5).
Despite the fact that initial studies had been carried out in a non-human system,
latest structures from the human spliceosome complex support the remarkable conserva-
tion of the spliceosome structure and mechanism between the yeast and human systems
((Bertram et al., 2017; Fica and Nagai, 2017; Yan et al., 2017; Zhang et al., 2017) and
reviewed in Plaschka et al. (2019)). Furthermore, even though detailed structural work
is very interesting from the point of view of spliceosomal catalysis, it provides little
information on splicing regulation. Regulation mostly occurs in the early stages of
spliceosome assembly, especially at the level of E complex, which is heterogenous in
composition between pre-mRNAs - and also in exon definition complexes, yet all of
the structural work is on cross intron complexes (Figure 1.5).
1.4 Alternative splicing
In addition to the discovery of the "split genes", studies of Ad2 mRNAs in the late stage
of infection also uncovered the production of multiple mRNAs from a single transcript
through alternative choices of exons and splice sites during splicing (Berget et al., 1977;
Chow and Broker, 1978; Chow et al., 1977; Nevins and Darnell, 1978). This differential
use of exons was then denominated alternative splicing (AS). Soon after, pre-mRNA
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Fig. 1.5 Schematic of the yeast splicing cycle. The pre-mRNA splicing is
concerted by a series of steps that can be divided into recognition and assembly,
catalytic stages and lastly disassembly and recycling. Several states of the spliceosome
have been isolated and are shown in the cycle, namely, E, A, pre-B, B, Bact, B*, C, C*,
P, and intron lariat spliceosome (ILS) complexes. Red arrows indicate stages that are
regulated during alternative splicing. Figure modified from (Plaschka et al., 2019).
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splicing was shown to be a more general mechanism also acting in the endogenous
eukaryotic mRNA processing as revealed by the production of membrane-bound and
secreted immunoglobulin by the same gene as well as the two peptide hormones encoded
by the single calcitonin gene (Alt et al., 1980; Amara et al., 1982; Early et al., 1980;
Rosenfeld et al., 1982). Nowadays, high-throughput sequencing studies have estimated
that at least 95% of all the human pre-mRNAs are differentially spliced (Pan et al.,
2008; Wang et al., 2008). These studies also highlighted the potential of genes to encode
two to thousands of mRNA isoforms. Therefore, it is possible that the generation
of multiple isoforms from a single gene by AS is sufficient to explain the paradox of
organisms with similar number of genes that yet display completely different levels of
complexity (Barbosa-Morais et al., 2012; Sharp, 2005).
AS affects the pattern of multiexon transcripts in many ways, being classified
into simple and complex patterns as illustrated in Figure 1.6 (Black, 2003). Simple
pattern events can be divided into seven basic types of splicing identified as skipped or
cassette exons (SE), mutually exclusive exons (MXE), alternative 5′ and 3′ splice sites
(A5SS and A3SS), retained intron (RI), alternative promoter and alternative poly(A)
sites. Briefly, skipped exons are exons that can either be included or excluded from
the mRNA. In mutually exclusive exons, multiple exons are included in an exclusive
manner that inclusion of one of the exons imply exclusion of the other one. A5SS and
A3SS extend or shorten the length of an exon by controlling the splice site choice. The
intron retention pattern results from the not removal of the intron sequence. Finally,
alternative promoter selection drives use of an alternative 5′ end exon and, alternative
3′ end exons can arise from either alternative splicing or poly-A site selection regulation.
Hence, in the transcriptome, the basic patterns are found combined, giving rise to more
complex splicing patterns that involve exon choices beyond binary modules (Figure
1.6).
The distinct classes of AS are found in different relative abundance. Interestingly,
the AS type landscape also varies among different organisms. In general, exon skipping
is the most predominant class whilst intron retention is the rarest in vertebrates,
especially mammals. In addition to that, they exhibit more complex events than
invertebrates. The accumulation of complex events might be explained by the increase
in the number of exons in more complex organisms. Thereby, together with the
expansion of the possible splicing combinations, a more sophisticated control of AS
has co-evolved in vertebrates (Sammeth et al., 2008).
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Skipped/Cassette exon (SE) Mutually exclusive exon (MXE)
Alternative 5’ splice site (A5SS) Alternative 3’ splice site (A3SS)
Retained intron (RI)
Poly(A) Poly(A)
Alternative poly(A) sitesAlternative promoter
Complex ASE
Fig. 1.6 Types of Alternative Splicing. Skipped exon also known as cassette exon
(red) can be included or excluded in the transcript. Mutually exclusive exons (orange)
consist of two adjacent exons out of which only one of them is included in the final
mRNA. Alternative 5′ and 3′ (green and light blue) allow modification of the length
of the exon included. Intron retention (dark blue) is defined by the non-removal of
an intron from the mRNA. Alternative promoters and poly(A) sites (red and orange)
affect the first and last exons of the final transcript respectively leading to alternative
transcription start site and polyadenylation. More complex alternative splicing events
(ASEs) can arise from the combination of the te different AS types. Constitutive exons
are shown in gray and the possible exon junctions indicated by the arches.
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1.4.1 Implications of alternative splicing to transcriptome and
proteome diversity
The contribution of AS to the molecular diversity is exemplified by the Drosophila
gene Dscam whose differential splicing could potentially give rise to an extraordinary
38,016 transcript variants (Schmucker et al., 2000). Through alternative choices of
exons, AS expands the coding capacity of the genome which is also reflected in the
great diversification of the transcriptome and proteome. The inclusion and exclusion
of different exons have direct impacts upon the properties of the transcript in the
cell, such as localization, stability and translational efficiency. On the other hand,
expansion of the proteome is only possible due to the fact that most of the alternatively
spliced events tend to maintain the reading frame and therefore be translated into
functional proteins (Barbosa-Morais et al., 2012; Merkin et al., 2012; Mockenhaupt
and Makeyev, 2015). In that way, the alternatively spliced protein isoforms can
have divergent structures and functions consequently affecting their roles in the cell.
Interestingly, disordered regions of proteins are more prone to AS regulation as implied
by the high enrichment of AS event in these regions. As an effect of that, AS could
modulate protein signaling and protein-protein interactions (PPI), known functions
of the disordered regions within proteins (Barbosa-Morais et al., 2012). Indeed, AS
has been implicated in the rewiring of protein-protein interactions by the regulation
of exons encoding binding motifs (Buljan et al., 2012). Furthermore, despite not all
splicing events being conserved, genes containing evolutionary conserved alternative
exons are likely to encode isoforms with distinct and important functions. For example,
the (TGF) beta-activated kinase Tak1 (MAP3K7) gene has an alternative exon event
which has been remarkably conserved in the deuterostome clade (Venables et al., 2012).
Tak1 muscle-specific exon was found used in a tissue-specific manner even in the most
ancient member of this group, suggesting a potentially conserved physiological role
that requires splicing-specific isoforms (Venables et al., 2012).
Besides generation of protein diversity, AS also allows quantitative regulation of
proteins by production of mRNA isoforms that are subjected to Nonsense Mediated
Decay (NMD) (McGlincy and Smith, 2008). Indeed, a significant subset of alternative
splicing events creates a premature termination codon (PTC) in the mRNA which are
then not translated into truncated proteins and instead are directed to mRNA degrada-
tion via NMD (Baek and Green, 2005; Weischenfeldt et al., 2012). Therefore, this RNA
surveillance pathway guarantees the specific expression of mRNAs that display the
correct arrangement of translational signals (Weischenfeldt et al., 2012). Although the
generation of mRNAs solely for degradation is arguably a cost of biological regulation,
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the biological importance of AS-NMD events is reinforced by their ultraconservation
(McGlincy and Smith, 2008).
The functional importance of AS in biological systems is demonstrated by the
numerous cases in which regulation of complex physiological processes depends on
AS. For instance, generation of different transcript isoforms regulates neurite-growth
promoting activity of NCAM, cell aggregation mediated by CD31 and apoptosis
regulation by the Fas receptor (reviewed in Kelemen et al. (2013); Stamm et al. (2005)).
Moreover, AS-NMD is critical in the control of the RBP PTBP2 during neuronal
differentiation (see below) and stabilization of Myogenin during myogenesis (Nickless
et al., 2017).
Therefore, AS provides biological systems with two post-transcriptional regulatory
motifs for establishment of a gene expression network. Firstly by generating multiple
protein isoforms and secondly by downregulating gene expression with the coupling of
AS and NMD. Eventually, the established network has direct implications on a variety
of biological processes in the cell such as proliferation, adhesion, differentiation and
death. Thus, AS has the potential to reshape the transcriptome establishing a "robust"
network that directly influences cell fate decisions (Jangi and Sharp, 2014).
1.4.2 Regulation of alternative splicing
1.4.2.1 Regulation by regulatory RBPs
Constitutive and alternatively spliced exons are mainly distinguished by the strength
of their splice sites (Garg and Green, 2007; Zheng et al., 2005). Constitutively spliced
exons normally display strong splice sites that contain the consensus sequences that are
recognized by the spliceosome machinery. Consequently, these exons are included in all
the transcripts in the cell. Nevertheless, constitutive exons containing non-consensus
splice sites are also found and in their case, consistent inclusion occurs due to the
presence of secondary splicing regulatory elements. On the other hand, alternatively
spliced exons are usually associated with weak splice sites that rely on extra signals
for their splicing. In addition to the consensus splicing sequences and core proteins,
alternatively spliced exons depend on exonic and intronic splicing enhancer sequences
involved in the recruitment of regulatory splicing factors (Garg and Green, 2007; Zheng
et al., 2005). The interplay between regulatory cis and trans-elements determine the
final AS outcome of the transcript in the cell.
The cis-elements are classified according to their position and function into exonic
splicing enhancers (ESEs), exonic splicing silencers (ESSs), intronic splicing enhancers
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(ISEs) and intronic splicing silencers (ISSs). These elements are found encoded in the
transcript sequence, making the trans-acting factors the main drivers of AS within a
specific cell type. The array of trans-regulatory proteins involved in the regulation of
AS in the cell is comprised of RNA-binding proteins (RBPs). RBPs are proteins that
bind to RNA molecules, either single or double stranded, forming ribonucleoprotein
complexes that are critical in other post-transcriptional functions beyond AS such as
polyadenylation, mRNA stabilization, mRNA localization and translation (Gerstberger
et al., 2014). They are evolutionarily conserved and highly abundant in the cell. RBPs
exhibit various arrangements of structural domains, sharing common domains but in
combination with various auxiliary domains (Figure 1.7). Among the RNA binding
domains, the RRM domain is the most abundant domain across RBPs, being present
in more than half of the RBPs that bind to mRNA and exhibiting a diverse range of
binding motifs (Ascano et al., 2012; Gerstberger et al., 2014).
K-Homology or KH
RS or related
RGG
DEAD Box
RNP-cs or RRM
Other specialized domains
Gln rich and others
Glycine rich
Sex-lethal
Transformer
Tra-2
SRSF1
SRSF2
TIA-1
hnRNP A1
PTBP1
KHSRP
ETR3
NOVA1
YB1
hnRNP H
DDX17
SRSF10
ELAV
Fig. 1.7 Structural domain diversity of splicing regulatory proteins. Splicing
regulators share common domains yet they are combined in different arrangements.
They usually contain RBP domains, such as RRM and KH, combined with other
accessory domains. Different domains are color coded. Figure adapted from (Black,
2003).
In spite of the great diversity of domain structures and arrangements of RBPs,
RNA splicing maps of different RBPs have revealed general principles underlining
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their splicing regulation (Witten and Ule, 2011). These maps are generated by inte-
grating genome-wide protein–RNA interactions studies, such as CLIP (cross-linking
and immunoprecipitation) of a single RBP, with the global effects of the same indi-
vidual RBP on splicing, as profiled by RNA-seq or microarray of overexpression or
knockdown (Yee et al., 2019). Therefore, RNA splicing maps are very informative,
providing global positioning principles determining splicing regulation by a specific
RBP. These RBP-maps highlighted that splicing factors are usually able to repress
and activate splicing according to their binding context. In this position-dependent
splicing regulation, binding of RBPs to the upstream intron as well as within the exon
is associated with silencing effects, whereas binding to the downstream intron enhances
splicing. These effects are probably due to the binding near upstream regulatory
regions, such as the branch point and splice sites, during repression and via interaction
with U1 snRNP or by facilitating the recognition of the 5′ splice site during splicing
activation (Witten and Ule, 2011). For example, hnRNP proteins form a large group of
RBPs that associates with pre-mRNAs, being able to negatively and positively regulate
pre-mRNA splicing according to their binding position (Fu and Ares, 2014). One of its
members, hnRNP H, recognizes G-rich sequences and inhibits splicing upon binding to
the exon, as shown in the regulation of β-tropomyosin exon 7 (Caputi and Zahler, 2001).
Other RBPs such as hnRNP A1, hnRNP F and Nova also inhibit exon inclusion upon
binding to exonic sequences (Fu and Ares, 2014). Nonetheless, exceptions to exonic
binding-mediated repression have also been reported. For instance, SR proteins bound
to elements within the exon promote exon inclusion instead (Mayeda and Krainer,
1992). Moreover, as a result of the positional dependent activity, RBPs can be found
promoting opposite effects. hnRNP H when bound to downstream intron is able to
activate splicing in contrast with its repressor role mediated by exonic binding. Another
example is the RBP PTBP1, whose pyrimidine-rich motifs are enriched downstream
of activated exons but within and upstream of repressed exons (Hamid and Makeyev,
2017; Llorian et al., 2010). Additionally, many other RBPs have been found under
a similar positional-activity control, e.g. hnRNP l, hnRNP F, NOVA and RBFOX
proteins, underlying global principles of splicing regulation by RBPs.
RBP regulation modes that elucidate the mechanism behind the global position-
dependent activity are summarized in Figure 1.8. Firstly, repression of splicing upon
the binding of RBPs to the upstream intron and to the exon could be explained by
the interference with components of the core spliceosome or SR proteins, since the
RBP-RNA interaction takes place near critical splicing regulatory sequences, such as
the branch point and splice site (Fu and Ares, 2014). RBPs can compete for binding, for
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instance in PTBP1 and U2AF65 competition to bind to a regulated polypyrimidine tract
(Spellman and Smith, 2006). Moreover, RBPs can also block access of splicing factors
by forming multimeric complexes that extend along the RNA in a propagative binding
manner. Lastly, RBPs are also able to affect the RNA structure upon interaction
with it, hiding the regulatory sequences present on the pre-mRNA (Fu and Ares, 2014;
Spellman and Smith, 2006; Witten and Ule, 2011). Secondly, RBPs bound to the intron
downstream of the alternative exon might activate splicing by stabilizing the U1 snRNP
on the pre-mRNA directly or indirectly via interaction with TIA proteins (Förch et al.,
2002; Witten and Ule, 2011). For example, downstream binding of PTBP1 can directly
recruit U1 snRNP and activate splicing of Dtx2 exon 6 (Hamid and Makeyev, 2017).
Like repression, changes in the RNA structure by RBPs can expose the 5′ splice site
and facilitate its interaction with U1 snRNP (Witten and Ule, 2011). Additionally,
homotypic and heterotypic protein-protein interactions between RBPs could play a
role in the exon inclusion by affecting intron definition (Fu and Ares, 2014), as shown
for hnRNP A1 or hnRNP H (Fisette et al., 2010). Finally, further studies of other
RBPs and RNA splicing maps will shed more light on the global principles of the
position-based splicing as well as identify other specific mechanisms that differ from
those proposed so far.
Thus, these modes of splicing regulation explain the role of individual proteins in
AS decisions, yet the control of an alternative exon consists of a multifactorial system
in which the splicing outcome depends on the combinatorial effects from the plethora
of regulatory proteins and sequences present in the cell. These different combinations
in distinct cell types have been proposed as the splicing code (Figure 1.9). Hence,
understanding how precise patterns of regulation affect splicing could allow deciphering
this splicing code and eventually predict splicing outcomes in specific cellular and
physiological contexts. In fact, the majority of the RBPs are ubiquitously expressed
and only 2% of the RBPs are actually found expressed in a tissue-exclusive manner
and these could be important in coordinating cell specific functions. Thus, these tissue
specific factors are potentially critical regulators in the establishment of tissue-specific
AS programs.
1.4.2.2 Other influences affecting alternative splicing
In addition to regulatory RBPs, AS decisions can also be influenced by chromatin
state and Pol II elongation rate (reviewed in (Bentley, 2014; Herzel et al., 2017; Luco
et al., 2011; Skalska et al., 2017)). These mechanisms of regulation result from the
coupling of AS with transcription. Their specific mechanisms and implications are
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Fig. 1.8 RBP positional binding in the control of AS.Models of the mechanisms
underlying RBP positional dependency activity in the regulation of AS. Top, models
of repression by binding upstream and within the alternative exon. Bottom, models of
activation by binding downstream of the alternative exon. Constitutive and alternative
exons are shown as gray and dark gray boxes, introns as black lines, branch-point
sequences indicated by an A and enhancer and silencer sequences as small blue and
red boxes respectively.
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Fig. 1.9 Schematic of alternative splicing regulation. Regulation of AS is driven
by protein-RNA interactions between trans and cis elements. Basic splicing signals
present in the pre-mRNA are the 5′ splice site (GU), 3′ splice site (AG), branch point
(A), and polypyrimidine tract (Yn). pre-mRNA cis regulatory motifs are represented
by exonic splicing enhancers (ESEs), exonic splicing silencers (ESSs), intronic splicing
enhancers (ISEs), and intronic splicing silencers (ISSs). These regulatory motifs recruit
various RNA-binding proteins (RBPs) (e.g., SR and hnRNP proteins). The final
splicing outcome is determined by the combination of the individual regulatory signals
from the different RBPs. Constitutive and alternative exons are labeled and color-coded
as well as the introns. Figure adapted from (Park et al., 2018).
briefly discussed below.
RNA polymerase elongation rates
Splicing mainly occurs during transcription and this opens a window for crosstalk
between nascent mRNA, Pol II, and spliceosome, in which Pol II elongation rate, and
Pol II CTD modifications are critical factors (reviewed in Herzel et al. (2017); Luco
et al. (2011); Skalska et al. (2017)). The contribution of Pol II transcription kinetics to
splicing was first hinted in Eperon et al. (1988). In this study, the differences between
the in vitro and in vivo splicing of an A5SS was determined by the length of a loop
formed by RNA secondary structure in vivo. Thereby, splicing could be indirectly
affected by the rate of RNA synthesis through formation of secondary structures in
the pre-mRNA. Nevertheless, this assumption was only possible, given the fact that
in vitro splicing assays utilize pre-mRNAs in vitro transcribed that are spliced in a
transcription-uncoupled manner. Another piece of evidence for the role of transcription
rate in splicing was provided by a study carried in this laboratory. In this study,
insertion of a sequence leading to Pol II pausing upstream of Tpm1 exon 3 regulatory
element promoted more inclusion of this exon (Roberts et al., 1998). Moreover, the fact
that the transcription rate determined by the nature of the promoter influenced splicing
of alternative exons reinforced the coupling of these two processes (Luco et al., 2011).
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Therefore, the standing model proposes that slow elongation by Pol II allows inclusion
of alternative exons by providing a "window of opportunity" for assembly of the splicing
machinery on the alternative exon. On the other hand, Pol II fast elongation rate is
more associated with exon skipping due to the competition of the weak splice sites in
the alternative exon and the strong splice sites of the downstream constitutive exon
already transcribed (Luco et al., 2011). Eventually, Pol II CTD modifications affecting
its kinetics can also lead to alterations in AS. Indeed, the splicing of FN1, CASP9 and
BCL2L1 were shown to be regulated upon UV-dependent hyperphosphorylation of the
Pol II CTD, which causes a reduction of Pol II elongation rate (Muñoz et al., 2009).
Thus, this study highlighted the transcriptional coupling to AS via modification of the
Pol II CTD in response to exogenous agents.
The importance of the Pol II rate-regulated AS during mammalian development
was recently addressed by generation of mouse embryonic stem cells (ESCs) knocked-in
for a slow mutant Pol II (Maslon et al., 2018). Reduction of the elongation rate affected
splicing and gene expression in ESCs and resulted in early embryonic lethality in
mice and impairment of neuronal differentiation (Maslon et al., 2018). Therefore, it is
evident that RNA polymerase elongation rates play a critical role in AS with direct
impacts upon the cell fate.
Chromatin context
The studies of epigenetic marks, such as DNA methylation and histone modifications,
at the level of transcription have unraveled their role in the organization of accessible
chromatin and thereby gene expression (Klemm et al., 2019). Nevertheless, chromatin
context has recently emerged as a possible key regulator of AS (Skalska et al., 2017).
Initially suggested in view of the coincidence of chromatin modifications with splicing
regulatory signals such as splice sites, regulation of AS by epigenetic modifications
was then shown to be mediated by recruitment of splicing factors through chromatin
remodeler proteins (Luco et al., 2011). Thus, it seems likely that chromatin organizing
complexes could facilitate correct assembly of the spliceosome on the nascent pre-mRNA
in a Pol II elongation rate independent manner (Luco et al., 2011). Furthermore, a
number of splicing events such as FGFR2, FN1 and NCAM genes have been found
to be sensitive to histone marks (reviewed in Luco et al. (2011)). An interesting
mechanism that was then further characterized to directly link these modifications
to the splicing machinery was the existence of an adaptor complex (Luco et al.,
2010; Sims et al., 2007). For instance, formation of a H3K36me3/MRG15/PTBP1
platform has been described, in which PTBP1 is recruited by the adaptor protein
MRG15 which specifically recognizes H3K36me3 (Luco et al., 2010). Therefore, many
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more combinations of splicing factors, chromatin-binding proteins, and epigenetic
modifications may exist to integrate chromatin context to AS, contributing to the
complexity of this post-transcriptional process.
1.4.3 Tissue-specific alternative splicing programs
AS is able to reshape tissue transcriptomes in a qualitative and quantitative manner
by generation of specific protein isoforms and regulation of transcript decay via NMD.
Indeed, a study of the AS isoforms in human tissue transcriptomes revealed over 60% of
alternative splicing events (ASE) to be tissue-regulated (Wang et al., 2008). Moreover,
switch-like splicing patterns were also observed, being this a recurrent feature in pair
of MXEs (Wang et al., 2008). Thus, this type of AS may be responsible for driving the
regulation of exons involved in tissue-specific functions. Surprisingly, SEs that showed
a switch-like splicing pattern not only had the exon sequence itself conserved, but also
their flanking introns, suggesting the requirement of additional regulatory sequences
in their regulation (Wang et al., 2008). Another feature that underlies these specific
programs is the expression of tissue-specific RNA-binding factors, for instance RBFOX
motifs were enriched downstream of exons more included in tissues where RBFOX
proteins are highly expressed (skeletal muscle, heart and brain) (Wang et al., 2008).
Consistent with that, RBFOX1 has been shown to be a key factor during neuronal
development mediating splicing of a neuro-developmentally important subset of ASEs.
Therefore, although tissue-specific regulators represent a marginal fraction of RBPs,
they can play a role in the biology of different human tissues via AS regulation (Fogel
et al., 2012). Additionally, it has been suggested that a small number of master splicing
regulators might control cell-specific programs and these regulators could be identified
via the proximity of their genes with transcriptional super-enhancers (Jangi and Sharp,
2014). This approach suggested by Jangi and Sharp (2014) relies on the fact that these
large clusters of transcriptional enhancers are associated with genes that control and
define cell identity (Hnisz et al., 2013).
Even though individual regulators can be critical to specific AS programs, changes in
AS actually respond to multiple factors involving concerted expression of tissue-specific
and ubiquitous RBPs (Jangi and Sharp, 2014). During cardiac and skeletal muscle
development, for example, a splicing program is achieved by mutual exclusive expression
of MBNL and CELF. These RBPs coordinate the splicing transition from embryonic
to adult stages by acting antagostically in the regulation of target ASEs (Kalsotra
et al., 2008). In agreement with a common feature of tissue-specific splicing programs,
other examples of opposing factors in the establishment of splicing networks have been
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described such as the ESRP proteins (Epithelial Splicing Regulatory Proteins) and
RBFOX during epithelial-mesenchymal transitions (EMT) (Jangi and Sharp, 2014).
Therefore, coordination of an ASE by opposing RBPs allows tight splicing regulation
and in most cases the switch-like splicing. Additionally, RBPs can also cooperate
strongly regulating ASEs, which is the case of RBFOX proteins and PTBP2 in neuronal
differentiation (Jangi and Sharp, 2014). Interestingly, these two RBPs are also an
example of cross-regulation and signal amplification in splicing cascades. RBFOX
proteins increase PTBP2 expression during neuronal differentiation by releasing PTBP2
from its autoregulatory NMD splicing. In that way, RBFOX proteins not only drive
AS of its direct targets, they also coordinate secondary splicing changes via PTBP2,
another splicing regulator (Jangi and Sharp, 2014).
Therefore, splicing networks are built upon regulation at multiple layers, involving
various cis and trans-factors that act synergistically, antagonistically as well as in
cross-regulation. Eventually, all the individual AS effects are integrated in order to
regulate a functional coherent set of ASEs characteristic of a specific adult tissue
program.
1.5 Smooth Muscle Cells
1.5.1 Smooth muscle cells phenotypic plasticity
Smooth muscle cells (SMCs) are important to the proper function of many physiological
systems and organs, such as the gastrointestinal system (stomach and small intestine)
ensuring the motility of the digestive tract, as well as the cardiovascular system (blood
vessels like aorta) controlling the contraction and dilatation of the vessels (Fisher, 2010;
Owens et al., 2004). Thus, as indicated above, the contractility of SMCs is the main
property of this cell type, but visceral and vascular SMCs themselves show different
contraction abilities. It is prolonged and tonic in vascular SMC (VSMC) whereas in
other tissues such as bladder tissue, a more rapid and phasic contraction is observed
(Fisher, 2010). An even more distinctive and general feature of SMCs is the fact that
they are not terminally differentiated and exhibit phenotypic plasticity unlike other
muscles, e.g. skeletal muscle cells (Frismantiene et al., 2018; Owens et al., 2004; Ross,
1993) (Figure 1.10). As a result, SMCs can switch from a differentiated and contractile
phenotype to a dedifferentiated and more proliferative phenotype. This interconversion
is triggered in response to environmental and signaling cues and leads to modulation
of several morphological and physiological features of the SMCs. The differentiated
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phenotype is characterized by its typical elongated spindle shape and the high expression
of a number of SM-specific contractile proteins, such as ACTA2 and CNN1. Together
these characteristics allow the contraction and generation of mechanical output by
the SMCs. Conversely, the dedifferentiated phenotype is marked by the expression of
genes involved in cell cycle progression and extracellular matrix (ECM) remodeling,
like cyclins and collagens respectively. Consequently, the dedifferentiated cells are
more proliferative, motile and synthetically active and display a more "hill and valley"
morphology instead (Frismantiene et al., 2018; Owens et al., 2004). However, SMCs
can revert to the contractile and functional phenotype, which in the case of VSMCs is
associated with healthy blood vessels. In this way, the phenotypic modulation consists
of a major mechanism by which the SMCs can promote renewing and repairing of the
tissue after injury (Frismantiene et al., 2018).
SMC dysfunction has been implicated in a number of pathological situations
including cardiovascular diseases, such as atherosclerosis and hypertension (Bennett
et al., 2016; Frismantiene et al., 2018), airway diseases like asthma (Panettieri, 2002)
and gastrointestinal motility disorders (Sanders et al., 2012). The relevance of the
study of SMCs is highlighted by the fact that cardiovascular diseases, only one of the
group of disorders affected by mis-regulation of SMC phenotype transition, are the
major cause of death worldwide and estimated by the World Health Organization
(WHO) to be the cause of death of 17.7 million people worldwide, representing 44%
of all deaths in 2015. Taken the biomedical importance of SMCs and the demand for
therapeutics, extensive studies have been done. However, the mechanism controlling
SMC phenotype remains not fully understood.
When SMCs harvested from human arteries were established in culture, a similar
transition from a contractile to a synthetic phenotype was observed (Thyberg, 1996),
suggesting that SMC phenotypic switching could be modeled in vitro. This paved the
way for much of the progress in the understanding of the regulation of this process. Since
then, several studies have uncovered the changes in gene expression levels revealing
the transcription control network during this process (Frismantiene et al., 2018; Owens
et al., 2004; Spin et al., 2012). In addition to that, the transcriptional control mediated
by miRNAs during SMC phenotypic modulation has also been intensely assessed (Davis-
Dusenbery et al., 2011; Owens et al., 2004; Wang and Atanasov, 2019). These studies
have shed some light on some of the mechanisms behind SMC phenotypic plasticity
by identifying various regulators of the SMC differentiation such as serum response
factor (SRF) and myocardin (MYOCD). SRF is a transcription factor associated with
development of other muscle types (skeletal and cardiac) and it has been implicated in
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Fig. 1.10 Phenotypic modulation of Smooth Muscle Cells. SMCs present
phenotypic plasticity switching between a differentiated (green) and a proliferative (blue)
state. Gene expression markers of differentiation and proliferation are indicated as well
as miRNAs and genes known to be differentially spliced during SMC dedifferentiation.
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SMC specification and differentiation (Sun, 2005). The transcription of many SMC
specific genes like SM22α and the α-actin are driven by the CArG boxes (CC[A/T]6GG)
located in their promoters which then can be regulated upon SRF binding (Frismantiene
et al., 2018; Owens et al., 2004). The latter, MYOCD, is a critical SMC-specific
co-activator of SRF and the formation of the complex SRF-MYOCD enhances the
transcription activation of the CArG containing genes. In addition to MYOCD,
myocardin-related transcription factors (MRTF) can also interact with SRF and act as
co-activator of SMC genes. Thereby, disruption of the CArG–SRF–MYOCD/MRTF
complex induces the SMC dedifferentiated phenotype. For example, repression of
SMC genes can occur by competition between SRF–MYOCD and the co-repressor
KLF4 that also binds to G/C elements or displacement of SRF–MYOCD by ELK-1.
Moreover, proteins involved in chromatin remodeling also impact activation of SMC
genes. However, the outcome of the chromatin remodeling is less clear since both
activation and repression roles via modulation of SRF-MYOCD complex and by altering
the accessibility to the CArG boxes have been reported. Lastly, miRNAs have been
pinpointed as an important regulator of VSMC development and phenotypic switching
(Davis-Dusenbery et al., 2011; Wang and Atanasov, 2019). mir-143 and mir-145 were
shown to regulate quiescent versus proliferative phenotype in SMCs by targeting
critical transcription factors (Cordes et al., 2009). More specifically, these two miRNAs
cooperatively regulated mRNA targets, stabilizing MYOCD while inhibiting KLF4
and ELK-1, to promote differentiation (Cordes et al., 2009). So, due to the complexity
of the SMC differentiation and phenotypic plasticity, it is likely that these biological
processes require numerous layers of regulation. However, while the transcriptional
program of SMCs has been well-investigated, the knowledge of the regulated splicing
programs of SMCs is more rudimentary. The progress in understanding the contribution
of post-transcriptional programs in the SMC is discussed below.
1.5.2 The alternative splicing program of differentiated SMCs
Detailed molecular analysis of specific splicing events and global approaches for tran-
scriptome profiling combined with bioinformatic tools have uncovered different AS
specific programs across several tissues and stages of development. However, the knowl-
edge of the SMC AS program is still limited compared to other more well-characterized
tissue-specific splicing, such as neurons and, skeletal and cardiac muscle (reviewed in
Baralle and Giudice (2017); Llorian and Smith (2011)).
Even though some SMC markers of the differentiated state are produced upon
differential splicing, e.g. h-Caldesmon and meta-Vinculin (Owens et al., 2004), little is
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known about their regulation. In fact, the study of individual SMC-specific ASE has
found a number of splicing regulators, such as PTBP1, CELF, MBNL, QKI, TRA2B
and SRSF1 (Gooding et al., 2013, 1998; Gromak et al., 2003; Shukla and Fisher, 2008;
van der Veer et al., 2013; Xie et al., 2017). Nevertheless, these factor were primarily
implicated in the splicing regulation of the proliferative state and were not exclusively
expressed in SMCs. Moreover, PTBP1, despite its role in the repression of the mutually
exclusive SM exon in the ACTN1 transcripts (Gromak et al., 2003), also acts in
the opposite direction when regulating the splicing of TPM1 mRNA, facilitating the
inclusion of the SM exon by repressing the non-smooth muscle exon, TPM1 exon 2
and exon 3 respectively (Gooding et al., 1998). Interestingly, the discovery of TRA2B
splicing regulation of Mypt1 brought to attention the differences in splicing within SM
tissues (Shukla and Fisher, 2008). Mypt1 exon 23 was more included in phasic SMCs,
in which TRA2B is more expressed. Eventually, this ASE confers unique contractile
properties to visceral SMCs allowing their typical fast contraction (Shukla and Fisher,
2008).
Thus, these studies provided interesting functional and mechanistic insights, yet
more general regulatory principles of the SM splicing program could not be drawn by
them. In an attempt to address that, in the laboratory, the SMC transcriptome was
profiled during mouse aorta and bladder de-differentiation using an exon-junction array
(Llorian et al., 2016). The global profiling confirmed PTBP1 as a repressor of exons
more included in the SM differentiated state (Figure 1.11) and unraveled the concerted
regulation of non-productive splicing of post-transcriptional regulators (Llorian et al.,
2016). Furthermore, no candidate RBP was identified to regulate the differentiated
SMC splicing program as indicated by the motif enrichment (Figure 1.11) and protein
expression analysis (Llorian et al., 2016). In fact, it is likely that the identification of
critical RBP regulators could be hindered by the rapidly dedifferentiation of SMCs in
the cell culture environment. Finally, SMCs are known for their great deal of diversity
(Fisher, 2010), even within single blood vessels (Cheung et al., 2012). Therefore, it is
possible that distinct RBPs regulate these specialized SMC types as highlighted by the
splicing regulator TRA2B.
The findings from the different studies in the SMC regulated AS are summarized
in Figure 1.12.
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Differentiated
Proliferative
Fig. 1.11 Motif enrichment analysis of SMC regulated ASE. k-mer and RNA
complete motifs found enriched in SMC differentiated (green) and proliferative (blue)
exons, top and bottom respectively. Motifs shown were significantly enriched (p <
0.01). Asterisks indicate motifs with FDR < 0.05 and numbers represent log2 fold
enrichment. Figure adapted from (Llorian et al., 2016).
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1.6 mRNA splicing in disease and therapeutics
Given the importance of AS in the control of gene expression, it is not surprising that
a large number of human diseases are caused by RNA mis-splicing (Table 1.1). Defects
in AS regulation due to mutations in cis-elements, trans-regulatory factors as well as in
the core spliceosome components are associated with several diseases such as Duchenne
muscular dystrophy (DMD), Spinal muscular atrophy (SMA) and Myelodysplastic
syndromes (MDS) respectively (reviewed in Scotti and Swanson (2016)). As introduced
before, although splicing occurs in two simple reactions, its proper function requires
a concerted series of events operated by the splicing machinery and auxiliary factors.
For instance, the 5′ and 3′ splice sites surrounding the right exon must be identified
among a large pool of intronic sequences to then drive correct splicing. Therefore, the
complexity of splicing makes it susceptible to mutations and genomic sequence variants.
Indeed, the Human Genome Mutation Database (HGMD) estimates about 9% of all
the reported mutations to affect splicing. Yet this number is underestimated since
missense or nonsense substitutions could consist of splicing mutations mainly if lying
within regulatory cis-elements. In addition to that, about 2000 splice site-disrupting
single nucleotide polymorphisms (SNPs) have been identified and are likely to affect
splicing (Kurmangaliyev et al., 2013). Moreover, by altering the protein sequence
beyond a single residue, splicing mutations have the potential to cause drastic effects.
In a way, a single nucleotide mutation within the exon, in spite of being able to
cause a change in the amino acid encoded by the codon, can also disrupt regulatory
elements that then have the potential to lead to the drastic loss of the complete exon
sequence. Additionally, splicing mutations can also result in frameshifting as well as
insert premature stop codons that then generate truncated proteins or direct mRNA
decay via NMD (reviewed in Montes et al. (2019); Scotti and Swanson (2016)).
A growing number of studies have also indicated mis-splicing events as drivers of
cancer progression and contributors of specific cancer hallmarks (El Marabti and Younis,
2018; Montes et al., 2019). Remarkably, cancer cells undergo a large transcriptome
reshaping that includes generation of cancer-specific splicing isoforms of oncogenes
and tumor suppressor genes (El Marabti and Younis, 2018). It is also notable that
all types of cancer cells display striking levels of intron retention, with this type of
AS being implicated in the greater diversity of cancer cell transcriptomes compared
to normal cells (Dvinge and Bradley, 2015). Additionally, cancer-specific mutations
and alterations in splicing factors, changes in signaling pathways controlling splicing
factors and, aberrations in core spliceosome components are all linked to deregulation
of AS in cancer (El Marabti and Younis, 2018). Finally, a systematic analysis of AS
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changes in thousands of tumor samples has underlined a subset of AS events whose
consequences have direct implications in the functional transformations characteristic
of cancer cells (Climente-González et al., 2017).
The large amount of knowledge gained about the transcript regulatory sequences
and auxiliary protein factors as well as their implications to splicing did not only allow
the better understanding of the effects of disease-associated mutations but has also
contributed to the development of novel therapies based on splicing. The two main
strategies being applied consist of antisense oligonucleotide molecules (ASOs) and small
molecules (reviewed in Montes et al. (2019); Scotti and Swanson (2016)). The former
targets recognition of splicing regulatory sequences in the transcript and its subsequent
modulation of splicing whereas the latter has been developed in an attempt to block
the binding of trans-factors to mutant sequences via regulation of the activity of
splicing factors and RNA structures. In fact, an ASO drug has recently been developed
consisting of the first medical therapy for spinal muscular atrophy (SMA). The drug,
Spinraza™, corrects SMN2 exon 7 splicing by targeting an intronic splicing silencer
(ISS) which then induces exon inclusion. SMA is a prominent genetic disease, a cause
of infant mortality, and results from the deletion or mutation of the survival motor
neuron (SMN1 ) gene, leading to its reduced protein levels (reviewed in Groen et al.
(2018)). In humans, the duplicated gene SMN2 is not sufficient to compensate for the
loss of SMN1 because of its exon 7 predominant skipping (Lorson et al., 1999; Monani
et al., 1999). However, defective splicing could be corrected by administration of ASOs,
restoring SMN expression in motor neurons after intracerebroventricular injection in
mice (Hua et al., 2011). These in vivo studies carried out by A. Krainer’s laboratory
in collaboration with F. Bennett from Isis Pharmaceuticals ultimately resulted in the
development of this new splicing-based drug, currently the only treatment approved
for SMA (reviewed in Groen et al. (2018)). Therefore, ASOs could be an approach
applicable to other mis-splicing disorders. Indeed, pre-clinical proof of concept for
another ASO-based targeted therapy have been provided for Familial Dysautonomia
(FD), a rare inherited neurodegenerative disorder (Sinha et al., 2018).
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During VSMC phenotypic switch in cardiovascular diseases, such as vascular resteno-
sis and atherosclerosis, several genes tightly involved in the phenotype conversion (e.g.
CALD1, TPM1 and SMTN1 ) are regulated at the isoform level by differential AS
(Llorian et al., 2016; van der Veer et al., 2013). The few studies that have attempted
to address the role of AS in VSMCs established a role for the RBP QKI in the dedif-
ferentiated vasculature (van der Veer et al., 2013). The role of RBPs in cardiovascular
diseases is not restricted to QKI in VSMC and several other RBPs including MBNL
and SRSF1 have been characterized in other cell types of the cardiovascular system
(reviewed in de Bruin et al. (2017)). Therefore, better understanding of the cis and
trans-regulatory elements that orchestrate the splicing of critical VSMC genes may,
in the future, lead to the development of new splicing-therapeutic approaches in the
treatment of cardiovascular diseases.
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1.7 Ph.D thesis research aim and outline
To further investigate the regulation of the AS program of differentiated SMCs, the
work described in this Ph.D thesis had the following as main questions:
Is there any splicing regulator controlling the SM tissue transcriptome?
If yes, what are the targets it regulates and how does it play its role in
alternative splicing?
The answers are divided into five chapters herein (Chapters 3-7). In Chapter 3, the
approach suggested in (Jangi and Sharp, 2014) for the identification of potential tissue-
specific regulators via association of their genes with transcriptional super-enhancers
was applied. This led to the discovery of the RNA-binding protein RBPMS. In Chapter
4, functional studies in SMCs by manipulation of RBPMS levels followed by mRNA-
seq were carried out to address any post-transcriptional role of this master regulator
candidate. In Chapter 5, bioinformatic analysis combined with in vitro and in vivo
biochemical assays, like in vitro binding and minigene transfections techniques, were
applied for the confirmation of RBPMS direct regulation of splicing. In Chapter 6,
possible indirect effects of RBPMS mediated splicing cascade were further examined,
focusing on transcriptional and post-transcriptional processes. Finally, in Chapter 7,
further systematic structural-functional studies shed some light onto the mechanisms
that could regulate RBPMS activity, e.g. PTM. Eventually, in addition to the summary
of the main findings of this work, general discussion and future studies are presented
in Chapter 8.
Chapter 2
Materials and Methods
2.1 Identification of potential master splicing reg-
ulators
For the identification of super-enhancer associated genes, a catalog of human super-
enhancers across different tissue and cell types from (Hnisz et al., 2013) was used. The
datasets corresponding to aorta (UCSD_Aorta), bladder (UCSD_Bladder), stomach
smooth muscle (BI_Stomach_Smooth_Muscle) and skeletal muscle (BI_Skeletal_
Muscle) were compared to identify smooth muscle super-enhancers marked genes.
Skeletal muscle was included as an outlier group. To obtain the list of genes associated
with each tissue super-enhancer, the dataset tables were loaded into the UCSD Table
Browser and data exported by GREAT version 3.0.0. Gene association was determined
as follows: "Basal+extension: 5000 bp upstream, 1000 bp downstream, 1000000 bp
max extension, curated regulatory domains included". Finally, a list of 1542 human
RBPs from Gerstberger et al. (2014) was used for the identification of potential master
post-transcriptional regulators.
2.2 Cloning and DNA manipulation
2.2.1 Growth conditions for bacterial cultures
Eschericia coli (E. coli) were grown at 37 °C overnight in the presence of the appropriate
selective antibiotic. Both LB agar and liquid media were used. For DNA purification,
E. coli was grown in liquid LB at 37 °C under agitation, using 2 mL and 50 mL LB for
small (miniprep) and large scale (maxiprep) purification respectively.
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2.2.2 Transformation of E.coli
The heat-shock method was carried out for bacterial transformation. Competent cells
(TG-1 of DH5a E. coli) were pre-made in the laboratory using CaCl2 and stored
at -80°C. 10 µL of ligation reaction or 100 ng of plasmid DNA was mixed with 100
µL of competent cells. The mix was then incubated on ice for 30 min followed by
heat-shock at 37°C for 2.5 min and another incubation on ice for 2 min. Eventually,
cells were spread on LB agar plates containing the appropriate antibiotic. In the case
of kanamycin selection, cells were allowed to recover of the heat-shock by addition
of 900 µL of LB media and incubation at 37°C for 15 min. Additionally, cells were
pelleted and re-suspended accordingly before spreading on LB agar plates.
2.2.3 Ligation of DNA fragments
Ligations were all performed in a final volume of 10 µL and incubated at 4°C for at
least an hour. Reactions were set in a 1:5 ratio of vector:insert and using T4 DNA
Ligase (Promega). E. coli TG1 competent cells were transformed with the ligation
reaction as described above.
2.2.4 Preparation of plasmid DNA
For preparation of plasmid DNA by miniprep or maxiprep, single colonies from LB
plates were picked and inoculated in LB liquid medium for growth. The bacterial
cultures were grown at 37°C for at least 6 hours for minipreps and overnight for
maxipreps. Cell were pelleted by centrifugation at room temperature at 8000 g for
minipreps and at 4°C at 6000 g for 10 min for maxipreps. Lysis and DNA purification
was carried out according to the manufacturer’s instructions, QIAGEN QIAprep Spin
Miniprep or Maxiprep kit. Concentration of the final purified plasmid DNAs was
measured using NanoDrop spectrometer (Thermo Scientific).
2.2.5 Purification of DNA fragments
Fragmented DNAs using restriction enzymes were purified by excision from agarose gel
and using QIAGEN QIAquick spin kit. Following steps were performed according to
the manufacture’s protocol. Final samples were eluted in water and stored at -20°C.
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2.2.6 Isolation of PAC1 genomic DNA
To extract genomic DNA from PAC1 smooth muscle cells (Rothman et al., 1992)
(Chapter 2.3), first, cells were washed twice with PBS and harvested by scraping
off from a single well from a 6-well plate. Cells were resuspended in 50 volumes of
1x proteinase K buffer and 1 volume of proteinase K (10 mg/mL stock) followed by
incubation at 37°C for 1 hour. Samples were then phenol extracted and RNase A treated
to remove proteins and RNAs from the preparations. Finally, ethanol precipitation was
carried to concentrate samples and final elution done with water. PAC1 genomic DNA
was then quantified using NanoDrop spectrometer (Thermo Scientific) and stored at
-20°C.
2.2.7 DNA constructs
Rattus norvegicus (rat) Rbpms isoforms were obtained by PCR amplification from
differentiated PAC1 cells cDNA and cloned into pGEM-Teasy (Promega) (see Table
2.2 for oligonucleotide sequences). RBPMS isoforms identified in the PAC1 cells are
indicated in Table 2.1. The paralog Rbpms2 was also cloned (NM_001173426.1/
NP_001166897.1). In order to generate N-terminal Venus and 3xFLAG RBPMS
constructs for in vivo overexpression, RBPMS isoforms were PCR amplified from the
pGEM-Teasy constructs and cloned into the XhoI and EcoRI sites of the pEGFP-C1
(Clontech) and pCI-neo-3x-FLAG vectors, respectively.
Table 2.1 RBPMS isoforms cloned from PAC1 cells and used in this study
Isoform name NCBI RNA reference NCBI protein reference
RBPMS A XM_006253240.2 XP_006253302.1
RBPMS A.2 XM_006253241.2 XP_006253303.1
RBPMS A.3 not annotated or predicted not annotated or predicted
RBPMS A.4 not annotated or predicted not annotated or predicted
RBPMS A.5 not annotated or predicted not annotated or predicted
RBPMS B NM_001271244.1 NP_001258173.1
RBPMS B.2 not annotated or predicted not annotated or predicted
RBPMS mutants were obtained by direct mutagenesis using PCR with oligonu-
cleotides containing the desired mutation, followed by digestion of parental plasmids
with DpnI enzyme. For generation of C-terminal truncated RBPMS, oligonucleotides
containing a stop codon at the position adjacent to the last amino acid codon fol-
lowed by the specific restriction site were used for PCR amplification. In the case
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of N-terminal deletions, oligonucleotides were designed containing the restriction site
upstream of the first amino acid codon in the truncated RBPMS.
RBPMS-A and B wild type and RBPMS-A binding mutant were also cloned
into a pCI-neo-3x-FLAG containing a nuclear localization signal (NLS) and an MS2
coat protein, both at the C-terminus. Those constructs were then used for in vivo
overexpression in the tethering assays.
For expression of recombinant RBPMS protein in E. coli, the coding sequences of
RBPMS-A and B containing an N-terminal 3xFLAG were PCR amplified and then
sub-cloned into the BamHI and XhoI sites of the pET21d plasmid (Novagen).
In the experiments where Venus tagged QKI was overexpressed, the construct used
was previously available in the laboratory and it was described in Llorian et al. (2016).
Rat minigene reporter constructs were used to assess splicing activity of RBPMS.
The Tpm1 exon 3 and Actn1 exon NM-SM were previously available in the lab and
their description can be found in Gromak and Smith (2002); Southby et al. (1999).
Briefly, the Tpm1 minigene reporter contains the rat genomic region between Tpm1
exons 1 and 4, with extensive deletion to intron 1 and 3 and of exon 2. Moreover, the
Tpm1 sequence is flanked by two SV40 sequences in the minigene reporter. The fusion
at the 5′ end of exon 1 allows efficient transcription initiation whereas the fusion at
the 3′ end of exon 4 drives the processing of the 3′ end of the Tpm1 minigene reporter
encoded transcript. The Actn1 minigene reporter was constructed in a similar manner,
however, the Actn1 minigene reporter spans over the rat genomic sequence that codes
for the pair of mutually exclusive exons, exon NM and exon SM, and both constitutive
flanking exons, EF1a and EF2 exons. Moreover, reporters containing only one of the
mutually exclusive exons were obtained by deletion of either the SM exon and its
flanking intronic regions or the NM exon and some of its flaking intronic sequence as
described in (Gromak et al., 2003).
Myocd exon 2a and Flnb exon H1 minigene reporters were obtained by PCR
amplification of the regulated exons and their flanking introns from PAC1 cells genomic
DNA (approximately 250 bp upstream and downstream of Myocd exon 2a and 500 bp
for Flnb reporter; Oligonucleotide sequence in Table 2.3). The PCR products were then
transferred into XhoI/EcoRV and NotI/SphI sites of the pCAGGs-EGF vector. The
pCAGGs-EGFP consists of a GFP expression cassette which has an intron inserted
into its second codon. Thus, the Myocd and Flnb reporters code for an RNA containing
three exons and their splicing generate two products that corresponds to the inclusion
or exclusion of the exon of interest (Wollerton et al., 2004).
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Point mutations of the CAC motifs in the minigene constructs were generated
by PCR, using oligonucleotides containing the A to C mutations and the reporter
wild-type DNA as template. Moreover, for the tethering assays, MS2 coat binding
hairpins were inserted into the CAC mutant Myocd and Tpm1 minigene reporters.
Prior to that, the MfeI and NheI restriction sites were inserted into the CAC clusters
locations downstream of the Myocd exon 2a and the MluI and BsiWI restriction sites
were included upstream of the Tpm1 exon 3. Oligonucleotides containing the sequence
of the MS2 coat protein binding hairpin flanked by the respective restriction site were
used for ligation to the minigene reporters.
For the in vitro transcription templates, intronic regions containing CAC motifs
from Tpm1, Flnb andMyocd were amplified by PCR and cloned into the HindIII/EcoRI
sites of the pGEM4Z plasmid (Promega).
The sequence of all the constructs were confirmed by Sanger sequencing. Finally,
the sequence of all the oligonucleotides used in this study is found in Tables 2.2 and
2.3.
2.3 Cell culture, transfection and inducible lentivi-
ral cell line
The rat pulmonary artery cell line (PAC1) was used as the SMC model in this study
(Rothman et al., 1992). This cell line has been shown to be a good system for SMC
phenotypic plasticity studies due to its ability to reproduce the differentiated and
proliferative states in cell culture. To achieve more differentiated PAC1 cells, they were
only passaged once a week. On the other hand, to stimulate the proliferative state,
PAC1 cells were passaged twice a week at higher dilution (Llorian et al., 2016).
The human embryonic kidney cell, HEK293, was also used for some of the experi-
ments as an alternative to the poor transfection efficiency of the SMC cell line as well
as to address the role of RBPMS in other cell types. Within that same purpose, HeLa
cells were used as another human cell line.
All the different cell lines were cultured in DMEM medium containing glutamax
and 10% fetal bovine serum (FBS) and under standard conditions. For maintenance,
HEK293 and HeLa cells were passaged twice a week in a 1:10 dilution.
For transient overexpression, 1x106 PAC1 cells were seeded in 6 well plate a day
before the experiment. Cells were then transfected by incubation with a transfection
reaction containing 5 µL of the Superfect transfection reagent (Qiagen) and 2 µg of
total amount of DNA diluted in OptiMEM. For all the transfections, the amount of
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Table 2.2 Sequence of the oligonucleotides used in this study for construction of effectors
Target 5′-3′ sequence Vector Cloning method Experiment
RBPMS A CGAAGGACCGGGAAGATGAACGGC pGEM Teasy PAC-1 PCR
CTCGAGTCAGCAGAACTGCCGGGA
RBPMS B CGAAGGACCGGGAAGATGAACGGC pGEM Teasy PAC-1 PCR
GCTTGCTAATAAATTCAACATGGGAGCTC
RBPMS2 TCACCATGAGCAACCTGAAGCC pGEM Teasy PAC-1 PCR
GAGGAGCTAACAGAACTGGCGATA
RBPMS A CGAAGGACCGGGCTCGAGGTAACGGCGGC Venus C1 XhoI -EcoRI in vivo OE
CGAGACGAATTCTCAGCAGAACTGCCG
RBPMS B CGAAGGACCGGGCTCGAGGTAACGGCGGC Venus C1 XhoI -EcoRI in vivo OE
TTGCTAGAATTCTCAACATGGGAG
RBPMS2 TTCGATTTCCTCGAGGTAGCAACCTG Venus C1 XhoI -EcoRI in vivo OE
GTGATTGAATTCCTAACAGAACTG
RBPMS A CGAAGGACCGGGGAATTCAACGGCGGC Flag3X EcoRI - XhoI in vivo OE
CGAGACCTCGAGTCAGCAGAACTGCCG
RBPMS B CGAAGGACCGGGGAATTCAACGGCGGC Flag3X EcoRI - XhoI in vivo OE
TTGCTACTCGAGTCAACATGGGAG
RBPMS2 GAATTCGATTTCGAATTCAGCAACCTG Flag3X EcoRI - XhoI in vivo OE
CTAGTGATTCTCGAGCTAACAGAACTG
RBPMS A K100E CGACTAGAGTTTGCTGAGGCAAACACGAAGATG Venus C1 mutagenesis in vivo OE
CGACTAGAGTTTGCTGAGGCAAACACGAAGATG
RBPMS A R38Q CTGGACATCAAGCCCCAAGAGCTGTACCTGCTCTTC Venus C1 mutagenesis in vivo OE
GAAGAGCAGGTACAGCTCTTGGGGCTTGATGTCCAG
RBPMS A R38A/E39A CTGGACATCAAGCCCGCAGCGCTGTACCTGCTCTTC Venus C1 mutagenesis in vivo OE
GAAGAGCAGGTACAGCGCTGCGGGCTTGATGTCCAG
RBPMS A CGAAGGACCGGGGAATTCAACGGCGGC Flag3X+NLS+MS2 EcoRI - XhoI in vivo OE
CGAGACACACTCGAGGCAGAACTGCCG
RBPMS B CGAAGGACCGGGGAATTCAACGGCGGC Flag3X+NLS+MS2 EcoRI - XhoI in vivo OE
CTAATACTCGAGACATGGGAGCTC
RBPMS T/E GAACAAACTCGTAGGGGAGCCAAACCCCAGTGAGCCTCTGCCCAACACTG Venus C1 XhoI -EcoRI in vivo OE
CAGTGTTGGGCAGAGGCTCACTGGGGTTTGGCTCCCCTACGAGTTTGTTC
RBPMS T/A GAACAAACTCGTAGGGGCTCCAAACCCCAGTGCTCCTCTGCCCAACACTG Venus C1 XhoI -EcoRI in vivo OE
CAGTGTTGGGCAGAGGAGCACTGGGGTTTGGAGCCCCTACGAGTTTGTTC
RBPMS A T113E GAACAAACTCGTAGGGGAGCCAAACCCCAGTACTCCTCTGCCCAACACTG Venus C1 XhoI -EcoRI in vivo OE
CAGTGTTGGGCAGAGGAGTACTGGGGTTTGGCTCCCCTACGAGTTTGTTC
RBPMS A T118E GAACAAACTCGTAGGGACTCCAAACCCCAGTGAGCCTCTGCCCAACACTG Venus C1 XhoI -EcoRI in vivo OE
CAGTGTTGGGCAGAGGCTCACTGGGGTTTGGAGTCCCTACGAGTTTGTTC
RBPMS A TST/E GAACAAACTCGTAGGGGAGCCAAACCCCGAGGAGCCTCTGCCCAACACTG Venus C1 XhoI -EcoRI in vivo OE
CAGTGTTGGGCAGAGGCTCCTCGGGGTTTGGCTCCCCTACGAGTTTGTTC
RBPMS A TST/D GAACAAACTCGTAGGGGATCCAAACCCCGATGATCCTCTGCCCAACACTG Venus C1 XhoI -EcoRI in vivo OE
CAGTGTTGGGCAGAGGATCATCGGGGTTTGGATCCCCTACGAGTTTGTTC
RBPMS K60R CATAAAGCTCACATCTCGACAGCCCGTAGGCTTTGTC Venus C1 XhoI -EcoRI in vivo OE
GACAAAGCCTACGGGCTGTCGAGATGTGAGCTTTATG
RBPMS K109R ACGAAGATGGCCAAGAACCGACTCGTAGGGACTCCA Venus C1 XhoI -EcoRI in vivo OE
TGGAGTCCCTACGAGTCGGTTCTTGGCCATCTTCGT
RBPMS A ∆N AGCGAGGCCACTCGAGGTGAGGAGGAGGTCCGGACC Venus C1 XhoI -EcoRI in vivo OE
RBPMS ∆C CAAGAACAAACTCGTATAGGAATTCAACCCCAGTACTC Venus C1 XhoI -EcoRI in vivo OE
RBPMS A ∆20 GGAGGGAGCTCGAGTTACTGGGC Venus C1 XhoI -EcoRI in vivo OE
RBPMS A ∆35 GAGTTAGCGCCTGCTCTTTGAGAATTCGCCGCTTTCACC Venus C1 XhoI -EcoRI in vivo OE
RBPMS RRM AGCGAGGCCACTCGAGGTGAGGAGGAGGTCCGGACC Venus C1 XhoI -EcoRI in vivo OE
CAAGAACAAACTCGTATAGGAATTCAACCCCAGTACTC
RBPMS AB AAGTCCCGGCAGTTCTGCCAGTGTTTCTCTCCAGAGGCA Venus C1 XhoI -EcoRI in vivo OE
GCAGAACTGCCGGGACTT
RBPMS BA GGGAGCTCCCATGTATGCGCTGGCTCCCTC Venus C1 XhoI -EcoRI in vivo OE
RBPMS B HSA CCTGTCTTTTGTCCACCCACTGCAGACCAAC Venus C1 XhoI -EcoRI in vivo OE
GTTGGTCTGCAGTGGGTGGACAAAAGACAGG
RBPMS A AAAAAGCAGGCTCCACCATGGACTACAAAGACCATGACGG pDONR Gateway cloning inducible OE line
AGAAAGCTGGGTTTTAGCAGAACTGCCGGGACTTCCAGCC
rec RBPMS A GCTGCTCGACGGATCCGACTACAAAGACCATG pET21d BamHI -XhoI rec protein
CGAGACACACTCGAGGCAGAACTGCCG
rec RBPMS B GCTGCTCGACGGATCCGACTACAAAGACCATG pET21d BamHI -XhoI rec protein
CTAATACTCGAGACATGGGAGCTC
2.3 Cell culture, transfection and inducible lentiviral cell line 39
Table 2.3 Sequence of the oligonucleotides used in this study for construction of minigene
reporters
Target 5′-3′ sequence Vector Cloning method Experiment
Myocd minigene ATGTCTCGAGGAGCAAGCTCAGAATG pGN-GFP XhoI -EcoRV in vivo
GGGGGATATCAGAGAGATGTTAGG
Myocd mCAC1 pGN-GFP mutagenesis in vivo
CTATGGGGAGGCTGCGGGGGGAGGGGACGGGGGG
Myocd mCAC2 pGN-GFP mutagenesis in vivo
CAGTCGGGGGGGGTAGGGGATGGGGGGGAGAAGC
Myocd mCAC1 MfeI CTATGGGGAGGCTGCGGCAATTGGGGACGGGGGGATGGCC pGN-GFP mutagenesis MfeI CAC1
CTATGGGGAGGCTGCGGCAATTGGGGACGGGGGGATGGCC
Myocd mCAC2 NheI GGCTTCTCCCCCCCATCCGCTAGCCCCCCCGACTGGCTGCC pGN-GFP mutagenesis NheI CAC2
GGCAGCCAGTCGGGGGGGCTAGCGGATGGGGGGGAGAAGCC
Myocd UBE2V1 CAC1 AATTGTACTCACTCACTCTCCACGAGC pGN-GFP MfeI UBE2V1 mCAC1
AATTGCTCGTGGAGAGTGAGTGAGTAC
Myocd UBE2V1 CAC2 CTAGCTACTCACTCACTCTCCACGAGG pGN-GFP NheI UBE2V1 mCAC2
CTAGCCTCGTGGAGAGTGAGTGAGTAG
Myocd RNA substrate GCCAAAGCTTGGACGGGCCATC pG4Z HindIII -EcoRI in vitro
GTGCCGTGAATTCCTCAGGCAGCC
Myocd MS2 hairpin1 AATTGCTAGCGACGATCACGCGCTATC Myocd mCAC MfeI MS2 tethering
AATTGATAGCGCGTGATCGTCGCTAGC
Myocd MS2 hairpin2 CTAGCCTAGCGACGATCACGCGCTATG Myocd mCAC NheI MS2 tethering
CTAGCATAGCGCGTGATCGTCGCTAGG
Flnb GCGGCCGCCCGTGTTCACATGAACACACATG pGEM-Teasy in vivo
GCATGCAATGTCTGAGTCCCAAGAGGC
Flnb minigene GCAGCTGTAGCGGCCGCCCGTGTTCACATG pGN-GFP NotI -SphI PAC1 PCR
GACTAGGTCGCATGCAATGTCTGAGTCC
Flnb mCAC1 GTCCCCCCCCCGATCCCCTCCTCATCCCAACCCCCCTCTCTCTCTC mutagenesis in vivo
GAGGCTCCACACCTAGAAAAGG
Flnb mCAC2 GTAAGATCCCCCTCATGTCCCCCCCTGCTCCCCCCGAATCGCCC mutagenesis in vivo
GAGGCTCCACACCTAGAAAAGG
Flnb mCAC3 GCCTGCTACCCCTCTGCCCCTTTAAAACCCCCCTTCTTTTCCAGGC mutagenesis in vivo
GAGGCTCCACACCTAGAAAAGG
Flnb RNA substrate CCTGGCCAAGCTTGTGTCCC pG4Z HindIII -EcoRI in vitro
GTTGGAATTCGCCTGGAAAAG
Tpm1 exon 3 mCAC GGCGCGCGGTGTGGCCCTGCCCACGAATGGCTAACTTTC pT2 mutagenesis in vivo
GAAAGTTAGCCATTCGTGGGCAGGGCCACACCGCGCGCC
Tpm1 exon 3 mCAC CCTTTATGGTCTACGCCCCCTCAACCCGCCCCTTGCGGGATCACG pT2 mutagenesis in vivo
CGTGATCCCGCAAGGGGCGGGTTGAGGGGGCGTAGACCATAAAGG
Tpm1 exon 3 mCAC GCCCCTTGCGGGATCCCGCTGCCTGCTGCATC pT2 mutagenesis in vivo
GATGCAGCAGGCAGCGGGATCCCGCAAGGGGC
Tpm1 exon 3 mCAC CTGCCTGCTGCATCCCCCCCCCTTCCCCCTTC pT2 mutagenesis in vivo
GAAGGGGGAAGGGGGGGGGATGCAGCAGGCAG
Tpm1 exon 3 mCAC CCCCCTTCCTTCCCCCCCCCCGTACTCCCCTGCCAACTCCCAGC pT2 mutagenesis in vivo
GCTGGGAGTTGGCAGGGGAGTACGGGGGGGGGGAAGGAAGGGGG
Tpm1 RNA substrate TCCACTAAGCTTCCGGGCGCGCG pG4Z in vitro
CAGAGATGCTACGTCAGCTTCAGC
Tpm1 MluI CCC1 CTGTCCTTTATGGTCTACGCGTCCTCAACCCGCCCCTTG mutagenesis MS2 hairpin
CAAGGGGCGGGTTGAGGACGCGTAGACCATAAAGGACAG
Tpm1 BsiWI CCC2 CCCTTCCTTCCCCCCCCCCGTACGCCCCTGCCAACTCCC mutagenesis MS2 hairpin
GGGAGTTGGCAGGGGCGTACGGGGGGGGGGAAGGAAGGG
Tpm1 MS2 hairpin CCC1 CGCGTCTGTGCACGATTACGGCACATGCGA pT2 mCAC MS2 hairpin MS2 tethering
CGCGTCGCATGTGCCGTAATCGTGCACAGA
Tpm1 MS2 hairpin CCC2 GTACGCTGTGCACGATTACGGCACATGCGC pT2 mCAC MS2 hairpin MS2 tethering
GTACGCGCATGTGCCGTAATCGTGCACAGC
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reporter DNA used was 200 ng whereas for RBPMS constructs, the DNA was titrated
to achieve similar levels of expression across isoforms. To keep the amount of DNA
constant, pGEM4Z (Promega) DNA was added to the transfection reactions.
Transfections for transient overexpression in the human cell lines, HEK293 and
HeLa, were achieved in a similar way to the PAC1 cells, although here the transfection
reagent Lipofectamine2000 was used instead. 2x105 cells were plated and incubated
with 2 µL of Lipofectamine2000 and 2 µg of DNA diluted in OptiMEM.
Rbpms depletion in differentiated PAC1 cells was carried out by siRNA knockdown.
1x105 differentiated PAC1 cells were plated on a 6 well plate and then transfected
with Oligofectamine reagent (Invitrogen) and 90 pmol of either the control siRNA
(C2: AAGGUCCGGCUCCCCCAAAUG, Dharmacon) or the Rbpms siRNAs (siRNA1:
RSS363828, GGCGGCAAAGCCGAGAAGGAGAACA , siRNA2: RSS363828, CGCU-
UCGAUCCUGAAAUCCCGCAAA, Stealth, Thermo Fisher Scientifics). After 24
hours, cells were treated one more time with siRNAs, using Lipofectamine2000 and siR-
NAs at the same concentration used in the first treatment. To assess any potential cross
regulation between Rbpms paralogs, an Rbpms2 knockdown was performed alongside a
double knockdown, Rbpms and Rbpms2, using the following Rbpms2 siRNA: RSS367260,
AAGCCUAGAGAACUCUACCUGCUUU (Stealth, Thermo Fisher Scientifics).
In all the transient overexpression and knockdown experiments, RNA and protein
samples were harvested 48 h after transfection.
During the period in which I was establishing the Rbpms knockdown experiments,
Clare Gooding in the laboratory generated inducible lentiviral Rbpms overexpression
cell lines. Firstly, C. Gooding cloned 3xFLAG rat RBPMS A cDNA into pINDUCER22
(Meerbrey et al., 2011) using the Gateway system. Lentiviral particles were then
produced by transiently transfecting 2x106 HEK293T cells with a combination of
0.75 µg of each of the lentiviral packaging plasmids (gag, pol, tat and VSV-G), 7 µg
of the pInduce22 plasmid and 30 µL of Mirus TransIT-lenti (MIR6604) transfection
reagent. The medium was collected 24 h after transfection and replaced with fresh
medium. After a further 24 h the medium was again collected and pooled together
with the first one, which had previously been stored at 4°C. Pooled medium was then
centrifuged at 1000 g for 5 min and filtered through a 0.45 micron PVDF filter. For
transduction of PAC1 cells, 1x104 proliferative PAC1 cells were plated on a 6 well
plate and 24 h later, medium was replaced with the lentiviral medium diluted 1:2 with
fresh medium containing 16 µg/mL polybrene. Cells were incubated with lentiviral
particles for 24 h and medium replaced by fresh medium. Transduced cells were further
expanded as necessary. Lentiviral control populations were obtained by incubating
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proliferative PAC1 cells with medium containing lentiviral particles lacking RBPMS-A
cDNA. Finally, overexpression was induced with 1 µg/mL doxyclycline in medium for
24 h when RNA and protein were harvested.
2.4 Western blotting
Protein levels in depletion and overexpression experiments were verified by western
blotting. Total lysates were harvested by direct addition of protein loading buffer to
the cells followed by nucleic acid digestion with 1 µL nuclease benzonase (Millipore).
Lysates were then run on a SDS-PAGE gel and transferred to Immobilon-FL membrane
(Millipore). The primary antibodies used for detection of specific proteins and loading
controls in this study are listed in Table 2.4. Moreover, donkey anti-mouse and anti-
rabbit IgG (Stratech Scientifica) antibodies conjugated with peroxidase were used at
a 1:10.000 dilution. Luminol/Iodophenol chemiluminescence system was carried for
detection using Fuji Medical X-ray film. Films were then developed and digitalized.
Table 2.4 List of antibodies used in this study
Gene name Antibody Concentration
ACTA2 Agilent/Dako, M0851 1:500
LSM14B Sigma Aldrich, HPA041274 1:1000
MBNL1 In-house polyclonal antibody 1:1000
RBPMS Sigma Aldrich, HPA056999 1:500
FLAG Sigma Aldrich, F-1804 1:2000
GFP Invitrogen, A-11122 1:1500
GAPDH Santa Cruz, sc-25778 1:1000
TUBULIN Abcam, ab6160 1:5000
2.5 Immunostaining
Immunodetection of RBPMS in differentiated and proliferative PAC1 cells was carried
out by growing 5x104 cell on coverslips. After 24 h, cover slips were incubated in 4%
paraformaldehyde (PFA) for 5 min and rinsed with phosphate buffer saline (PBS). To
permeabilize cells, cover slips were transferred to 0.5% NP-40 for 2 min and then rinsed
with PBS. Subsequently, cells were incubated for 1 h with 1% bovine serum albumin
(BSA) in PBS blocking buffer which was then replaced with RBPMS antibodies diluted
in blocking buffer (1:50) and incubation carried for another hour. Primary antibodies
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were removed by PBS washes and coverslips incubated for 1 h with anti-rabbit Alexa
Fluor 647 secondary antibodies (1:500 in blocking solution). After washing off the
secondary antibodies with PBS, coverslips were mounted on ProLong Diamond Antifade
with DAPI (Thermo Fisher Scientific). All the washes and incubations were conducted
at room temperature. For visualization and image acquisition, a fluorescence microscope
(Zeiss Ax10, 40X) attached to CCD AxioCam was used. Finally, acquired images were
analyzed on AxioVision V4.8.2 software.
2.6 RT-PCR and qRT-PCR
Total RNA was extracted using TRI reagent (Sigma) according to manufacturer′s
instructions. Then, RNAs were DNase (Ambion) treated and quantified using a
NanoDrop spectrometer (Thermo Scientific). Next, cDNAs were synthesized and
eventually used to monitor changes in gene expression and splicing by PCR and
qRT-PCR as described below.
cDNA was prepared with 1 µg of total RNA, oligo dT or gene specific oligonucleotides
(Table 2.6) and SuperScriptII (Thermo Fisher Scientific) according to manufacturer′s
protocol. Minus RT reactions lacking the reverse transcription enzyme were also made
to be used as negative controls.
In order to assess gene expression levels, qRT-PCRs were carried out using 50
ng of cDNA, specific oligonucleotides for target gene (Table 2.5) and SYBER Green
JumpStart Taq Ready Mix (Sigma). For the quantitative PCR, the three-step ampli-
fication protocol was carried out in a Rotor-Gene Q instrument (QIAGEN). Finally,
comparative quantitative analysis was performed in the Rotor-Gene Q Series Software
1.7. Relative expression values were obtained by normalizing the quantification of
the target gene to the geometric mean of the quantification of two housekeeper genes,
Gapdh and Rpl32.
Table 2.5 Sequence of the oligonucleotides used in this study for qRT-PCR
Target Species Forward (5′-3′) Reverse (5′-3′)
Rbpms R. norvegicus AAAGCCGAGAAGGAGAACACC TTGAATGGCCTGAAGAGCAG
Rbpms2 R. norvegicus TACGAAGGGTCCTTGATCAAGC TGCGTTTTTGGCTGCTTCTG
Acta2 R. norvegicus TGAAGAGGAAGACAGCACAGC AAACAGCCCTGGGAGCATC
Cnn1 R. norvegicus ACAGATCAACCCCTGGATCAG TTGAGCGTGTCACAGTGTTC
Smtn R. norvegicus CACGCAAGGCCATGATTGAG ATCTGCTTGATGCTGTTGGC
Gapdh R. norvegicus GCCTTCTCTTGTGACAAAGTGGA CCGTGGGTAGAGTCATACTGGAA
Rpl32 R. norvegicus GCCCAAGATCGTCAAAAAGAGG ATCAGGATCTGGCCCTTGAATC
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Table 2.6 Sequence of the oligonucleotides used in this study for minigene reporter
PCR
Minigene Reporter RT oligonucleotide (5′-3′) Forward (5′-3′) Reverse (5′-3′)
Tpm1 and Actn1 GCAAACTCAGCCACAGGT GGAGGCCTAGGCTTTTGCAAAAAG ACAAAAACTCACTGCGTTCCAGGCAATGCT
Myocd and Flnb TAGTTGTACTCC TTGGCAAAGAATTCGCCACCATGGT CGTCGCCGTCCAGCTCGACCAG
To detect splicing isoforms, PCRs were prepared with 50 ng of cDNAs, specific
oligonucleotides (Table 2.6 and 2.7) and Jumpstart Taq DNA polymerase (Sigma). For
visualization and quantification of the splicing isoforms, PCR products were separated
in a QIAxcel Advanced System (QIAGEN) and the percentage of spliced in (PSI) value
calculated with QIAxcel ScreenGel software. In addition to the minus RT reaction, a
no template reaction was also included in all the experiments. PSIs are herein shown
as the mean (%) ± standard deviation (sd) of three experiments, unless otherwise
specified in the text and/or figure legend.
Statistical significance was tested by two tailed unpaired Student t-test for all the
experiments except for the RBPMS-A inducible overexpression where a paired Student
t-test was used. p-value is shown as * p < 0.05, ** p < 0.01 and *** p < 0.001.
2.7 RNAseq and analysis
To globally evaluate RBPMS regulation of mRNA abundance and splicing, an RNAseq
experiment was performed for RBPMS depletion and overexpression in PAC1 cells.
Total RNA was harvested from three biological replicates of RBPMS knockdown in
differentiated PAC1 and three populations of proliferative PAC1 cells overexpress-
ing RBPMS-A and their respective controls. Thereby, the comparison between the
knockdown differentiated PAC1 control and the overexpression proliferative PAC1
control provided insights into the mRNA changes in the biological context of the SMC
phenotypic plasticity in the PAC1 cell line.
PAC1 cells were lysed with TRI reagent and total RNA extraction carried out by
Direct-zol purification column (Zymo research). RNAs were DNase treated (Ambion) to
remove genomic DNA traces from the preparations and next quantified using NanoDrop
spectrometer (Thermo Scientific). polyA RNAseq libraries were then prepared using
NEBNext RNA library kit by the NGS facility in the Wellcome Trust - Medical Research
Council Stem Cell Institute where the sequencing was also conducted on an Illumina
HiSeq4000 platform. Libraries were multiplexed across two lanes and sequenced on a
150 bp paired end mode to generate approximately 60 million reads per sample. Both
RNA samples and RNAseq libraries had their qualities assessed prior to their use.
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Table 2.7 Sequence of the oligonucleotides used in this study for splicing PCR
Gene name Genome Regulated Exon 5′-3′ sequence
Flnb hg19 Chr3:58127584-58127623(+) ATCGCCTCCACTGTGAAAAC
AATCCCAGGCCGTTCATGTC
Mprip hg19 Chr17:17083920-17083983(+) ACCCGGCAACTCAGAAACATC
AGCTTCAACCGTTCTTGCAC
Tpm1 hg19 Chr15:63335905-63336030(+) GAGCTGGCAGAGAAAAAG
AGGAGGACATCGCGGCCA
TCCAACTCTTCCTCAACCAG
Actn1 hg19 Chr14:69345705-69345786(-) ATCAGCCAGGAACAGATG
ACATGAAGTCAATGAAGGCYTG
Ncor2 hg19 Chr12:124811955-124812179(-) ACACCCACAACCGGAATGAGCCTG
GGACTTGGCTTTTCGGCTGCTG
Itga7 rn6 Chr7:3363146-3363278(+) GGGGAGTGGAAGTTCTGTGA
CCTTCCCAGAATCAATGGAG
Tpm1 rn6 Chr8:72840038-72840164(-) AGGAGGACATCTCAGCAA
GAGCTGGCGGAGAAAAAG
CCAACTCCTCCTCAACCAG
Actn1 rn6 Chr6:103379819-103379900(-) ATCAGCCAGGAACAGATG
ACATGAAGTCAATGAAGGCYTG
Flnb rn6 Chr15:18780269-18780341(-) CAGGGAAGGGGAAAGTCACC
ACTCACTGGGACATAGGCCT
Piezo1 rn6 Chr19:55313726-55313798(-) CAACTCCAGTCCACAGACCC
TTCCTCCTCACTGTCCGACT
Ptprf rn6 Chr5:137046364-137046397(-) CGTCAAAGGATGAGCAGTCAATC
CCCATCATTGGCTTTGAGAC
Hspg2 rn6 Chr5:155853492-155853543(+) CTGGGGGTTCAAGTTCCGAC
CGTGCAGACTCTTGGGAACT
Ppfia1 rn6 Chr1:217680291-217680366(-) GCCAGTTGCAAGAACGTCTG
TTGCCATGTCTCTCCTCAGC
Ppfib1 rn6 Chr4:181394960-181394993(+) GACGAAAGGAGAAGGGGTCG
CCATCAGAGACTCCACTGCC
Mbnl1 rn6 Chr2:150864085-150864121(+) AGCTGTACTTCCCCCATTGC
TGGCTAGTCAGATGTTCGGC
Mbnl2 rn6 Chr15:105772324-105772403(+) GCCTTCCCTCCCGGTGCTCTTC
GCAGATTCTTGGCATTCCATTCC
Myocd rn6 Chr10:51733970-51734014(-) CAGTTACGGCTTCAACAGAGAA
TTTTCCTCGGGTCATGGAAC
Arhgef7 rn6 Chr16:83023988-83024213(-) GAAGGTCACGTCTGTGAGCAACC
GTCTTGGGACTCCTGCTGAG
Smtn rn6 Chr14:83758453-83758596(-) TTCTTCCCTGAGGCTTTTGA
TGGTTGTACAGCGATTGCAC
Cald1 rn6 Chr4:62260091-62260175(+) CAGGATGCTGAAGACAAAAAGA
AGGCACAAGACGACAGACTG
TGTGGGTCATGAATTCTCCA
Lsm14b rn6 Chr3:175415535-175415613(+) GCTAAGAAGCTGTTGCCCAG
GCGATTTTGCCCTCTGGAAC
Ncor2 rn6 Chr12:37030871-37031101(+) ACACCCATAACCGGAATGAGCCTG
GGACTTGGCTTTTCGGCTGCTG
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Initial RNAseq analysis as well as the mRNA abundance and splicing analysis
described below were performed by Dr. Miriam Llorian. Briefly, Trimmomatic version
0.36 (Bolger et al., 2014) was used for read trimming and adapter removal. Then reads
were aligned to the Ensembl rat genome Rnor_6.0 release 89 by using STAR version
2.5.2a (Dobin et al., 2013). Finally, RSEM package version 1.2.31 (Li and Dewey, 2011)
was used to perform gene level counts.
2.7.1 mRNA abundance analysis
DESeq2 package (version 1.18.1 ) (Love et al., 2014) was used to identify differ-
ential mRNA abundance levels. Analysis was carried out within R version 3.4.1
(https://www.r-project.org/). A p-adjust less than 0.05 was applied to the paired
analysis results to distinguish genes with statistically significant changes in mRNA
abundance. The p-adjust is the corrected p-value for multiple comparisons, reducing the
number of false positives due to the number of tests. Alterations in mRNA abundance
are expressed in log2 fold change, where a log2 fold change of 1 was used as a threshold
for substantial change.
2.7.2 AS changes analysis
To detect differential alternative splicing in the RBPMS knockdown and overexpression,
Dr. Miriam Llorian used rMATS v 3.2.5 (Shen et al., 2014), allowing for new splicing
event discovery by applying flag novelSS 1. rMATS identifies splicing events from five
main categories: skipped exons (SE), mutually exclusive exons (MXE), alternative 5′
and 3′ splice sites (A5SS and A3SS) and retained intron (RI). Furthermore, rMATS
calculates the inclusion level and provides the statistical significance of each event
identified.
We then applied an additional filter to the exon junctions and reads on target data
to remove false positives generated by events with low read count. For that, all the
identified events that showed a total of read counts in the replicates below 50 reads
were discarded. In addition to that, an FDR less than 0.05 was imposed to the ASEs
to distinguish statistically significant changes. Changes in ASEs were only considered
substantial when displaying an inclusion level difference (∆PSI) greater than |10%|.
For further analysis, unique IDs were created by combining the AS type, gene name
and the chromosomal coordinates of the regulated exon and flanking exons separated
by a ".".
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Sashimi plots were generated by Dr. Miriam Llorian using rmats2sashimiplot (Gohr
and Irimia, 2018). Sashimi plots allow visualization of the differentially regulated
exons by displaying the RNAseq coverage and the reads mapping to the exon-exon
junctions, which are represented by the arches. Moreover, they also show the PSI
values calculated by the geometric mean of the PSI values from the triplicates.
ASEs identified in the RNAseq were experimentally validated by RT-PCR as
described before in Section 2.6. In total twenty eight splicing events from knockdown and
overexpression experiments were validated between me and Clare Gooding. Eventually,
a Pearson correlation between RNAseq predicted and RT-PCR observed ∆PSIs was
tested in RStudio (http://www.rstudio.com/).
Proportional Venn diagrams for visualization of different comparisons in this study
were generated using BioVenn (Hulsen et al., 2008). Venn diagrams were produced to
compare the overlap between genes whose mRNAs were regulated at the abundance
level and also differentially spliced, and also to compare common AS events across
RBPMS knockdown, overexpression and PAC1 dedifferentiation.
The experimental design of the RNAseq experiments, sample preparation and final
data analysis are summarized in Figure 2.1.
2.7.3 Aorta Tissue dedifferentiation dataset
Previously in the laboratory, Adrian Buckroyd and Clare Gooding started the inves-
tigation of the AS in VSMC dedifferentiation. In order to do that, they isolated rat
aortas from 8-12 weeks old Wistar rats. Adventitia was cleaned away by treating tissue
samples with 3 mg/mL collagenase (Sigma C-0130) for 30 min at 37°C. Tissue samples
were then treated to achieve dispersed single cells. Briefly, tissue pieces were treated
with 5 ml 1 mg/mL elastase (Worthington Biochemical Corporation LS002292) for 30
min at 37°C followed by a further 1-2 h treatment with 5 mL collagenase (3 mg/ml).
Dispersed single cells were washed, counted and 4x105 cells transferred to 1 mL of M199
media containing 10% FBS, 2 mM Glutamine and 100 U/mL Penicillin-Streptomycin.
SMCs were then further cultured to promote the proliferative state. For that, cells were
maintained in DMEM media containing Glutamax and 10% FBS and passaged 1:2.
The dedifferentiation of rat aorta VSMC is illustrated in Figure 2.2. Total RNA from
three replicas of the following stages were extracted: aorta tissue (T), enzymatically
dispersed single cultured SMCs (SC), passage 0 (P0) and passage 9 (P9). Each replica
is a result of pooling five rat aorta dissections. Extraction was carried out using
TRI-reagent (Sigma) and mRNA libraries prepared using Ribozero and TrueSeq kits.
Sequencing was performed on a HiSeq2000 in a paired end mode at the Genomic Core
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Fig. 2.1 RNAseq experiment and analysis workflow.
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Facility at the EMBL Heidelberg. Dr. Miriam Llorian conducted the RNAseq analysis
for mRNA abundance and alternative splicing changes using DEseq2 and rMATS as
previously described in this section.
This tissue dataset was then used as a source of genes transcriptionally as well as AS
regulated during aorta tissue dedifferentiation. As a note, in most of the comparisons
with PAC1 experiments, the comparison between the most differentiated and most
proliferative VSMC samples, T and P9 respectively, was used.
Rat Aorta Tissue
(T)
Single Cells
(SC)
Passage 0
(P0)
Passage 9
(P9)
Enzymatically
dispersed
in vitro
culture 
in vitro
culture 
Fig. 2.2 Aorta dedifferentiation schematic.
2.8 RBPMS motif enrichment analysis
To identify RBPMS recognition elements around regulated skipped/cassette exons,
the toolkit Matt (Gohr and Irimia, 2018) was used. Motif enrichment analyses were
performed by Dr Aishwarya Jacob in the laboratory. Enrichment of optimal RBPMS
binding sites, CAC-N1-12-CAC (Farazi et al., 2014), were carried out for aorta tissue and
PAC1 dedifferentiation and RBPMS depletion and overexpression data-sets. During the
analysis ASEs were separated into three groups: 1) unregulated, 2) downregulated and
3) upregulated. Events were considered unregulated when showing an FDR between
0.1 and 1 and a |∆PSI| lower than 5%. Significantly regulated events (FDR<0.05) were
separated into downregulated, ∆PSI< -10%, and upregulated, ∆PSI> 10%. Intronic
sequence analysis was performed by using 250 bp upstream and 250 bp downstream of
the regulated skipped exon. For the motif analysis, Matt toolkit divides the exon and
introns into three segments that are individually analyzed for motif fold enrichment
and statistical significance. For the RBPMS maps, also generated using Matt, a sliding
window of 31 was applied to the motif enrichment analysis that extended to the flanking
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exons and far intronic sequences. The regions used in the motif analysis are further
described in the figures.
2.9 Gene ontology analysis
Gene ontology (GO) terms enriched in the differentially abundant and spliced genes
were obtained using Gorilla (Eden et al., 2009). A background list of all the genes
expressed in either the PAC1 cells or aorta tissue was generated by filtering out genes
whose expression was below 1 TPM (transcripts per million) in both conditions within
the comparison. For gene expression, genes with statistical significant changes in
mRNA abundance were divided into differentially upregulated or downregulated and
the enrichment analysis individually carried for each list. For the differentially spliced
genes, GO analysis was restricted to the SE category. Moreover, only genes containing
AS events with |∆PSI| greater than 10% were used in the analysis. Enriched terms
were then sorted by p-value and only the top five significant GO terms from each
category (biological process, cell component and molecular function) are shown in the
results.
2.10 PPI analysis
To get insights into the potential protein-protein network affected by RBPMS splicing
control, a PPI analysis was carried out using STRING version 10.5 (Szklarczyk et al.,
2017). The PPI network was constructed focusing on core functions of RBPMS.
Therefore, target events were restricted to events that were co-regulated between
PAC1 dedifferentiation and RBPMS knockdown in combination with events commonly
spliced in aorta tissue dedifferentiation and RBPMS overexpression. Furthermore, a
|∆PSI| greater than 10% was again applied. In view of its better curation, the human
database was chosen for the analysis. Default parameters were also adjusted as followed:
confidence as the meaning of the network edges, experiments and databases as the only
sources of interaction and the minimum interaction score as high confidence (0.700).
Functional GO enrichments were also retrieved from STRING analysis, although the
whole human genome was used for the statistical enrichment in this case.
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2.11 Recombinant protein
2.11.1 Induction of protein expression
Recombinant RBPMS-A and RBPMS-B containing a T7 and a 3xFLAG tag at the
N-terminus and a His6 tag at the C-terminus were expressed in E. coli (Figure 2.3).
pET21d vectors containing either RBPMS-A or RBPMS-B were obtained as described
in Section 2.2. BL21 competent E. coli cells were then transformed and a single colony
was inoculated in 400 mL 2x yeast extract-tryptone (YT). At an OD of 0.7, 1 mM
IPTG was added to induce expression of recombinant protein at 37°C for 3 h. Cells
were resuspended in lysis buffer (50 mM NaPO4 pH8, 200 mM KCl, 3 mM MgCl2, 0.1
mM EDTA, 1 mM DTT, 0.05% NP-40, 5% glycerol and 1 mM PMSF) and lysed using
a French Press. Lysates were centrifuged at 8.000 rpm for 10 min at 4°C to collect
soluble and insoluble fractions. An SDS-PAGE gel was run for analysis of the soluble
and insoluble fractions alongside uninduced and induced samples previously collected
(Figure 2.3).
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Fig. 2.3 RBPMS protein expression. Induction of RBPMS-A and RBPMS-B
containing an N-terminal T7 and FLAG tags and a C-terminal His6. Arrows indicate
induced RBPMS isoforms.
2.11.2 Purification of RBPMS
Soluble recombinant RBPMS-A was then first purified using Blue Sepharose 6 and
finally a HisTrap HP column in the AKTA protein purification system. Recombinant
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RBPMS-B was purified only through the latter column, given the low affinity to the
first purification column. After that, recombinant proteins were then dialysed overnight
in buffer E (20 mM Hepes pH7.9, 20% glycerol, 0.1 M KCl, 0.2 mM EDTA and 0.5 mM
DTT). Purity and integrity of the recombinant proteins were assessed by SDS-PAGE
polyacrylamide electrophoresis. Furthermore, amino acid sequence was confirmed by
western-blot using RBPMS specific antibodies and also by mass mapping by mass
spectrometry. Proteins were quantified by BSA titration and NanoDrop spectrometer
(Thermo Scientific).
2.12 In vitro transcription and binding assays
2.12.1 In vitro transcription
RBPMS direct binding to target RNAs was addressed by using two in vitro binding
assays: electrophoretic mobility shift assay (EMSA) and UV-crosslinking. For both
assays in vitro transcribed RNAs were produced from the constructs described in
Section 2.2. Briefly, RNAs corresponding to the intronic regions containing CACs
downstream of the regulated FlnB exon H1 and Myocd exon 2a and upstream of the
Tpm1 exon 3 were transcribed in vitro by SP6 RNA polymerase. The gel purified
linearized DNA constructs containing the promoter sequence for SP6 RNA polymerase
were used as templates. Each transcription reaction used 1 µg of DNA. For in vitro
binding assays, high-specific activity protocol was performed. The reaction containing
2 µL of 5x transcription buffer (30 mM MgCl2, 10 mM spermidine, 0.2 M Tris-HCl,
pH 7.5), 0.5 µL RNase inhibitor (Dundee Cell), 0.5 µL 10 mM RNA cap analogue
(Promega), 1 µL water, 1 µ RNA polymerase and lastly 2 µL of 0.37 MBq/µL [α-
32P]UTP was then added to the transcription reaction for incorporation in to the
RNAs. Reactions were incubated at 37°C for an hour and diluted in water in a 1:5
dilution. 1 µL of the dilution was separated for total count quantification. Finally,
RNAs were purified by phenol extraction and through a G-50 column (ProbeQuant)
by centrifugation at 3.000 rpm for 2 min to remove unincorporated nucleotides. Lastly,
1 µL of the final purified RNAs and the previously reserved 1 µL total sample were
quantified using a Beckman LS 3801 scintillation counter. The [incorporated RNA
counts x final volume]/[total RNA counts x 50 µL] could then be used to calculate the
percentage yield. Amount of RNA transcribed is finally calculated as [%yield/100] x
[mass of the nucleotide x number of nucleotides x UTP concentration x volume]. In
vitro transcribe RNAs were then diluted to 20 fmol/µL.
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2.12.2 EMSA
EMSA or band shifts were performed to detect binding between in vitro transcribed
RBPMS-splicing target RNAs and RBPMS. Firstly, binding reactions were achieved
by incubating the recombinant protein in a serial dilution (0, 0.125, 0.5 and 2 µM)
with 10 fmol of in vitro transcribed RNAs in binding buffer (10 mM Hepes pH7.2-7.9,
3 mM MgCl2, 5% glycerol, 1 mM DTT and 40 mM KCl) for 25 min at 30°C. 1µL
of 50% glycerol was added to the reactions that were then loaded onto a 4% 60:1
acrylamide and Bis ratio nondenaturing gel. "Conventional" gels were initially used
(6% 30:1 acrylamide and Bis ratio), but RBPMS-RNA complexes did not go through
the gel and remained retained in the well. Therefore, a different Bis/acrylamide ratio
as well as percentage were optimized for the band shift assays. Gels were then dried
and Fuji Medical X-ray film used for detection. Films were then developed.
2.12.3 UV Crosslink
For UV-crosslinking, the same binding reaction for EMSA was performed followed by
UV-crosslink on ice in a Stratalinker with 1920 mJ. Next, an RNase mix, containing
RNase A and T1, was added and reactions further incubated for 10 min at 37°C.
Finally, 4X SDS sample buffer was added to the binding reactions which were then
heated at 80°C for 5 min prior to loading on a 20% denaturing polyacrylamide gel.
Gels were then dried and Fuji Medical X-ray film used for detection. Films were then
developed.
2.13 Statistical analysis
Statistical tests applied in each experiment are explained in its corresponding method
section and it is also described in the figure legends. In all the experiments, p-value is
shown as * p < 0.05, ** p < 0.01 and *** p < 0.001. Data analysis and visualization
was carried out using RStudio (http://www.rstudio.com/).
2.14 Data availability
All mRNAseq data from this study have been deposited in NCBI Gene Expression
Omnibus (GEO) repository under GEO accession GSE127800, in which GSE127799
represents the RBPMS knockdown and overexpression in rat PAC1 cells and GSE127794
the rat aorta tissue dedifferentiation in culture.
Chapter 3
RBPMS: a potential SMC master
regulator
3.1 Introduction
3.1.1 Splicing master regulators
For a long time, cell-identity has been studied under the transcription perspective,
which led to the identification of a small number of transcription factors so called master
transcription factors (Young, 2011). These factors determine cell states by initiating
the gene expression program of a particular cell type. Interestingly, the existence of
similar regulators at the post-transcriptional level has recently been proposed. Such
"master splicing regulators" would consist of a subset of splicing factors able to reshape
and maintain a tissue transcriptome upon external cues during development (Jangi
and Sharp, 2014). Indeed, AS contributes to a layer of a cell specific transcriptome by
generating protein isoforms and also quantitatively regulating transcripts via NMD.
Therefore, the highly interconnected splicing regulated genes form a robust cell specific
network that retains its capability to respond to environmental stimuli (Jangi and
Sharp, 2014).
For Jangi and Sharp, some of the properties expected for a master regulator would
be:
1. Requirement for differentiation, specification and/or maintenance of a cell-type
2. Expression in a tissue-specific manner
3. Wide dynamic range of activity not limited by auto-regulation
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4. Highly regulated only responding to external signals, in other words not regulated
from within the splicing network itself
5. Likely to control transcription factors and other post transcriptional regulators
6. Regulation of functionally related direct and indirect targets that are important
for cell phenotype and identity
Taken these hallmarks of master splicing regulators, manipulation of their levels
such as by depletion or misexpression would result in either incomplete differentiation
or promotion of the differentiation towards the cell-type in which that master regulator
is normally expressed (Jangi and Sharp, 2014). Even though these characteristics dis-
tinguish master regulators from other splicing factors, identification of these regulators
in a cell type is still very difficult.
Master regulators of splicing could be identified by either their response to particular
cell type signal or by the tissue specific transcriptional control (Jangi and Sharp, 2014).
Due to the difficulties faced by the former approach (Heyd and Lynch, 2011), the
latter seems to be the best strategy for the identification of cell-type master regulators.
In fact, Jangi and Sharp suggested key splicing factors of a tissue are likely to be
activated by super-enhancers (Figure 3.1). Thereby, master regulators could potentially
be identified via the association of their genes with super-enhancers.
3.1.2 Super-enhancer associated RBPs
Different from normal transcriptional enhancers, super-enhancer regions consist of
clusters of enhancers highly occupied by transcription factors, driving high-level of
expression of their associated genes (Hnisz et al., 2013). Tissue-specific super-enhancers
drive the expression of genes important for cell identity and function as revealed by a cat-
alog of human tissue super-enhancers generated in (Hnisz et al., 2013). Super-enhancer
sequences are distinguished by the enrichment for transcriptional machinery compo-
nents, histone modifications marks such as methylation and acetylation (H3K4me1 and
H3K27ac) and lastly the presence of conserved binding sites for transcription factors
(Shin, 2018). Therefore, it is plausible that RBPs activated by super-enhancers could
be critical for the reshaping of a cell-type transcriptome, acting as master splicing
regulators, as suggested in Jangi and Sharp (2014).
RBM24 and RBM38 are examples of post-transcriptional master regulators of
myogenesis whose gene expression is driven by super-enhancers (Jangi and Sharp,
2014). Rbm24 and its paralog, Rbm38, are marked by super-enhancers in adult skeletal
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Fig. 3.1 Super-enhancer associated RBPs could act as master splicing regu-
lators. Illustration of a cell type specific super-enhancer associated with the activation
of a master splicing regulator that can then reshape the cell transcriptome, as suggested
in Jangi and Sharp (2014).
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muscle and have been implicated in myogenesis by post-transcriptionally controlling
p21 (Jin et al., 2010; Miyamoto et al., 2009). Both proteins are known to be activated
by the master transcription factor, MyoD, early in the differentiation, which leads to
the stabilization of myogenin and p21, an important myogenesis factor and a cell-cycle
key regulator respectively (Jin et al., 2010; Miyamoto et al., 2009). Moreover, these
two RBPs can build a robust skeletal-muscle splicing network by co-regulating events
with another splicing regulator, Rbfox1 (Zhang et al., 2008).
Finally, it has also been shown that super-enhancers are enriched for disease-
associated variations, expanding the implications of super-enhancers from healthy
tissues to also disease states. Not surprisingly, super-enhacers have more recently also
been involved in tumorigenesis, in which acquisition of super-enhancers were observed
for oncogenic genes (Hnisz et al., 2015). Therefore, super-enhancers have also been
exploited as targets for disease treatment and diagnosis, by small molecule inhibitors
and potential gene therapy (Shin, 2018).
In this chapter we set to find RBPs that could act as master splicing regulators of
the SMCs via their association with super-enhancers, thereby identifying regulators that
could potentially play a critical role in establishing or maintaining the differentiated
splicing program of these cells.
3.2 Results
3.2.1 RBP genes associated with SM super-enhancers
To identify potential master splicing regulators of SM tissues, publicly available datasets
of super-enhancer associated genes across different human tissues (Hnisz et al., 2013)
and the curated list of human RBPs containing 1542 proteins (Gerstberger et al.,
2014) were used. Datasets of super-enhancer associated genes from aorta (1143 genes),
bladder (412 genes) and stomach SM (974 genes) were selected as SMC rich tissues as
described in Chapter 2. In addition to that, skeletal muscle (1078 genes) was chosen
as an outlier tissue dataset. Firstly, the RBP genes associated with super-enhancers
in each tissue were identified. 67, 36, 70 and 98 RBP genes were found associated
with super-enhancers in aorta, bladder, stomach SM and skeletal muscle respectively.
Next, RBP genes associated with SM tissues but not skeletal muscle were found by
comparing the lists as shown by the Venn diagram (Figure 3.2). Only nine RBP
genes met this criteria: CPSF4L, DHX16, IMP3, LSM4, RBPMS, RPL10A, RPL11,
SETD1B and TNRC6C. Furthermore, using a set of super-enhancer associated genes
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in the dbSUPER database (Khan and Zhang, 2016), two RBP candidates were found
in SM tissues, of which only RBPMS was shared with the original nine candidates
(Figure 3.2).
RBP genes associated with human super-enhancers
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Fig. 3.2 Nine RBP genes were found associated with human SM tissue
super-enhancers. Venn diagram comparing the RBP genes associated with human
super-enhancers from three SM tissues (aorta, bladder and stomach - all in green) and
one outlier tissue, skeletal muscle (purple). On the left, RBP genes found specifically
associated with SM super-enhancers.
The mRNA levels of these RBP genes were then investigated in the rat aorta tissue
dedifferentiation dataset (samples generated in the laboratory by Adrian Buckroyd
and Clare Gooding and RNAseq analyzed by Miriam Llorian - Chapter 2.7.3). mRNA
abundance levels were obtained from rat aorta tissue (T), enzymatically dispersed SMCs
(SC), and from SC grown in cell culture to promote dedifferentiation and harvested at
passage 0 (P0) and passage 9 (P9). Expression data was retrieved for all the candidate
regulators, but Cpsf4l, which was not found in the RNAseq analysis (Figure 3.3). From
the eight RBP genes only Rbpms, Setd1b and Tnrc6c showed a significant gradual
decrease in their mRNA abundance during dedifferentiation. Furthermore, in terms of
the absolute expression levels, measured in transcripts per million (TPM), apart from
the ribosomal protein coding genes, Rpl10a and Rpl11, Rbpms was the only gene that
showed considerable expression level in aorta tissue (∼ 50 TPM), which was around
five-fold greater than the other candidates (∼10 TPM).
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Fig. 3.3 mRNA expression levels of potential SM master regulators in rat
aorta dedifferentiation. mRNA expression of the nine RBP identified associated
with SM super-enhancers was assessed during rat aorta dedifferentiation. Expression
in transcripts per million (TPM) is shown for aorta tissue (T), enzymatically dispersed
SMCs (SC), passage 0 (P0) and passage 9 (P9). Smtn, Acta2 and Cnn1 are shown
as SMC markers. Statistical significance calculated by DESeq2 between T and P9 is
displayed as * p < 0.05, ** p < 0.01 and *** p < 0.001. Cpsf4l was not found to be
expressed in the rat VSMCs.
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Rbpms expression during rat aorta dedifferentiation was then compared to its paralog
Rbpms2 levels (Figure 3.4). Rbpms mRNA abundance decreased ∼4-fold from tissue
to passage 9 whereas Rbpms2 showed a greater fold change in its mRNA level, ∼8 fold
lower in P9. However, Rbpms2 mRNA absolute level (∼4 TPM) was approximately ten
times lower than Rbpms expression (Figure 3.4). Moreover, changes in Acta2, a SMC
transcriptional marker, are consistent with the rat aorta dedifferentiation. Changes in
the expression of other RBPs known to regulate AS in SMC, e.g. MBNL1, PTBP1
and QKI, were either small or increased in aorta proliferative state (P9) (Figure 3.4).
In addition to that, all these RBPs were expressed at similar levels at their maximum
expression level (40 to 80 TPM range).
TP
M
Rbpms2
T SC P0 P9
0
1
2
3
4
***
Mbnl1
T SC P0 P9
0
20
40
60
80 ***
Ptbp1
T SC P0 P9
0
10
20
30
40
**
LOC108348175 (Qki)
T SC P0 P9
0
10
20
30
40
**
−10
−5
0
5
10
100 101 102 103 104 105 106
Mean of normalised counts
Lo
g2
 F
ol
d 
Ch
an
ge
P9 vs T
2529
3131
Rbpms
Rbpms2 Acta2
Fig. 3.4 Rbpms2 is less expressed in VSMC. Left, MA plot for the alterations
in mRNA abundance between rat aorta tissue and passage 9 (P9 vs T). Genes with
significant change (padj<0.05) in their mRNA abundance are coloured in dark gray.
Genes with p-adj values ≥0.05 are shown in light gray. Rbpms, Rbpms2 and Acta2, a
SMC marker of differentiation, are highlighted in red. Horizontal lines indicate log2
fold change 1 and -1. Numbers found at top and bottom right indicate upregulated
and downregulated genes, respectively. Right, mRNA expression level of Rbpms2
and other RBPs (Mbnl1, Ptbp1 and Qki) during rat aorta dedifferentiation are shown
in transcripts per million (TPM). Aorta tissue (T), enzymatically dispersed SMCs
(SC), passage 0 (P0) and passage 9 (P9). Statistical significance calculated by DESeq2
between T and P9 is displayed as * p < 0.05, ** p < 0.01 and *** p < 0.001.
RBPMS transcript expression was further examined across different human tissues
in the Genotype-Tissue Expression (GTEx) project (Lonsdale et al., 2013) (Figure
3.5). RBPMS was highly expressed in SM tissues, as highlighted by the top ten human
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tissues expressing RBPMS, which includes bladder and three different arteries (tibial,
aorta and coronary).
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3.2.1.1 RBPMS in PAC1 cells
Rbpms expression was also assessed in the rat pulmonary arterial SM cell line, PAC1
(Rothman et al., 1992) (Figure 3.6). This cell line maintains differentiated properties
in culture and can also be grown towards a more proliferative phenotype in culture
as described in (Llorian et al., 2016). Therefore, PAC1 cells allow modeling of SMC
phenotypic modulation in culture. In the PAC1 cells, qRT-PCR revealed that Rbpms
mRNA expression was also downregulated in the proliferative state, ∼5 fold reduction
compared to the differentiated PAC1 (Figure 3.6A). On the other hand, Rbpms2
expression was not regulated during PAC1 dedifferentiation. PAC1 dedifferentiation
was confirmed by the downregulation of SMC transcriptional markers (Acta2, Cnn1
and Smtn). RBPMS protein levels were then assessed by western blotting, showing that
RBPMS protein was reduced to below detection in the proliferative cells (Figure 3.6B).
The SMC marker ACTA2 was also only detected in the differentiated PAC1 state.
In agreement with the qRT-PCR and western blot, immunofluorescence confirmed
RBPMS high expression in the differentiated PAC1 cells (Figure 3.6C). Furthermore,
immunofluorescence disclosed RBPMS predominantly nuclear localization, consistent
with its potential role as a splicing regulator.
Therefore, RBPMS association with SM super-enhancers, its high expression in
human SM tissues, modulation of its expression during rat aorta and PAC1 dediffer-
entiation, together with its nuclear localization supported this RBP as a promising
candidate for a master post-transcriptional regulator of SMCs.
3.2.2 Splicing regulation by RBPMS
To test the hypothesis that RBPMS regulates alternative splicing in SMC, rat Rbpms
cDNAs were cloned from differentiated PAC1 cells (Chapter 2.2.7). In total, seven
protein isoforms were identified and their exon arrangement are found in Figure 3.7.
The differences in the protein sequence of isolated RBPMS isoforms and RBPMS2
are highlighted in the alignment in Figure 3.8. The two main isoforms identified were
RBPMS A and B, determined by the inclusion of either exon 7 (alternative 3′ end)
or exon 8. Consequently this ASE affects the C-terminus of the protein isoforms
(Figure 3.9). Hence, the two bands observed in the western blot corresponded in size
to RBPMS-A and B (Figure 3.6B). The other RBPMS minor isoforms, apart from
Rbpms-A.3, are mainly generated by exclusion of exon 6. In that way, they all contain
an intact RRM domain (encoded by exons 2-5) with protein variation mainly restricted
to their C-terminus (Figure 3.7 and 3.8). In Rbpms-A.3 transcript isoform, exons
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Fig. 3.6 RBPMS is strongly downregulated during PAC1 cells dedifferenti-
ation. A Relative mRNA expression levels of Rbpms and Rbpms2 in differentiated
(green) and proliferative (blue) PAC1 cells quantitated by qRT-PCR. Expression levels
of SMC differentiation markers, Acta2, Cnn1 and Smtn, are also shown. Points in
the bar graphs show data from individual samples from the triplicate and the mean is
indicated with the bar. Statistical significance from a two tailed unpaired Student’s
t-test is shown as * p < 0.05, ** p < 0.01 and *** p < 0.001. B Western blot for
RBPMS in rat PAC1 cells. ACTA2 was used as a SMC differentiation marker and
GAPDH as a loading control. C Immunofluorescence in rat PAC1 cells for RBPMS.
Middle panel show DAPI staining for nuclei. Differentiated and proliferative PAC1
cells are indicated as D and P, respectively.
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2-4 are not included, encoding an RBPMS isoform lacking most of its RRM domain
(Figure 3.7 and 3.8). On the other hand, only one isoform from Rbpms2 was cloned
from PAC1 cells. This single RBPMS2 isoform shares ∼70% identity with RBPMS-A.
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Fig. 3.8 Alignment of RBPMS protein isoforms and RBPMS2 identified in
PAC1 cells Multiple alignment of rat RBPMS isoforms and RBPMS2 was generated
using CLUSTAL O (1.2.4) and visualized with MView. Amino acids were colored using
RBPMS2 as the reference sequence (bright green - hydrophobic, dark green - large
hydrophobic, purple - polar, red - positive charge, dark blue - negative charge, bright
blue - small alcohol, yellow - cysteine).
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Fig. 3.9 RBPMS-A and RBPMS-B are the major isoforms in PAC1 cells
Schematic of the two main RBPMS protein isoforms identified in rat differentiated
PAC1 cells. The alternative 3′ end exon that gives rise to the RBPMS isoforms is
shown in the middle. Amino acid sequences of the distinct C termini are highlighted.
Because RBPMS motifs had previously been resolved as tandem CACs separated
by variable spacer length (1-12 nt) (Farazi et al., 2014), an RBPMS motif enrichment
analysis was carried out for skipped exons differentially regulated between rat aorta
tissue and passage 9 (Figure 3.10). Significant enrichment for RBPMS binding sites
was observed upstream of and within exons more included in proliferative cells (∼1.4
fold) (Figure 3.10). Interestingly, this location of RBPMS motifs, if in agreement
with a position-dependent alternative splicing activity shown for many other splicing
regulators (Fu and Ares, 2014; Witten and Ule, 2011), suggests RBPMS as a repressor
of proliferative exons. Thus, RBPMS binding sites around exons regulated during rat
aorta dedifferentiation further supported a potential function of RBPMS as a splicing
regulator in SMCs.
Consistent with the RBPMS motif enrichment analysis, SMC-specific splicing events
previously characterized in the laboratory, such as the mutually exclusive pair of exons
in Tpm1 and Actn1 (Gromak and Smith, 2002; Southby et al., 1999), contain conserved
clusters of CACs (Figure 3.11). Conserved CACs were found around Tpm1 exon 3
and upstream of Actn1 NM exon (Figure 3.11). These two exons are repressed in
differentiated SMC, being more included in proliferative SMCs. So, both Actn1 and
Tpm1 exons were expected to be targets for repressive regulation by RBPMS.
To address whether RBPMS could regulate AS of SMC exons, RBPMS isoforms
and paralog were tested upon regulation of the SMC minigene splicing reporters Tpm1
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Dierentiated cassette exon
Proliferative cassette exon
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CACN1-12CAC enrichment
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Fig. 3.10 RBPMS motifs are enriched upstream of exons less included in
aorta tissue. Enrichment for optimal RBPMS motif, a pair of CAC separated by 1-12
nt (Farazi et al., 2014), around regulated skipped exons in the rat aorta tissue - passage
9 comparison (T - P9) was obtained by using Matt toolkit (Gohr and Irimia, 2018).
Motif enrichment analysis for aorta differentiated (green) and proliferative (blue) exons.
Numbers represent the motif fold enrichment and statistical significance is shown as *
p < 0.05, ** p < 0.01 and *** p < 0.001.
(Figure3.12A) and Actn1 in PAC1 cells (Figure3.12B). Initially, all the RBPMS isoforms
cloned from PAC1 cells were tested, but exon 6 skipped isoforms were either expressed
at very low levels or not even detected. This was part of the evidence for dismissing
some of these isoforms. Also the C-terminal amino acid sequences of these framshifted
isoforms are less conserved than RBPMS-A and B, consistent with them not being
functional protein-coding isoforms. Therefore all the overexpression experiments were
carried out only using RBPMS-A, RBPMS-B and RBPMS2. In both experiments,
PAC1 transfections were carried out in proliferative PAC1 cells, in which RBPMS
is less expressed therefore its overexpression would lead to stronger effects. Indeed,
both minigene reporters showed a starting splicing pattern of less differentiated SMC -
nearly complete inclusion of the Tpm1 exon 3 and the Actn1 exon NM (Figures 3.12).
RBPMS was sufficient to promote the differentiated splicing pattern, yet different
splicing activity was observed between isoforms. RBPMS-A overexpression led to a
switch of Tpm1 and Actn1 splicing isoforms, by reducing inclusion of exon 3 from
94.7% to 43.5% and exon NM from 100% to 21%. RBPMS2 showed similar activity to
RBPMS-A but switching splicing to a less extent. Strikingly, RBPMS-B was the least
active protein causing minor changes in splicing of Tpm1 reporter, ∼10% skipping of
exon 3 compared to Venus and no changes in Actn1 exon NM splicing. RBPMS-B
lower activity in repression of Tpm1 exon 3 could be due to its lower protein expression
compared to RBPMS-A, as indicated by the western blotting. On the other hand,
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Tpm1
Actn1
Fig. 3.11 SMC splicing markers contain conserved CAC motifs. Screenshots
from USCS genome browser. A Conserved CAC motifs upstream, top, and downstream,
bottom, of Tpm1 exon 3 are highlighted in blue. Top dark blue box correspond to
Tpm1 exon 3. B CAC motifs conserved upstream of Actn1 exon NM is shown in blue.
Top purple box indicates Actn1 exon NM. Basewise conservation track and multiple
alignment were generated by PhyloP and Multiz Alignments in the UCSC genome
browser. Chr coordinates from rn6 : chr8:72,840,094-72,840,283; chr8:72,839,906-
72,840,095; chr6:103,379,884-103,379,963.
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Actn1 exon SM was only included upon RBPMS-A overexpression despite RBPMS-B
being more expressed than RBPMS-A in this experiment. Thus, at least in the case of
Actn1 splicing, RBPMS isoforms showed differential activity not associated with its
protein expression levels.
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Fig. 3.12 RBPMS promotes the SM splicing pattern of Tpm1 and Actn1
in PAC1 cells. A Splicing of Tpm1 minigene reporter was tested upon overexpression
of Venus tagged RBPMS isoforms, A and B, and RBPMS2 in PAC1 cells. Reporter
only and Venus controls were also tested. Top, RT-PCRs to detect exon 3 included
and excluded isoforms, larger and smaller products, respectively. Moreover, schematics
on the left indicates the RNA isoforms. Percentage of spliced in (PSI) values for exon
3 are shown below the gel image. Bottom, western blot anti-GFP for detection of
the expression of Venus tagged proteins. GAPDH was used as a loading control. B
Splicing of the Actn1 minigene reporter was also tested upon overexpression of Venus
tagged RBPMS isoforms A and B, and RBPMS2 in PAC1 cells as similarly described
for the Tpm1 reporter. For the Actn1 minigene reporter, the PSI of the NM exon is
shown. Top, RT-PCR for the different splicing isoforms and bottom, western blot to
verify overexpression. In the schematics for the RNA splicing isoforms, green indicates
differentiated exons and blue proliferative exons. A minus RT and a no template
control were also carried out for every RT-PCR (data not shown). Protein size markers
are also indicated on the right of the western blots. Both experiments are n =1, so no
statistical significance test was performed for any of the experiments.
Due to the difficulties in achieving reasonable transfection efficiency in PAC1 cells,
RBPMS ability to switch AS was tested in the human cell line HEK293, which is
generally easier to transfect (Figures 3.13). Rat RBPMS-A, RBPMS-B and RBPMS2
were transiently overexpressed in HEK293 cells and changes in endogenous AS assessed.
As expected from non-smooth muscle cells, TPM1 and ACTN1 smooth muscle specific
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exons were not included at all in the Venus controls (Figures 3.13). Transfection of
RBPMS-A, RBPMS-B and RBPMS2 caused a substantial shift towards TPM1 exon
2 (∼37% average inclusion), which is more included in differentiated SMC. On the
other hand, RBPMS effects on ACTN1 splicing in HEK293 cells were similar to the
regulation of the Actn1 minigene reporter in PAC1 transfections. RBPMS isoforms
showed differential activity, where RBPMS A and 2 were the most active proteins
despite being less expressed then RBPMS-B. RBPMS-A and RBPMS2 produced more
ACTN1 transcripts with the NM exon excluded in HEK293 cells, ∼60% (Figure 3.13).
In addition to the proliferative exons, two new activation events were also tested,
FLNB exon H1 and MPRIP exon 23. These splicing targets were identified by re-
analysis of RBPMS overexpression in HEK293 RNAseq data from Farazi et al. (2014).
This reanalysis of the RNAseq data was performed by Dr. Miriam Llorian using rMATS
instead of DEXSeq as in the original study. Validation of these differentiated events
surprisingly showed that all the proteins were able to activate splicing of both exons.
RBPMS promotion of inclusion was clear in the HEK293 cells (Figure 3.13) in which
the basal inclusion levels of FLNB and MPRIP in the controls were low (∼30% and 7%
respectively). RBPMS overexpression in HEK293 cells increased the inclusion of FLNB
exon H1 by ∼10 folds (from 5% up to 57%). Exon 23 was included in the majority
of MPRIP transcripts upon overexpression of RBPMS proteins, approximately 70%.
Therefore, these data indicate that RBPMS can regulate splicing by activating SM
exons and repressing NM exons and that RBPMS is also sufficient to promote the SM
differentiated splicing in non-smooth muscle cells. Curiously, RBPMS-A was more
active than isoform B, despite higher expression of RBPMS-B than RBPMS-A in some
experiments. In that way, this suggests that the differential activity between isoforms
results from their distinct protein sequences.
The human cell line, Hela, was also tested upon RBPMS overexpression (Figure
3.14). In HeLa cells, endogenous TPM1 was not detected, so RT-PCRs are not shown.
Likewise HEK293 and PAC1 transfections, RBPMS was able to regulate splicing of
ACTN1, FLNB and MPRIP. However, the effects upon the activation events, FLNB
andMPRIP were less impressive, mainly because the starting splicing pattern is already
most of the way towards inclusion. Thus, RBPMS could not promote the inclusion
pattern much more, yet significant changes were observed. Once more, differential
splicing activity in the regulation of ACTN1 was observed, being RBPMS-B less active,
even though its protein level was similar to RBPMS2. Thus, RBPMS overexpression
was sufficient to promote SMC splicing patterns not only in the SM cell line, PAC1,
but also in two unrelated human cell lines with similar effects.
72 RBPMS: a potential SMC master regulator
ACTN1
***
MPRIP
Mo
ck
Ven
us
RB
PM
S-A
RB
PM
S-B
RB
PM
S2
Mo
ck
Ven
us
RB
PM
S-A
RB
PM
S-B
RB
PM
S2
PSINM
± sd
100.0
± 0.0
100.0
± 0.0
42.5
± 3.2
***
100.0
± 0.0
43.1
± 4.3
***
PSI23
± sd
34.7
± 0.9
33.0
± 0.7
72.0
± 5.7
***
68.2
± 1.0
***
75.1
± 3.1
***
PSISM
± sd
4.7
± 7.8
0.0
± 0.0
40.9
± 12.6
**
31.8
± 9.8
**
38.7
± 14.7
*
PSIH1
± sd
6.7
± 1.9
4.8
± 0.2
57.4
± 9.3
***
45.1
± 3.1
***
72.2
± 1.0
***
FLNBTPM1
***
GFP
GAPDH
58 kDa
25 kDa
32 kDa
Fig. 3.13 RBPMS switches the SM differentiated splicing in HEK293 cells
Venus tagged RBPMS isoforms and RBPMS2 were overexpressed in HEK293 cells.
Splicing of endogenous TPM1, ACTN1, FLNB and MPRIP were assessed by RT-PCR.
Mock and Venus controls were also tested. Schematics of the splicing isoforms are
shown on the left and indicate differentiated exons (green) and proliferative exons(blue).
Mean ± sd (n= 3) of PSI values for TPM1 exon 2, ACTN1 exon NM, FLNB exon
H1 and MPRIP exon 23 are shown below the gel images. Western blot anti-GFP for
detection of Venus tagged proteins. GAPDH was used as a loading control. Minus RT
and no template controls were also carried out for every RT-PCR (data not shown).
Protein size markers are also indicated on the right side of the western blot. Statistical
significance from a two tailed unpaired Student’s t-test is shown as * p < 0.05, ** p <
0.01 and *** p < 0.001.
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Fig. 3.14 RBPMS switches the SM differentiated splicing in HeLa cells Venus
tagged RBPMS isoforms and RBPMS2 were overexpressed in HeLa cells. Splicing of
endogenous ACTN1, FLNB and MPRIP were assessed by RT-PCR. Mock and Venus
controls were also tested. Schematics of the splicing isoforms are shown on the left and
indicate differentiated exons (green) and proliferative exons(blue). Mean ± sd (n= 3)
of PSI values for ACTN1 exon NM, FLNB exon H1 and MPRIP exon 23 are shown
below the gel images. Western blot anti-GFP for detection of Venus tagged proteins.
GAPDH was used as a loading control. Minus RT and no template controls were also
carried out for every RT-PCR (data not shown). Protein size markers are indicated on
the right side of the western blots. Statistical significance from a two tailed unpaired
Student’s t-test is shown as * p < 0.05, ** p < 0.01 and *** p < 0.001.
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3.3 Discussion
3.3.1 Identification of SMC master regulators via association
of RBP genes with SM super-enhancers
By using the approach of identifying RBPs associated with super-enhancers in SMCs,
nine candidate master regulators were found. The list includes a cleavage and polyadeny-
lation factor (CPSF4L), a putative RNA helicase (DHX16), a U3 snoRNP protein
(IMP3), a core U6 snRNP protein (LSM4), an RBP with an RNA Recognition mo-
tif - RRM (RBPMS), ribosomal proteins (RPL10A and RPL11), a histone modi-
fier (SETD1B), and a scaffolding protein involved in RNA-mediated gene silencing
(TNRC6C). Although RBPMS was the most promising candidate, there could be scope
for critical roles played by the other RBPs. Nevertheless, it is hard to expect some
essential role for the RBPs that were expressed at a very low level in adult SMC
(Figure 3.3). Moreover, the candidates with substantial level of expression did not
show significant changes between the differentiated and proliferative states nor were
they more expressed in the latter.
3.3.2 RBPMS a potential master splicing regulator
RBPMS was the only RBP candidate whose expression level was regulated during SMC
dedifferentiation, being more expressed in the differentiated state (Figure 3.3). Even
though previous studies consistently confirmed RBPMS expression in the retina, heart,
kidney, liver, and lungs by different methodologies (Farazi et al., 2014; Kwong et al.,
2010; Shimamoto et al., 1996), human Rbpms seems to be expressed in a tissue-specific
manner as indicated by RBPMS GTEX RNA-Seq data from multiple tissues and
individuals (Figure 3.5). Additionally, RBPMS nuclear localization in the PAC1 cells
was consistent with previous studies (Farazi et al., 2014; Fu and Ares, 2014; Kwong
et al., 2010; Sagnol et al., 2014) and provided further support for its role as a splicing
regulator (Figure 3.6). In that way, RBPMS was chosen as the main master regulator
candidate to be tested. As seen in Figure 3.12, RBPMS regulated the splicing of SMC
minigene reporters, promoting the differentiated state. Unlike other RBPs found to
regulate these splicing markers (PTBP1 and MBNL1) (Gooding et al., 2013; Gromak
et al., 2003), RBPMS was sufficient to cause the switch to the SMC isoform. More
surprisingly, ectopic expression in non-smooth muscle cell lines could also recapitulate
the SMC splicing (Figure 3.14 and 3.13). Once again, these are all features mentioned
by Jangi and Sharp (2014) as characteristics of master splicing regulators. Additionally,
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it is very likely that a tissue specific transcriptome requires an interplay between RBPs,
so it is very interesting that RBPMS regulates splicing events like Tpm1 and Actn1
previously shown to be regulated by other RBPs, PTBP1 and MBNL1, highlighting a
potential cooperative interaction between them.
RBPMS is an RBP that contains a single RRM responsible for protein dimerization
and binding to CAC motifs (Farazi et al., 2014; Sagnol et al., 2014). As stated by its
name (Shimamoto et al., 1996), RBPMS transcripts are highly regulated by AS, leading
to multiple transcript isoforms, from which some are predicted to be NMD targeted.
Therefore, conversely to what has been suggested for a master regulator (Jangi and
Sharp, 2014), RBPMS could potentially be regulated by other splicing regulators and
that yet remains to be determined. On the other hand, the two main isoforms, RBPMS
A and B, did not seem to be differentially regulated in the PAC1 cells, as shown by the
western blots against RBPMS in the differentiated and proliferative states (Figure 3.6).
In terms of functions, RBPMS has mainly been described in cytoplasmic roles. Its
range of functions spans from formation of granules upon stress to transcriptional
co-activator by regulating SMAD proteins localization (Farazi et al., 2014; Fu et al.,
2015; Sun et al., 2006). Moreover, RBPMS2 has been studied as a dedifferentiation
factor in gastrointestinal SMCs (Notarnicola et al., 2012; Sagnol et al., 2014), contrary
to what is being proposed for RBPMS in here. In contrast, RBPMS2 was expressed at
very low levels in VSMC, not showing upregulation upon dedifferentiation in rat aorta
tissue (see Figure 3.4). Nevertheless, RBPMS2 ectopic expression resulted in regulation
of splicing at a similar level to RBPMS, suggesting that both proteins share similar
functions. A global study involving RBPMS overexpression in HEK293 cells revealed
its RNA recognition element by PAR-CLIP but did not uncover any role in mRNA AS
or stability after RNAseq analysis (Farazi et al., 2014). However, re-analysis of the
RNAseq dataset by Dr. Miriam Llorian unraveled a few significant events regulated by
RBPMS such as ACTN1, FLNB and MPRIP. Detection of events regulated by RBPMS
overexpression in HEK293 cells in the reanalysis of the dataset is probably explained
by two factors. First, a better RNAseq splicing analysis software was used allowing
detection of more ASE. Secondly, in the original study events identified differentially
spliced by RNAseq were discarded since they were not classified as direct targets
according to the PAR-CLIP tags. Nonetheless, the events re-identified by rMATS
expanded RBPMS activity range from Tpm1 repressor to also an activator of splicing
as seen in the regulation of FLNB exon H1 and MPRIP exon 23 (Figure 3.13 and
3.14). Interestingly, manual inspection of the intronic sequences flanking the AS exons,
revealed conserved CACs, indicating a potential position-dependent activity. Finally,
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RBPMS isoform B which was the least active in the splicing of Tpm1 and Actn1,
surprisingly showed to have similar activity to RBPMS-A and RBPMS2 when acting
as an activator (Figures 3.14 and 3.13). These isoforms are very conserved in their
N-termini, varying only in the very C-terminus (Figure 3.15). Therefore, it is expected
that the isoform-specific amino acid sequence determines its activity. Nevertheless, it
remains to be determined whether RBPMS-A residues confers it a repressor role or if
RBPMS-B amino acid tail inhibits its repressive function.
RBPMS-A
RBPMS-B
RBPMS-A
RBPMS-B
RBPMS-A
RBPMS-B
RBPMS-A
RBPMS-B
RBPMS-A
RBPMS-B
Fig. 3.15 RBPMS-A and RBPMS-B vary in their C-termini. Multiple align-
ment of rat RBPMS isoforms A and B was generated using CLUSTAL O (1.2.4) and
visualized with MView. Amino acids conserved with the reference sequence, RBPMS-A,
were colored (bright green - hydrophobic, dark green - large hydrophobic, purple -
polar, red - positive charge, dark blue - negative charge, bright blue - small alcohol,
yellow - cysteine).
3.4 Final conclusions
This chapter aimed to identify master splicing regulators in SMCs via association
of RBP genes with super-enhancers as well as initially validate the candidates by
testing regulation upon some SM-specific AS events. Out of nine RBPs identified
associated with SM super-enhancers, RBPMS was the most promising candidate, being
predominantly nuclear and highly expressed in the differentiated SMC but strongly
down-regulated in proliferative SMC. This feature of Rbpms met one of the criteria of a
master splicing regulator described in Jangi and Sharp (2014): wide dynamic range of
expression. Furthermore, RBPMS overexpression was sufficient to switch the splicing
isoforms of Tpm1 and Actn1 towards the SM specific pattern in the PAC1 cells. More
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surprisingly, RBPMS also promoted the SM differentiated patterns in unrelated cells,
HeLa and HEK293 cells. In these cell lines, it was possible to screen for endogenous
splicing changes, which revealed RBPMS role as an activator of FlnB exon H1 and
Mprip exon 23. Finally, overexpression of the different isoforms, RBPMS A and B,
shed some light onto differential activity between isoforms, with isoform B being the
least active. Therefore, these data established a new function for RBPMS as a splicing
regulator of a few SMC ASEs and supported further analysis for the identification of
RBPMS targets in SMCs by global approaches such as RNAseq of PAC1 cells where
RBPMS levels were manipulated either by knockdown and overexpression (see Chapter
4).
In conclusion, this chapter has the following points as the main findings:
1. Nine RBP genes were found associated with human SM super-enhancers: CPSF4L,
DHX16, IMP3, LSM4, RBPMS, RPL10A, RPL11, SETD1B and TNRC6C.
2. Rbpms expression is regulated during rat aorta and PAC1 cells dedifferentiation,
being more expressed in the differentiated state.
3. RBPMS predominantly localized to the nucleus but was also present in the
cytoplasm.
4. RBPMS recognition elements, CAC motifs, were conserved upstream of SM
proliferative exons such as Tpm1 and Actn1 and downstream of SM differentiated
exons.
5. RBPMS promotes the SMC splicing pattern in the rat SM cell line PAC1 cells,
switching the splicing isoforms of the Tpm1 and Actn1 minigene reporters towards
the differentiated transcripts.
6. RBPMS promotes the SMC splicing pattern in non-SM cell lines, HeLa and
HEK293, switching the splicing of endogenous transcripts, e.g. repressing the
NM exon in TPM1 and potentially also in ACTN1, and activating SM exons in
FLNB and MPRIP.
7. Rbpms was found to be expressed in several isoforms in PAC1 cells, being
RBPMS-A and B the major protein isoforms.
8. RBPMS A was the most active isoform together with its paralog, RBPMS2.
In addition to that, this chapter also led to other questions listed below:
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• What are the other mRNA targets of RBPMS?
• What are the cytoplasmic functions of RBPMS?
• How are the different isoforms regulated?
• Does RBPMS repress the exon NM or activate exon SM in Actn1 splic-
ing?
• Does RBPMS directly regulate splicing of these targets?
• What is the importance of the conserved CACs in the RBPMS regulation
of the SMC splicing?
• What is the mechanism behind RBPMS regulation of splicing?
• How do the isoforms display different activities in splicing?
• What are functional consequences of the splicing changes regulated by
RBPMS to the SMC phenotype?
The questions highlighted in bold font were addressed in the following chapters.
Chapter 4
RBPMS: a regulator of the
differentiated SMC splicing
program
4.1 Introduction
4.1.1 RBPMS
The RNA-Binding Protein with Multiple Splicing (RBPMS) protein family was first
described in a human library screening (Shimamoto et al., 1996) and it was also
subsequently reported in a second screening using X. laevis embryonic heart devel-
opment library (Gerber et al., 1999). Thereby, RBPMS is also known as HERMES
which stands for HEart RRM Expressed Sequence. However, the Xenopus HERMES,
originally thought to be RBPMS ortholog, is now known to be RBPMS2. As a result,
in some species HERMES might refer to RBPMS2 instead. RBPMS protein family
consists of RBPs containing a single RRM (RNA recognition motif), an RNA-binding
domain presented in a large number of other RBPs (Ascano et al., 2012; Farazi et al.,
2014). In humans, the family consists of RBPMS and its paralog, RBPMS2, which
share 67% amino acid identity and variation observed mostly in the N and C-termini.
RBPMS, as indicated by its name, is highly alternatively spliced, generating several
mRNA isoforms that result in multiple protein isoforms (Shimamoto et al., 1996). For
humans, four RefSeq RBPMS mRNA transcripts are annotated encoding three protein
isoforms that are very similar in the majority of their sequence. On the other hand,
RBPMS2 seems to be predominantly expressed as one single isoform. In rats, only
one Refseq transcript isoform is annotated for RBPMS, however the rat genome is not
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well annotated. For instance when searching for RBPMS in mouse, a close relative of
rat with a better annotated genome, several isoforms similar to human isoforms were
found. Indeed in this study two major RBPMS isoforms, A and B, were isolated from
rat PAC1 cells. Human and rat RBPMS proteins are very similar displaying ∼99%
amino acid identity. In fact, the RBPMS family is conserved across vertebrates (Figure
4.1) and orthologs, CPO and MEC-8, are also found in Drosophila and C. elegans
respectively.
RBPMS was found associated with transcriptional super-enhancers in three different
SM tissues in Chapter 3. These large clusters of transcriptional enhancers drive high
transcription of genes important for cell identity (Hnisz et al., 2013). Although the
proximity to this elements could explain RBPMS expression level in differentiated
SMC, the constellation of factors that occupy these super-enhancers remains unknown.
Investigation of RBPMS transcriptional control is limited to a single study in HEK293
cells (Ye et al., 2018), which revealed the importance of Sp1 binding sites (GC boxes)
for RBPMS transcriptional regulation. However, these experiments were performed
in a cell line in which RBPMS is not very abundant. Therefore, the role of these
transcription factor binding sites is expected to vary in different cell types.
RRM containing RBPs are known to be involved in a range of RNA processes, for
example pre-mRNA splicing, transport, localization and stability (Maris et al., 2005).
Indeed, suggested functions of RBPMS involve mRNA stability, transport, localization
in stress granules and also translation, as well as heart and kidney development, X.
laevis oocyte maturation, retinal differentiation and lastly co-transcriptional activation
(Farazi et al., 2014; Furukawa et al., 2015; Gerber et al., 2002; Hörnberg et al., 2016,
2013; Sun et al., 2006). RBPMS functions described in previous studies are summarized
in Figure 4.2.
A systematic study of RBPMS in HEK293 cells defined its transcriptome-wide
mRNA targets using photoactivatable-ribonucleoside-enhanced crosslinking and im-
munoprecipitation (PAR-CLIP) (Farazi et al., 2014). Further biochemical and com-
putational approaches resolved the RBPMS RRM RNA-binding site as tandem CAC
trinucleotide motifs separated by variable spacer length (1 to 12 nt) (Farazi et al.,
2014). RBPMS mainly bound to the 3′ UTR and intron regions, but it also bound
coding and repeat elements. Additionally, the structure of RBPMS (1.79 Å) and its
paralog RBPMS2 (Sagnol et al., 2014; Teplova et al., 2016) uncovered the basis of
the CAC RNA recognition as well as the dimeric nature of the RBPMS RRM. The
dimerization state is then consistent with the PAR-CLIP detected RBPMS binding
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Fig. 4.1 RBPMS is conserved in vertebrates. Multiple alignment of RBPMS-A
and RBPMS2 protein sequences across different vertebrate species was generated using
CLUSTAL O (1.2.4) and visualized with MView. Only amino acids conserved with the
reference sequence, RBPMS H. sapiens, were colored (bright green - hydrophobic, dark
green - large hydrophobic, purple - polar, red - positive charge, dark blue - negative
charge, bright blue - small alcohol, yellow - cysteine).
82 RBPMS: a regulator of the differentiated SMC splicing program
Transcriptional
co-regulation
Stress granules
Neuronal granules
P-bodies
Translational control
AAAAAA
RBPMS
ERG
CNOT2
CCR4-NOT
RBPMS SMAD
P
RBPMS cFos
cJun cFos
Balbiani body AAAAAA
RBPMS
Bucky Ball
AAAAAA
RBPMS
Noggin
eEF2
RBPMS
NonO
PSF
Notarnicola et al., 2012
Sagnol et al., 2014
Farazi et al., 2014
Rambout et al., 2016
Aguero et al., 2016
Kaufman et al., 2018
Hörnberg et al., 2013
Furukawa et al., 2015
Sun et al., 2006 
Fu et al., 2015
Fig. 4.2 RBPMS protein family functions. Summary of RBPMS and RBPMS2
reported to date. Green color indicate RBPMS localization obtained from COMPART-
MENTS (Binder et al., 2014).
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sites comprised of tandem CAC repeats. These structural features are further discussed
in following chapters.
Therefore, despite all the studies involving RBPMS and RBPMS2 proteins in
different cell types and stages of development, the nuclear role of RBPMS in adult
VSMCs was still neglected. In this chapter, motivated by the initial results observed
in Chapter 3, we sought to uncover RBPMS potential function in the regulation of
mRNA abundance and more specifically AS in the VSMC phenotypic switching by
manipulating its levels in the differentiated and proliferative PAC1 cell states followed
by mRNAseq.
4.2 Results
4.2.1 Manipulation of RBPMS levels
To investigate other targets of RBPMS post-transcriptional control in a more global
manner, RBPMS levels were manipulated by siRNA knockdown in differentiated PAC1
cells and lentiviral inducible RBPMS-A overexpression stable cell lines were produced
using proliferative PAC1 cells (Figure 4.3). The latter was obtained by Clare Gooding
in the laboratory.
RBPMS protein levels were verified by western blot after siRNA treatment and
induction of overexpression with doxycycline (Figure 4.3). RBPMS knockdown resulted
in 75% reduction of the protein levels of both isoforms with no observed changes in the
SMC marker, ACTA2. Moreover, induction of the overexpression of the 3xFLAG tagged
RBPMS-A showed to be specific to the RBPMSA cell lines and to the doxycycline
treatment. In agreement with the pattern of RBPMS expression in PAC1 cells, no
endogenous RBPMS was detected in the proliferative lentiviral cell lines.
Next, changes in endogenous Flnb and Actn1 splicing due to RBPMS levels manipu-
lation were assessed by RT-PCR (Figure 4.4). For Flnb, RBPMS knockdown decreased
the level of exon H1 inclusion to nearly half of the observed in the control treatment
(94.8% to 52.3%) whereas overexpression nearly promoted its complete inclusion (PSI=
93.3%). For the Actn1 mutually exclusive pair of exons, a similar pattern was observed,
where RBPMS knockdown reduced the smooth muscle exon inclusion and RBPMS
overexpression increased the SM exon inclusion (23.4% and 84.0%). In both splicing
examples, RBPMS down and upregulation resulted in significant reciprocal changes,
switching the splicing isoforms towards the opposite cell state pattern. Furthermore,
the splicing levels from the knockdown and overexpression controls, D Ctr and P Ctr,
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Fig. 4.3 Manipulation of RBPMS levels by knockdown and overexpression.
Top, schematic of the experimental designs of RBPMS knockdown and overexpression
in PAC1 cells. Bottom, western blots anti-RBPMS and anti-FLAG for detection
of endogenous and overexpressed RBPMS respectively. ACTA2 was used as a SMC
differentiation marker and GAPDH and TUBULIN were used as loading controls.
Protein size markers are also indicated on the side of the western blots.
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supported the different PAC1 cell states used in each experiment, differentiated and
proliferative respectively.
In parallel to the RT-PCR analysis of the RBPMS overexpression regulated ASE,
Clare Gooding in the laboratory also validated the lentiviral control cell lines (P
LV) that contain the empty pInd22 construct. No splicing changes were observed
upon doxycycline induction (Appendix - Figure A.1). Thus, these data ensured that
the alterations in splicing observed in the P OE were due to the overexpression of
RBPMS-A.
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P Ctr P  OE
68.9 
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 33.0
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P Ctr P  OED Ctr  D KD
Fig. 4.4 RBPMS knockdown and overexpression affected Flnb and Actn1
splicing. RT-PCR validation of endogenous Flnb exon H1 and Actn1 mutually
exclusive exons upon RBPMS knockdown and overexpression. Schematics of the
splicing isoforms are shown on the left and indicate differentiated exons (green) and
proliferative exon (blue). PSI values are shown as mean ± sd (n= 3). A minus RT
and a no template control were also carried out for every RT-PCR (data not shown).
Statistical significance from a two tailed Student’s t-test is shown as * p < 0.05, ** p
< 0.01 and *** p < 0.001.
To further verify whether the effects of RBPMS knockdown were reproducible,
a second siRNA was tested alongside (Figure 4.5). Both siRNAs efficiently reduced
RBPMS protein levels to a similar degree, below 75% compared to cells treated with
control siRNA (Figure 4.5). Moreover, similar to the previous knockdown results,
RBPMS silencing by both siRNAs led to changes in Flnb and Actn1 splicing, as well
as Tpm1 (Figure 4.5). In all the ASE assessed, both knockdowns resulted in equivalent
effects and again promoted the non smooth muscle isoforms.
The role of RBPMS2 in the regulation of PAC1 cells AS and its possible com-
pensation upon RBPMS silencing were investigated by RBPMS2 siRNA knockdown
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Fig. 4.5 RBPMS knockdown with a second siRNA. A Western blot anti-
RBPMS for detection of endogenous RBPMS upon the knockdown with two different
siRNAs (KD1 and KD2). Control sample in a serial dilution (1, 1:2, 1:4). GAPDH was
used as a loading control. Protein size markers are also indicated on the side of the
western blots. B RT-PCR validation of differentiated and proliferative exons regulated
upon RBPMS knockdown. Schematics of the splicing isoforms are shown on the left
and indicate differentiated exons (green) and proliferative exon (blue). PSI values for
the SM exons are shown as mean ± sd (n= 3). A minus RT and a no template control
were also carried out for every RT-PCR (data not shown). Statistical significance from
a two tailed unpaired Student’s t-test is shown as * p < 0.05, ** p < 0.01 and *** p <
0.001.
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(Figure 4.6). In Chapter 3, it was shown that RBPMS2 mRNA expression was not
affected during PAC1 dedifferentiation and its overexpression revealed a potential role
in splicing regulation. However, in aorta tissue, RBPMS2 transcript abundance was
much lower than RBPMS. Thus, in agreement with that, despite an ∼80% reduction of
RBPMS2 mRNAs (Figure 4.6A), minimal effects to splicing of Actn1 and Tpm1 were
observed (Figure 4.6B). Additionally, no cross-regulation between paralogs was revealed
by the qRT-PCR. Lastly, manipulation of both RBPMS and RBPMS2 levels did not
show further effects to the ASE than the observed with RBPMS only knockdown.
Therefore, this eliminated the need for a double knockdown in order to achieve maximal
effects of RBPMS in splicing.
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Fig. 4.6 RBPMS2 knockdown in PAC1 cells has minimal effects on Actn1
and Tpm1 splicing. Top qRT-PCR assessing transcripts level after RBPMS,
RBPMS2 and combined knockdown. GAPDH was used a housekeeper gene for normal-
ization. Number 1 and 2 indicate RBPMS siRNA1 and siRNA2 respectively. Bottom
RT-PCR validation of endogenous Actn1 and Tpm1 mutually exclusive exons upon
knockdown. Schematics of the splicing isoforms are shown on the left and indicate
differentiated exons (green) and proliferative exon (blue). Experiment of n= 1, so no
sd or statistical test shown.
Having confirmed the efficacy of RBPMS knockdown and overexpression, RNA
samples were prepared for polyA mRNA sequencing. Samples were from three RBPMS
knockdowns (siRNA1) in differentiated PAC1 cells and three independent RBPMS-A
inducible lentiviral populations of proliferative PAC1, corresponding to the experi-
ments shown in Figures 4.3 and 4.4. Moreover, comparison of the knockdown and
overexpression controls provided insights on the PAC1 transcriptional and AS program
during dedifferentiation.
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4.2.2 RNAseq of RBPMS knockdown and overexpression
cDNA libraries and mRNA sequencing of RBPMS knockdown and RBPMS-A over-
expression in PAC1 cells were carried out by the CRUK Genomics Facility. Prior to
sequencing, RNA and cDNA libraries were controlled for their qualities. RNAseq data
were then primarily analyzed by Dr Miriam Llorian who also performed the mRNA
abundance and splicing analyses. Further data exploration and visualization were
carried out by me using R Studio.
4.2.2.1 mRNA abundance analysis
Analysis of differential mRNA abundance was carried out by DESeq2 (Love et al.,
2014) and changes were analyzed for PAC1 dedifferentiation (D Ctr vs P Ctr), RBPMS
knockdown (D KD vs D Ctr) and RBPMS-A overexpression (P OE vs P Ctr), Figure
4.7. First, as expected, RBPMS knockdown and overexpression reduced and increased
RBPMS levels by 0.6 and 70 folds respectively. In addition to that, RBPMS transcript
abundance was ∼4 fold more abundant in the differentiated than in the proliferative
state. In terms of global transcripts regulated, the differentiated and proliferative
PAC1 cell comparison showed the greatest number of genes differently abundant (2274
genes), followed by overexpression (725) and knockdown (192). Furthermore, a bias
towards reduction of mRNA abundance was observed in the D Ctr vs P Ctr (1444
down and 830 upregulated) whereas the RBPMS experiments, mainly overexpression,
showed genes more associated with an increased level of transcripts. ∼78% of the
genes differentially abundant in RBPMS-A overexpression were upregulated. Moreover,
although high levels of Rbpms and Acta2 co-existed in the differentiated state of PAC1
cells, no changes in Acta2 or other SMC markers, such as Smtn and Cnn1 (data not
shown), were detected upon manipulation of RBPMS expression (Figure 4.7).
The top ten up and downregulated genes during PAC1 dedifferentiation, RBPMS
knockdown and overexpression are found in Table 4.1. Apart from LOC100911692 in
RBPMS overexpression and knockdown, little overlap was observed in the top expressed
genes between all comparisons. In addition to that, motivated by the similar profile of
up regulated genes between the PAC1 dedifferentiation and overexpression, correlation
was verified for the genes showing differential abundance in the different experiments
(Figure 4.8). As previously highlighted in the table for top regulated genes (Table 4.1),
little overlap was observed between genes with changes in mRNA abundance in the
different experiments. RBPMS knockdown showed the best correlation, -0.64, but no
significant relationship was observed between RBPMS experiments. Thus, changes in
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Fig. 4.7 RBPMS is associated with a few changes in mRNA abundance MA
plots of the changes in mRNA abundance in PAC1 dedifferentiation (D Ctr vs P Ctr),
RBPMS knockdown (D KD vs D Ctr) and RBPMS overexpression (P OE vs P Ctr)
detected by DESeq2. Genes with significant changes (p-adj<0.05) in mRNA abundance
are highlighted in dark gray and genes with non-significant changes (p-adj≥0.05) are
shown in light gray. Rbpms, Rbpms2 and Acta2, a SMC marker, genes are indicated in
red. Numbers at the top and bottom correspond to the number of genes upregulated
and downregulated, respectively. Horizontal lines in the MA plots represent log2 fold
change = 1 and -1.
mRNA abundance associated with the manipulation of RBPMS levels seem to be a
minor effect, due to its variability between knockdown and overexpression. Moreover, it
is hard to draw any biological importance of these genes as little overlap was observed
with the PAC1 dedifferentiation regulated genes.
To address the consequences of the mRNA abundance changes to the samples
grouping, a Principal Component Analysis (PCA) based on mRNA abundance was
performed (Figure 4.9). Differentiated and proliferative samples were clearly separated
by PC1, 82% variance. The differences between the independent lentiviral transduc-
tions for the generation of the overexpression cell lines are reflected by PC2, 10%
variance. Consistent with the previous analyses, the PCA results support the fact that
manipulation of RBPMS levels is not sufficient to overcome the differences between
differentiated and proliferative PAC1 cells at the level of mRNA abundance.
4.2.2.2 AS analysis
Analysis of mRNA alternative splicing was carried out by rMATS (Shen et al., 2014)
and changes were analyzed for PAC1 dedifferentiation (D Ctr - P Ctr), RBPMS
knockdown (D KD - D Ctr) and RBPMS-A overexpression (P OE - P Ctr), Figure
4.10. ASEs were classified into five categories: skipped exons (SE), mutually exclusive
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Table 4.1 Top ten upregulated and downregulated genes detected by DESeq2
PAC1 dedifferentiation RBPMS knockdown RBPMS overexpression
Gene name log2FC Gene name log2FC Gene name log2FC
Trpc6 9.5 Cpne1 6.9 LOC100911692 9.3
Galnt18 9.2 Aldh3a1 4.2 Hells 8.7
Clec4m 8.7 LOC100909857 3.8 Cyp2d2 8.5
AABR07035650.1 8.5 Sprr1a 3.5 Chrne 8.1
Wfdc21 8.1 Me3 3.2 Ccdc87 8.1
Hoxc6 8.1 Slurp1 2.8 Cacna1d 8.0
Spon1 7.9 Kcnk2 2.8 Slc5a5 7.9
Nckap1l 7.7 Rtp4 2.6 Nyx 7.8
Lin7a 7.7 Il18rap 2.6 Tnfsf8 7.7
MGC114427 7.6 Dhrs9 2.4 Tekt5 7.7
Ntrk1 -10.5 Zfp804a -2.4 Ttyh3 -2.4
Rbm46 -10.5 Hist2h2be -2.7 Lima1 -2.4
Tex19.2 -10.6 Ak4 -2.9 Zfp93 -2.6
Slc7a3 -10.9 LOC100911692 -4.7 Lgr5 -2.8
Mael -11.2 AABR07035375.1 -6 Mettl21b -3.2
Slc6a17 -11.3 Tnks2 -7.9 LOC108348161 -4.2
Aass -11.4 LOC102549115 -8.3 ACEA_U3 -5.9
Adad2 -11.9 Sbk1 -8.3 Cracr2b -6.2
Cdh5 -12.2 LOC100909505 -8.5 Brms1 -7.2
Tmem200b -20.3 Rbm12 -8.7 Rfxapl1 -22.6
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Fig. 4.8 Genes showing changes in mRNA abundance in the different com-
parisons display little overlap Fold change correlation of the overlapping genes
across the different experiments: PAC1 dedifferentiation (PAC1), RBPMS knockdown
(KD) and RBPMS-A overexpression (OE). Black lines indicate the linear regression
model. Pearson correlation test results are shown in the plot. The correlation statistical
significance and coefficient are indicated by the p-value and r2 in the plot.
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Fig. 4.9 Changes in mRNA abundance due to RBPMS manipulation do
not overcome changes during PAC1 dedifferentiation. Principal Component
Analysis (PCA) based on mRNA abundance variance of RBPMS knockdown (D Ctr
and D KD) and overexpression (P Ctr and P OE).
92 RBPMS: a regulator of the differentiated SMC splicing program
exons (MXE), alternative 5′ and 3′ splice sites (A5SS and A3SS) and retained introns
(RI) (Figure 4.10). ASE were considered differentially spliced if showing an FDR less
than 0.05 and |∆PSI| greater than 10%. First, the proportion of each type of ASE
identified in the different experiments were verified (Figure 4.10). RBPMS knockdown
and overexpression did not show any preference towards regulation of a specific type
of AS, since its AS distribution was similar to the PAC1 dedifferentiation. Moreover,
SE and MXE together corresponded to the majority of the regulated events (∼60%).
Absolute numbers of the AS analysis uncovered the substantial effects of RBPMS as
an activator and repressor of splicing in PAC1 cells (Figure 4.11). RBPMS knockdown
regulated 318 ASEs, 136 more included and 182 more excluded exons, whereas RBPMS
overexpression showed a much larger number in AS changes, 4934 ASEs of which 1286
more included and 3648 more excluded exons. During PAC1 cells dedifferentiation,
635 exons were regulated, 352 activated and 283 repressed exons. Given that RBPMS
knockdown regulated only 2-fold less ASEs than PAC1 dedifferentiation, by far RBPMS
manipulation affected more splicing than mRNA abundance in the PAC1 cells. On the
other hand, RBPMS-A overexpression resulted in a strong regulation of AS, beyond
5-fold more ASE than during dedifferentiation of PAC1 cells. It is also notable that
RBPMS acts more as a repressor as suggested by the skewed number of SE towards
less inclusion. The top ten activated and repressed exons identified by rMATS during
the PAC1 dedifferentiation, RBPMS knockdown and overexpression are found in Table
4.2, 4.3 and 4.4. Consistent with previous validation of RBPMS role in splicing (see
Figure 4.4), Actn1 and Flnb ASEs were among the top ten RBPMS regulated exons.
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Fig. 4.10 RBPMS affects all types of AS with no preference to a specific
type. Proportion of significant ASEs identified by rMATS (FDR < 0.05 and |∆PSI| >
10%) for each type of splicing. Schematics of the five different AS types identified by
rMATS are shown on the right.
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Fig. 4.11 RBPMS regulates AS in PAC1 cells. AS changes in PAC1 dedifferenti-
ation (D Ctr - P Ctr), RBPMS knockdown (D KD - D Ctr) and RBPMS overexpression
(P OE - P Ctr). Plots include only ASE that showed FDR < 0.05 and |∆PSI| greater
than 10%. ASEs were divided into Skipped Exon (SE), Mutually Exclusive Exon
(MXE), Alternative 5′ and 3′ Splice Site (A5SS and A3SS) and Reteined Intron (RI) by
rMATS. In each comparison, the colors indicate exons more included in the respective
sample (see Figure 4.3). Numbers highlight the numbers of significant ASE found
activated or repressed (top and bottom) in each type of event.
Table 4.2 Top ten activated and repressed exons in PAC1 dedifferentiation detected by
rMATS
Gene name ∆PSI ASEID AStype
Elovl1 71.9 5.137257786.137257979.137257479.137257708.137258385.137258445 SE
Elovl1 70.0 5.137257776.137257979.137257479.137257708.137258385.137258445 SE
Col4a5 53.0 X.112958131.112958140.112956286.112956472.112964677.112964811 SE
Osbpl6 51.2 3.63412201.63412294.63411343.63411447.63421091.63421257 SE
Fnip2 51.1 2.178273858.178274004.178272369.178272441.178274159.178274260 SE
Fmnl3 47.4 7.140993715.140993748.140992495.140992604.140996289.140996373 SE
Flnb 46.1 15.18780302.18780341.18779402.18779505.18783400.18783648 SE
Pdlim7 45.8 17.9659208.9659229.9658265.9658294.9659478.9659615 SE
Alg14 45.3 2.224915567.224915697.224916092.224916217.224886636.224886768.224930476.224931459 MXE
Mprip 45.2 10.46129845.46129896.46129339.46129425.46132876.46133571 SE
Axl -37.5 1.82566746.82566773.82563906.82564039.82568169.82568380 SE
Fam193b -37.9 17.9617725.9617866.9617725.9617770.9618366.9618606 A5SS
Zfyve19 -38.8 3.111015802.111016048.111015802.111015853.111015924.111016048 RI
Serpinh1 -39.2 1.164307482.164307705.164307482.164307640.164308246.164308317 A3SS
Pls3 -41.8 X.119065134.119065209.119076730.119076854.119030418.119030494.119078761.119078842 MXE
Actn1 -42.6 6.103379313.103379379.103379819.103379900.103378007.103378166.103380858.103381005 MXE
Zfp532 -44.8 18.61335535.61335698.61328527.61328704.61361848.61361961 SE
Nutf2 -51.2 19.37831236.37831400.37839121.37839238.37830916.37830949.37845351.37845478 MXE
Elovl1 -57.7 5.137257479.137257708.137257830.137257979.137255923.137256002.137258385.137258445 MXE
Elovl1 -58.9 5.137257479.137257708.137257786.137257979.137255923.137256002.137258385.137258445 MXE
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Table 4.3 Top ten activated and repressed exons in RBPMS knockdown detected by
rMATS
Gene name ∆PSI ASEID AStype
Prnp 43.8 3.124519940.124520061.124527946.124528058.124518258.124518356.124529319.124531316 MXE
Pusl1 38.5 5.173336675.173336884.173336033.173336421.173337515.173337691 SE
Prnp 38.0 3.124519940.124520061.124527962.124528054.124518258.124518356.124529319.124531316 MXE
Mbnl1 37.4 2.150864085.150864121.150858305.150858459.150864801.150864896 SE
Slfn13 34.8 10.70337408.70337518.70336023.70337090.70342232.70342411 SE
Actn1 34.4 6.103379313.103379379.103379819.103379900.103378007.103378166.103380858.103381005 MXE
Tmem109 33.2 1.226929746.226929869.226932378.226932595.226928607.226928852.226935626.226935689 MXE
Mbnl1 32.9 2.150864085.150864121.150858305.150858459.150867718.150867793 SE
Arhgap17 32.0 1.193243546.193243595.193245127.193245237.193239039.193239872.193246163.193246715 MXE
Camk2g 31.3 15.3983819.3983888.3974330.3974374.3985004.3985049 SE
Hspg2 -42.1 5.155853492.155853543.155851503.155851664.155853919.155854048 SE
Itga7 -42.2 7.3363146.3363278.3363529.3363649.3362381.3362637.3364518.3364726 MXE
Nutf2 -42.3 19.37839121.37839238.37840879.37841075.37830916.37830949.37845351.37845478 MXE
Mprip -42.5 10.46129845.46129896.46129339.46129425.46132876.46133571 SE
Itga7 -44.0 7.3363146.3363278.3363529.3363649.3362381.3362637.3364823.3365017 MXE
Dhdh -44.3 1.101474797.101474961.101471873.101472126.101476777.101476867 SE
Flnb -48.3 15.18780269.18780341.18779402.18779505.18783400.18783648 SE
Dhdh -50.4 1.101474797.101474959.101471873.101472126.101476777.101476867 SE
Itga7 -55.9 7.3363146.3363278.3362564.3362637.3363529.3363649 SE
Flnb -63.6 15.18780302.18780341.18779402.18779505.18783400.18783648 SE
Table 4.4 Top ten activated and repressed exons in RBPMS-A overexpression detected
by rMATS
Gene name ∆PSI ASEID AStype
Gkap1 82.3 17.6816561.6816708.6807553.6807576.6816946.6817048 SE
Actn1 73.6 6.103379313.103379379.103378007.103378166.103379819.103379900 SE
Prtfdc1 72.2 17.87929406.87929517.87928989.87929066.87931271.87931318 SE
Svil 71.6 17.55289394.55290249.55288179.55288214.55297975.55298582 SE
Mical3 70.6 4.153559892.153560000.153559120.153559307.153571656.153571830 SE
Prtfdc1 69.7 17.87929429.87929517.87928989.87929066.87931271.87931318 SE
G2e3 68.0 6.72099285.72099362.72097747.72097788.72099699.72099797 SE
Brd1 65.7 7.129690628.129690688.129690244.129690349.129696841.129697102 SE
Dennd1b 65.6 13.56120365.56120425.56115264.56115341.56121584.56121638 SE
Ptprf 65.2 5.137046364.137046397.137045483.137045581.137048659.137048775 SE
6.103379313.103379379.103379819.103379900.103378007.103378166.103380858.103381005
E2f1 -82.2 3.150064424.150064575.150062894.150064333.150064738.150064853 SE
Qtrt1 -82.8 8.22453468.22453550.22453278.22453388.22453991.22454439 SE
E2f1 -82.9 3.150064424.150064585.150062894.150064333.150064738.150064853 SE
Phldb2 -83.9 11.57457745.57457820.57454353.57454443.57462008.57462108 SE
Rnf44 -84.2 17.10468564.10468738.10467852.10468011.10469413.10469501 SE
Duoxa1 -84.6 3.114242245.114242455.114241056.114241591.114242701.114242915 SE
Brd4 -86.1 7.14230130.14230322.14228763.14229354.14230480.14230533 SE
Uckl1 -86.3 3.177066994.177067073.177066785.177066908.177067188.177067435 SE
Homer3 -91.9 16.20882892.20883024.20881517.20881783.20883116.20883227 SE
Homer3 -92.8 16.20882892.20883018.20881517.20881783.20883116.20883227 SE
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To confirm RBPMS regulation of the ASEs identified in the RNAseq analysis, a
subset of ASE was then validated by RT-PCR, using the same RNA samples originally
used for the sequencing (Figure 4.12). Among the novel events validated, there were
differentiated and proliferative cassette exons, some whose AS had previously been
shown to be regulated in SMC, such as Smtn (Llorian et al., 2016). All the events
tested by RT-PCR showed significant changes upon manipulation of RBPMS levels
(Figure 4.12A). Although only the knockdown events are shown herein, C. Gooding, in
the laboratory, validated the same events in the overexpression cell lines. In total, a
subset of 28 ASEs was validated and all of them were found in good agreement with
the RNAseq predicted ∆PSI (Figure 4.12B).
A
−100
−50
0
50
100
−100 −50 0 50 100
∆PSI RNAseq (%)
∆P
SI
 R
T−
P
C
R
 (%
)
KD
OE
n =  28
r2 = 0.96 
p-value = 2.3x10-16  
BDifferentiated exons
SM
D Ctr  D KD
Hspg2
66.7
± 1.0
31.3 
± 0.9
*** 
Ppfibp1
91.7 
± 0.6 
55.9 
± 3.5
***
D Ctr  D KD
Ppfia1
 54.4
± 0.9
D Ctr  D KD
34.1 
± 7.9
*
PSI
± sd
Proliferative exons
NM
Arhgef7
32.4 
± 7.0 
45.9 
± 3.6
* 
PSI
± sd
D Ctr  D KD
Smtn
 76.8
± 1.5
89.0 
± 1.7
***
D Ctr  D KD
Fig. 4.12 RBPMS ASE ∆PSI values from RNAseq and RT-PCR highly
correlated. A Validation of differentiated and proliferative cassette exons by RT-
PCR. A minus RT and a no template control were also carried out for every RT-PCR
(data not shown). Values shown as mean of the PSI ± sd (n = 3). Statistical significance
was calculated using Student’s t-test (* P < 0.05, ** P < 0.01, *** P < 0.001). B
Correlation between ∆PSI values from rMATS prediction and RT-PCR validated
experiments from RBPMS knockdown and overexpression (n=28). Black line indicates
the linear regression model. Results from the Pearson correlation test are shown in
the plot. The correlation statistical significance and coefficient are indicated by the
p-value and r2 in the plot.
Ptprf, Piezo1 and Itga7 are shown as other examples of differentiated and pro-
liferative cassette exons as well as mutually exclusive exons (Figure 4.13). RT-PCR
validations are shown along side Sashimi plots, which allow visualization of the RNAseq
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data (Figure 4.13). Differentiated and proliferative exons were defined based on the
inclusion levels in the two states in PAC1 cells. It is evident that both RBPMS knock-
down and overexpression affected splicing consistently promoting the opposite effects.
Furthermore, in all the three cases, RBPMS knockdown led to proliferative isoforms
whereas overexpression of RBPMS-A regulated towards differentiated patterns.
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Fig. 4.13 RBPMS regulates splicing towards the differentiated state. Differ-
entiated and proliferative cassette exons (green and blue, respectively) and mutually
exclusive exons identified by rMATS were validated by RT-PCR. Top, sashimi plots
for Ptprf, Piezo and Actn1 are shown as examples. Numbers on top of the arches
indicate number of reads mapping to the exon junctions. Mean of the PSI values
calculated by rMATS are shown on the right. In the case of Actn1 the PSI shown
corresponds to inclusion of exon SM. Schematic of the alternative transcripts are shown
below the sashimi plots, as well as the chromosome coordinates. Bottom, RT-PCR
gel images from QIAxcel. Minus RT and no template controls were also carried out
for every RT-PCR (data not shown). Values shown are mean of the PSI ± sd (n =
3). Statistical significance was calculated using Student’s t-test (* P < 0.05, ** P <
0.01,*** P < 0.001).
Finally, we looked for any overlap between genes regulated at the mRNA abundance
and AS levels (Figure 4.14). Only a few genes were found to be regulated at both levels;
41, 3 and 90 genes in the PAC1 dedifferentiation, RBPMS knockdown and RBPMS-A
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overexpression respectively. Yet those numbers represent less than 4% all the genes
regulated in either mRNA abundance or splicing.
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Fig. 4.14 Only a few genes are regulated at both mRNA level and splicing.
Venn diagrams showing the overlap between genes displaying changes in mRNA
abundance and splicing in the PAC1 dedifferentiation, RBPMS knockdown and RBPMS-
A overexpression. Fold-change (FC) enrichments are shown below Venn diagrams.
Significance was tested by a hypergeometric test and P-value is described as * P <
0.05, ** P < 0.01, *** P < 0.001.
Therefore, the initial global data analyses confirmed RBPMS as a splicing regulator
with minor effects upon mRNA abundance. The data presented so far also further
support RBPMS as a master splicing regulator of the SMC differentiated program,
since RBPMS promoted splicing towards the differentiated profile in the PAC1 cells.
4.2.2.3 SMC dedifferentiation ASEs regulated by RBPMS
Having obtained the PAC1 and rat aorta tissue dedifferentiation RNAseq datasets,
biological comparisons could be made to address the importance of the ASE regulated
in the RBPMS experiments (Figure 4.15). First, ASEs identified in PAC1 dedifferen-
tiation and RBPMS overexpression and knockdown were compared by proportional
Venn diagrams (Figure 4.15A). The diagram shows substantial overlap mainly between
knockdown and PAC1 dedifferentiation datasets, representing 20% of the PAC1 regu-
lated ASEs and ∼40% of RBPMS knockdown ASEs. To confirm that the overlapping
events were reciprocally regulated, the correlation of the PSIs was verified (Figure
4.15B, left). Strikingly, all the 127 events regulated in both sets showed opposite
regulation as demonstrated by the high negative correlation (r2= -0.95). Moreover,
the PAC1 dedifferentiation and overexpression also showed a reasonable correlation
but positive, r2= 0.86 (Figure 4.15B, right). Thus, the correlations between the PAC1
dedifferentiation dataset and both knockdown and overexpression experiments make
biological sense. In order to better visualize those co-regulated events, 289 skipped
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exons (SE) events identified in PAC1 dedifferentiation were plotted in a heatmap after
performing hierarchical clustering of the samples and events (Figure 4.16). RBPMS
was sufficient to reciprocally switch the splicing patterns towards the other SMC state
in two identified clusters, 1 and 4, corresponding to RBPMS activated and repressed
cassette exons respectively.
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Fig. 4.15 RBPMS controls ASEs also regulated during PAC1 cells dediffer-
entiation. A Venn diagram of ASEs identified in RBPMS knockdown, overexpression
and PAC1 dedifferentiation. Fold-change (FC) enrichment are also shown. Significance
was tested by a hypergeometric test and P-value is described as * P < 0.05, ** P <
0.01, *** P < 0.001. B ∆PSI correlation of the ASEs overlapping between PAC1 cells
dedifferentiation and either RBPMS knockdown (green) or RBPMS-A overexpression
(blue). Black line indicates the linear regression model. Pearson correlation test
results are shown in the plot. The correlation statistical significance and coefficient are
indicated by the p-value and r2 in the plot.
In the same manner, comparisons were carried out using the aorta tissue dedifferen-
tiation dataset (Figure 4.17). Of the 1714 regulated ASEs between fully differentiated
aorta tissue and proliferative passage 9 (T-P9), ∼15% were also regulated by RBPMS-A
overexpression in PAC1 cells (265 events). On the other hand, only a fifth of that
number was found to be regulated by RBPMS knockdown (48 ASEs). The regulation
of tissue-like splicing was also confirmed by the correlation of the PSI values of the
overlapping ASEs, r2= -0.39 and 0.68 for knockdown and overexpression, respectively.
Additionally, in the examples shown in Figure 4.13, RBPMS-A overexpression activated
and repressed the alternative exons of Ptprf and Piezo1 beyond the inclusion levels
observed in the differentiated PAC1. We therefore hypothesized that RBPMS over-
expression could rescue fully differentiated patterns characteristic of SMC tissue-like
state which are usually not seen in the PAC1 cells. Consistent with RBPMS regulation
of SMC tissue-like patterns, a heatmap of tissue-regulated cassette exons (590 SE
events) revealed two clusters consisting of events regulated upon RBPMS-A overex-
pression and during aorta dedifferentiation but not PAC1 cells nor knockdown (Figure
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Fig. 4.16 RBPMS knockdown and overexpression reproduces PAC1 prolif-
erative and differentiated splicing, respectively. Heatmap of PAC1 dedifferen-
tiation regulated events (D Ctr - P Ctr comparison, 289 cassette exons). Columns
represent the triplicates (1-3) from RBPMS knockdown and overexpression (D Ctr, D
KD, P Ctr and P OE). Rows indicate ASEs and the blue and green colors represent
low and high PSI Z-scores. Hierarchical clustering was applied to samples and ASE
(columns and rows). Dendrogram illustrating hierarchical relationship between samples
is shown at the top. ASE clusters are shown on the left as well as the number of events
in each cluster. The PSI Z-score pattern of each cluster is plotted on the right. Mean
of the PSI Z-score is shown in red.
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4.18). Clusters 1 and 4, representing RBPMS activated and repressed aorta tissue SEs,
accounted for ∼23% of all the SE events regulated in aorta tissue dedifferentiation.
To further investigate these events in which RBPMS promoted the tissue-like state,
sashimi plots were generated including RBPMS samples in PAC1 cells alongside aorta
tissue dedifferentiation for comparison (Figure 4.19). Fermt2 for example is a member
of cluster 1 in which its differentiated cassette exon is only included in the aorta
tissue (PSI= 36.5) and not in the PAC1 cells (PSI= ∼2.8) except when RBPMS-A
is overexpressed (PSI= 38.7). Another example is Tsc2 from cluster 4, in this case
RBPMS-A overexpression repressed (PSI= 49.7) this exon which is more included in
the proliferative P9 (PSI= 83.1) and not regulated in the PAC1 cells (PSI= ∼79).
Lastly, Cald1 is another example of a tissue splicing event that is never seen regulated
in culture, but of which its inclusion is recapitulated by overexpression of RBPMS
(∼90 folds increase in PSI). This ASE is a complex event involving a cassette exon 4 as
well as an A5SS on exon 3. The use of the downstream alternative 5′SS together with
exon 4 produces a transcript that encodes the heavy caldesmon isoform (h-CALD1), a
well known marker of differentiated SMCs. Cald1 AS was also validated at the protein
level in western blots carried out by C. Gooding (Appendix - Figure A.2).
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Fig. 4.17 RBPMS controls ASEs also regulated during aorta tissue dediffer-
entiation. A Venn diagram of ASEs identified in RBPMS knockdown, overexpression
and rat aorta tissue dedifferentiation. Fold-change (FC) enrichment are also shown.
Significance was tested by a hypergeometric test and P-value is described as * P <
0.05, ** P < 0.01, *** P < 0.001. B ∆PSI correlation of the ASEs overlapping between
rat aorta tissue dedifferentiation and either RBPMS knockdown, green, or RBPMS-A
overexpression, blue. Black line indicates the linear regression model. Pearson corre-
lation test results are shown in the plot. The correlation statistical significance and
coefficient are indicated by the p-value and r2 in the plot.
In summary, it was shown here that RBPMS can regulate splicing of a subset
of SMC-specific ASEs consisting of a 20% of all the ASEs regulated during PAC1
dedifferentiation. RBPMS not only reproduced the PAC1 differentiated splicing pattern,
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Fig. 4.18 RBPMS overexpression rescues rat aorta tissue differentiated
splicing patterns. Heatmap of aorta tissue dedifferentiation regulated events (T -
P9 Ctr comparison, 590 cassette exons). Columns represent the triplicates (1-3) from
aorta dedifferentiation, RBPMS knockdown and overexpression (T, P9, D Ctr, D KD,
P Ctr and P OE). Rows indicate ASEs and the blue and green colors represent low and
high PSI Z-scores. Hierarchical clustering was applied to samples and ASE (columns
and rows). Dendrogram illustrating hierarchical relationship between samples is shown
at the top. ASE clusters are shown on the left as well as the number of events in each
cluster. The PSI Z-score pattern of each cluster is plotted on the right. Mean of the
PSI Z-score is shown in red.
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Fig. 4.19 RBPMS strongly regulates tissue patterns of Fermt2, Tsc2 and
Cald1 Sashimi plots of ASEs in which RBPMS overexpression recapitulates patterns
only seen in tissue. Fermt2 from Cluster 1, and Cald1 mis-clustered to Cluster 3
are examples of RBPMS activation whereas Tsc2 represents a repression event from
Cluster 4. Numbers on top of the arches indicate number of reads mapping to the exon
junctions. Means of the PSI values calculated by rMATS are shown on the right. For
Cald1, an alternative PSI was manually calculated to account its A5SS and is shown in
front of the rMATS PSI. Schematic of the alternative transcripts are shown below the
sashimi plots, are the chromosome coordinates.
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but also recapitulated tissue-like splicing patterns that are rarely observed in cultured
cells.
4.2.2.4 RBPMS global target functional analysis
To gain more information about the genes regulated by RBPMS, Gene Ontology (GO)
analyses were carried out as described in the Material and Methods chapter. Genes
with changes in their transcript levels upon RBPMS manipulation either did not show
enrichment or were enriched for functions involved in stress response (Tables 4.5 and
4.6). On the other hand, the PAC1 dataset was enriched for functions involved in the
SMC phenotypic switch, such as muscle development, contraction, cell proliferation
and migration (Table 4.7).
Table 4.5 GO analysis of genes differentially abundant upon RBPMS knockdown
GO.Term Description Enrichment N Category
Downregulated
No enrichment CC
No enrichment MF
No enrichment BP
Upregulated
GO:0005615 Extracellular space 3.5 16 CC
GO:0005576 Extracellular region 4.6 11 CC
No enrichment MF
GO:0051707 Response to other organism 7.0 20 BP
GO:0009607 Response to biotic stimulus 5.1 25 BP
GO:0043207 Response to external biotic stimulus 5.17 24 BP
GO:0009615 Response to virus 9.0 13 BP
GO:0006952 Defense response 5.0 19 BP
Next, GO enrichment was assessed for the genes whose splicing was affected
by RBPMS knockdown, overexpression or during PAC1 and aorta dedifferentiation
(Figure 4.20). RBPMS knockdown targeted genes involved in processes, components
and functions similar to the SMC dedifferentiation (PAC1 and aorta), for instance actin
filament based process, cell junction and regulation of GTPase (Appendix - Table A1,
for list of genes from enriched GO terms). RBPMS-A overexpression affected splicing
of genes associated with regulation of GTPase activity and microtubule organization
which are relevant to SMC biology, however it also affected genes with various other
functions with less clear implications on the SMC biology.
In view of the fact that genes marked by super-enhancers are important for the cell
function and identity, it was tested whether RBPMS knockdown-mediated ASEs were
enriched for SM super-enhancer associated genes (Figure 4.21). Enrichment was verified
for three different SM tissues super-enhancers (aorta, bladder and stomach smooth
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Fig. 4.20 RBPMS regulated ASE are enriched for SMC functions. GO
analysis of genes differentially spliced by RBPMS knockdown (KD), overexpression
(OE), PAC1 dedifferentiation (D Ctr - P Ctr) and aorta tissue dedifferentiation (T
- P9). Enriched GO terms were ranked by p-value and only the top five are shown
for each category. Numbers in front and within the bars indicate the fold enrichment
relative to the background number of genes and the number of genes in the enriched
term.
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Table 4.6 GO analysis of genes differentially abundant upon RBPMS-A overexpression
GO.Term Description Enrichment N Category
Downregulated
No enrichment CC
No enrichment MF
GO:0006575 Cellular modified amino acid metabolic process 8.42 11 BP
Upregulated
GO:0005887 Integral component of plasma membrane 2.3 37 CC
GO:0005615 Extracellular space 2.1 45 CC
GO:0044421 Extracellular region part 1.9 56 CC
GO:0031226 Intrinsic component of plasma membrane 2.2 39 CC
GO:0099056 Integral component of presynaptic membrane 5.6 10 CC
GO:0004888 Transmembrane signaling receptor activity 3.0 29 MF
GO:0038023 Signaling receptor activity 2.6 35 MF
GO:0005230 Extracellular ligand-gated ion channel activity 14.9 6 MF
GO:0060089 Molecular transducer activity 2.4 37 MF
GO:0005231 Excitatory extracellular ligand-gated ion channel activity 18.7 5 MF
GO:0006952 Defense response 3.1 55 BP
GO:0098542 Defense response to other organism 4.1 32 BP
GO:0051707 Response to other organism 3.2 43 BP
GO:0051607 Defense response to virus 4.86 20 BP
GO:0009615 Response to virus 3.8 25 BP
muscle), revealing significant enrichment for genes associated with super-enhancers
in all of them. Approximately 15% of the splicing events were in super-enhancer
associated genes with an average of 2 fold increase in the enrichment compared to the
background. Thus, these data further enhance the importance of the RBPMS-affected
genes to the SMC biology.
Finally, the potential protein-protein interaction network affected by RBPMS
regulation of splicing was assessed using STRING (Szklarczyk et al., 2017) (Figure
4.22). For that, a more restricted list of ASE was created by combining the RBPMS
knockdown and PAC1 dedifferentiation co-regulated ASEs with the events commonly
regulated between RBPMS overexpression and aorta tissue (Material and Methods
Chapter). The PPI network obtained for RBPMS regulated ASEs showed genes
involved in protein phosphorylation (red), cell-substrate adherens junctions (yellow)
and cytoskeletal protein binding (blue). Many of the ASEs strongly regulated by
RBPMS, e.g. ACTN1, FLNB and ITGA7 (Table 4.3), are found as hubs in the network.
Furthermore, the functional importance of several of the nodes in the PPI network
was reinforced by their association with SM super-enhancers as highlighted in green
(Figure 4.22).
Therefore, in agreement with the hypothesis of RBPMS being a master regulator
of SMC, its targets comprised a functionally coherent set of genes involved in critical
SMC functions that were also associated with super-enhancers themselves.
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Table 4.7 GO analysis of genes differentially abundant upon PAC1 dedifferentiation
GO Term Description Enrichment N Category
Downregulated
GO:0005887 Integral component of plasma membrane 3.0 140 CC
GO:0044459 Plasma membrane part 2.0 293 CC
GO:0031226 Intrinsic component of plasma membrane 2.9 145 CC
GO:0031224 Intrinsic component of membrane 1.6 430 CC
GO:0016021 Integral component of membrane 1.6 416 CC
GO:0004888 Transmembrane signaling receptor activity 3.2 113 MF
GO:0060089 Molecular transducer activity 2.7 89 MF
GO:0004930 G protein-coupled receptor activity 3.9 118 MF
GO:0005216 Ion channel activity 2.8 42 MF
GO:0022838 substrate-specific channel activity 2.83 50 MF
GO:0007165 Signal transduction 1.5 364 BP
GO:0032501 Multicellular organismal process 1.6 304 BP
GO:0051239 Regulation of multicellular organismal process 1.5 345 BP
GO:0007166 Cell surface receptor signaling pathway 1.7 197 BP
GO:0032502 Developmental process 1.3 489 BP
Upregulated
GO:0031224 Intrinsic component of membrane 1.7 234 CC
GO:0016021 Integral component of membrane 1.7 227 CC
GO:0044459 Plasma membrane part 2.0 152 CC
GO:0044425 Membrane part 1.5 303 CC
GO:0044421 Extracellular region part 2.2 96 CC
GO:0004888 Transmembrane signaling receptor activity 3.2 46 MF
GO:0038023 Signaling receptor activity 2.7 55 MF
GO:0060089 Molecular transducer activity 2.5 57 MF
GO:0048018 Receptor ligand activity 3.0 28 MF
GO:0004930 G protein-coupled receptor activity 3.8 20 MF
GO:0007165 Signal transduction 1.5 196 BP
GO:0051239 Regulation of multicellular organismal process 1.5 178 BP
GO:0007166 Cell surface receptor signaling pathway 1.7 101 BP
GO:0009582 Detection of abiotic stimulus 5.6 14 BP
GO:0050920 Regulation of chemotaxis 3.2 27 BP
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Fig. 4.21 RBPMS regulated ASE are enriched in genes associated with
SM super-enhancers. Enrichment for SM super-enhancer associated genes in the
RBPMS knockdown regulated ASE. The set of all cassette exons detected by rMATS
(unregulated and regulated) in RBPMS knockdown is shown as background. Significance
was tested by a hypergeometric test and P-value is described as * P < 0.05, ** P <
0.01, *** P < 0.001.
4.3 Discussion
4.3.1 RBPMS is an AS regulator
RBPMS and RBPMS2 are conserved across vertebrates with orthologs present in
the animal models Drosophila and C. elegans, known as Couch Potato and MEC-8
respectively (Soufari and Mackereth, 2017). Although RBPMS and RBPMS2 proteins
localize to both nucleus and cytoplasm, it is mainly their cytoplasmic roles that have
been investigated. The nuclear role of RBPMS is restricted to transcriptional co-
regulation (Fu et al., 2015; Sun et al., 2006) whereas its cytoplasmic roles are involved
in several RNA biology processes such as mRNA stability (Rambout et al., 2016),
transport (Hörnberg et al., 2013) and localization in cytoplasmic granules (Farazi et al.,
2014; Furukawa et al., 2015; Hörnberg et al., 2013). RBPMS2 was shown to interact
with eEF2, eukaryote elongation factor-2, to regulate translational control of specific
RNAs of gastrointestinal SMC (Sagnol et al., 2014).
RBPMS has been reported to act as a transcriptional co-activator by enhancing the
transcription activity of SMAD proteins and also by repressing a family of transcrip-
tional factors, AP-1 (Fu et al., 2015; Sun et al., 2006). However, reciprocal changes in
mRNA abundance upon manipulation of RBPMS levels were restricted to only four
genes other than Rbpms (Fst, P4ha2, AABR07022144.1, LOC100911692 ), providing no
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Fig. 4.22 RBPMS affects a PPI network involved in SMC functions. Protein-
Protein Interaction (PPI) network was generated using STRING and a set of ASEs from
the combination of the overlap between RBPMS knockdown and PAC1 dedifferentiation
and the overlap between RBPMS-A overexpression and aorta dedifferentiation. Network
edges indicate interaction confidence. GO terms enriched in the dataset are also
highlighted in red, blue and yellow. Genes associated with SM super-enhancers are
shown in bold font and are also highlighted in green according to the number of SM
tissues where they were found associated with super-enhancers (aorta, bladder or
stomach SM), dark green represents association in all the SM tissues.
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evidence for a transcriptional role by RBPMS. In agreement with the SMC literature,
PAC1 cells dedifferentiation was accompanied by substantial changes in the mRNA
abundance of many genes, such as SMC differentiation markers (Owens et al., 2004;
Rothman et al., 1992). In terms of splicing changes, both RBPMS knockdown and over-
expression dramatically affected AS of the PAC1 cell transcriptome. In fact, changes
in mRNA abundance upon RBPMS were largely outnumbered by regulated AS events.
Furthermore, other studies disclosed the remarkable feature that transcriptional and
post-transcriptional controls tend to focus on different set of genes. Therefore it is
not surprising that little overlap was observed between the genes controlled at the
expression and AS for all the comparisons analyzed here (Blencowe, 2006).
RBPMS family members, apart from MEC-8, have not been implicated in splicing
regulation. In the nematode C. elegans, RBPMS homolog, MEC-8, was described to
regulate splicing of Unc-52 transcripts (Lundquist et al., 1996). In the only study
that focused on RBPMS functions in mRNA processing in the human HEK293 cell
line PAR-CLIP and mRNA-seq were performed for the identification of RBPMS
preferred sites and transcriptome-wide targets, but no regulated ASEs associated with
RBPMS binding was identified (Farazi et al., 2014). Nevertheless, reanalysis of RBPMS
overexpression in HEK293 from Farazi et al. (2014) using rMATS was performed by Dr.
Miriam Llorian and it revealed a few regulated ASEs, including ITGA7, FLNB (Figure
4.23) and FN1 also identified in the PAC1 cells. Actually, as a splicing regulator
RBPMS can only regulate actively transcribed genes, thus it is unsurprising that only a
few genes were found differentially spliced in HEK293 cells, given that RBPMS mainly
regulated SMC transcripts. In that way, it seems unlikely that RBPMS is sufficient to
initiate SMC differentiation.
Finally, although related family members are sometimes able to compensate for
the manipulation of an RBP level (Mockenhaupt and Makeyev, 2015), no alterations
in Rbpms2 transcript levels were observed in any of the treatments. Additionally,
Rbpms2 knockdown alone had no effects on splicing and when combined with Rbpms
knockdown it did not increase the splicing changes. This is probably explained by the
low expression levels of the paralog in the SMCs (Figure 3.4 and 4.7).
Therefore, the data presented here provide the strongest evidence to date for the
widespread molecular function of RBPMS as a splicing regulator.
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Fig. 4.23 FLNB alternative splicing event found by reanalysis of Farazi et
al 2014 using rMATS. Sashimi plot for Flnb exon H1, identified in the reanalysis of
Farazi et al 2014. Numbers on top of the arches indicate number of reads mapping to
the exon junctions. Mean of the PSI values calculated by rMATS are shown on the
right. Schematics of the transcript isoforms are shown at the bottom. Regulated H1
exon is highlighted in green.
4.3.2 RBPMS promotes the differentiated AS program of
VSMCs
RNAseq of PAC1 cells in which RBPMS levels were manipulated revealed this RNA-
binding protein (RBP) as a splicing regulator in SMCs, repressing and activating
hundreds of ASEs (Figure 4.11), majority of which were regulated towards a more
differentiated SMC program, as indicated by the correlation coefficients (Figure 4.15).
Indeed, RBPMS was found associated with super-enhancers in adult human SM tissues
(Hnisz et al., 2013) and besides promoting the SMC patterns in the PAC1 cells, RBPMS
overexpression was able to reproduce aorta tissue splicing patterns in the proliferative
PAC1 cells (Figure 4.18 and 4.19). Cald1, Fermt2, Tsc2, Tns1, Tpm1 and Actn1
were some of the ASEs whose splicing levels were comparable to fully differentiated
tissue SMC. In the case of Cald1, Fermt2, Tsc2 and Tns1 their regulation was never
seen in the cultured PAC1 cells; but RBPMS was sufficient to promote their fully
differentiated tissue-like splicing. Thereby, this suggests that RBPMS may play a
key role in maintaining adult SMC phenotype. In addition, several studies have
reported RBPMS anti-proliferative tumor-suppressive activity, supporting its role in
the non-proliferative SMC state (Fu et al., 2015; Hou et al., 2018; Rastgoo et al., 2018).
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Despite the lack of RBPMS studies in SMCs, its paralog RBPMS2 has been
implicated in a critical role in gastrointestinal SMCs. RBPMS2 is indeed found to be
associated with super-enhancers in stomach SM and it was shown to be expressed in
visceral SMC during early developmental stages, decreasing in mature cells (Notarnicola
et al., 2012). In contrast with the hypothesis suggested here and with the results
observed upon manipulation of RBPMS levels in PAC1 cells, sustained overexpression
of RBPMS2 in chicken visceral SMCs induced their dedifferentiation and loss of
contractility (Notarnicola et al., 2012). RBPMS2 stimulated the proliferative phenotype
by increasing Noggin expression as well as translationally upregulating Noggin via
interaction with an elongation factor, eEF2 (Notarnicola et al., 2012; Sagnol et al., 2014).
Noggin then leads to inhibition of the BMP signaling, a pathway that prevents SMC
dedifferentiation (Notarnicola et al., 2012; Sagnol et al., 2014). However, no regulation
of Noggin transcripts was observed in any of the PAC1 conditions analyzed by mRNA-
seq. Indeed its expression was only detected in the proliferative cells at a very low
level ( ∼3 TPM). Finally, similar to RBPMS-A, RBPMS2 promoted the SMC splicing
pattern when overexpressed in PAC1, HeLa and HEK293 cells (Figure 3.12, 3.14, 3.13),
indicating that RBPMS paralogs have an intrinsically similar molecular activity. The
reasons determining the discrepancy between the promotion of differentiated splicing
patterns by RBPMS2 but the dedifferentiation phenotype reported in visceral SMCs
remain unclear. Variation of pre-mRNAs and mRNA targets, subcellular localization,
interacting protein partners, post-translational modifications and in cell signaling
pathways are all plausible explanations for the differential modulation of RBPMS and
RBPMS2 activity across SM tissues.
Thus, in VSMC RBPMS acts as a splicing regulator by activating and repressing
splicing of ASEs towards the mature differentiated SM AS program. Moreover, previous
results suggest this to be a feature shared between the paralogs.
4.3.3 RBPMS regulates AS of mRNAs important for SMC
functions
SMC phenotypic plasticity is marked by the capability of interconversion between a
more contractile state and proliferative, migratory and secretory phenotype (Owens
et al., 2004). This switching is concerted by the modulation of the repertoire of
contractile proteins as well as its rearrangement in order to confer more motility to
individual cells instead of composing the tissue-contraction machinery (Ye et al., 2014).
This remodeling is achieved by regulation of the actin cytoskeleton network and by its
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anchoring to integrins in focal adhesions, which then determines the connections to
the extracellular matrix (ECM). Furthermore, this reorganization of contractile and
cytoskeletal proteins has been reported to also happen to aortic SMC in culture (Worth
et al., 2001). Strikingly, RBPMS-regulated AS of transcripts that are involved in the
cytoskeleton organization process, including targets with functions in cytoskeleton
binding and more specifically actin binding (Figure 4.20 and 4.22). Additionally,
the integrin adhesome (Horton et al., 2015), ECM components and GTPase activity
regulators were other targets of RBPMS-mediated AS. These functions are all critical
for the cytoskeleton reorganization by contributing to the cell-matrix adhesion and
cytoskeleton dynamics (Bar-Sagi and Hall, 2000; Frismantiene et al., 2018; Horton
et al., 2015). Consistent with that, both PAC1 cells and aorta tissue dedifferentiation
exhibited similar GO terms enrichment to the RBPMS-regulated AS events. Further
evidence of the importance of RBPMS targets was provided by the fact that they
also show proximity to super-enhancers in SM tissues (Figure 4.21). Actually, some
of these, for instance Actn1, Flnb and Tns1, are super-enhancer associated, directly
interact with actin and integrins and constitute three of the four modules defined by
the consensus integrin adhesome (Horton et al., 2015). In fact, Vcl, which was also
found to be regulated by RBPMS overexpression, is a major component of the fourth
module, establishing interactions to components of the other modules. However, its
interaction to integrin is indirect and mediated by Talin proteins (Horton et al., 2015).
Focal adhesions and the integrin adhesome comprise multi-molecular mechanosen-
sitive complexes, participating in both adhesion to the ECM as well as intracellular
signaling by sensing mechanical cues from the environment (Wehrle-Haller, 2012).
The adhesion dynamics are in part controlled by phosphorylation of tyrosine residues
of its components, such as PXN and FAK (Wehrle-Haller, 2012). Interestingly, a
small cluster formed by the receptor tyrosine phosphatase PTPRF and two interacting
proteins PPFIA1 and PPFIBP1 are found regulated by RBPMS (Figure 4.12 and 4.13).
RBPMS promoted inclusion of the LAR Alternatively Spliced Element-a (LASE-a) in
the Ptprf transcripts. This exon adds a short peptide sequence, GSSAPSCPNISS, to
the proximal membrane region of the PTPRF protein (Honkaniemi et al., 1998). This
event has been associated with intraneuronal localization via potential targeting of the
introduced serine residues to phosphorylation (Honkaniemi et al., 1998). In contrast,
the roles of the interacting proteins splicing isoforms, PPFIA1 and PPFIBP1, are
less understood. Another regulator of cell adhesion found differentially spliced upon
RBPMS is the mechanosensitive ion channel coding gene Piezo1 (Figure 4.13). PIEZO1
is critical in SMCs during arterial remodeling in hypertension (Retailleau et al., 2015)
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and although functional differences of its paralog, PIEZO2, splicing isoforms have
been reported (Szczot et al., 2017), not much is known about the RBPMS-repressed
exon. The regulated event lies within the conserved Piezo1 domain, neighboring the
mechanosensing "beam" (Liang and Howard, 2018). Therefore, it could probably lead
to effects on its protein function.
Components of the ECM were also affected by RBPMS, including FN1, COL6A3
and HSPG2. Fibronectin (FN1) exon EDB (also referred as EDII) was more included by
RBPMS. Functional consequences are restricted to in vitro studies showing mild defects
in matrix assembly and proliferation by EDB-/- embryonic fibroblasts (MEF) (White
et al., 2008). However, no significant phenotype was observed in vivo EDB-/- mice
(White et al., 2008). The COL6A3 splicing isoforms have not yet been functionally
characterized, although these ASEs were reported to be affected in colon cancer
(Gardina et al., 2006). Notably, Hspg2 encodes the perlecan protein, a key component
of the vascular ECM, which is actually the identified splicing target of MEC-8 in C.
elegans (Lundquist et al., 1996).
Interestingly a small network identified in the PPI analysis, involves proteins from
the secretory pathway, GOLIM4, GOLGA2, GOLGB1 and COG1. This reflects the
transition from a differentiated phenotype to a more synthetically active cell state
observed in the proliferative SMC (Owens et al., 2004). Indeed, a recent genome-wide
study identified AS as a regulator of the protein transport efficiency by generation of
alternative isoforms in a tissue-specific manner (Neumann et al., 2019). Therefore, it
is possible that regulation of these events by RBPMS could have direct effects in the
SMC secretory pathway, yet more functional studies are required to elucidate the role
of these isoforms in the SMC biology.
In a previous study from this laboratory, the AS program of the differentiated
SMCs was for the first time profiled using an exon-junction microarray (Llorian et al.,
2016). Dedifferentiation of mouse SM tissues (aorta and bladder) was shown to
be achieved by concerted non-productive splicing of post-transcriptional regulators,
involving both auxiliary RBP and core splicing machinery components (Llorian et al.,
2016). However, significant changes in the expression of these factors were not observed
in the PAC1 dedifferentiation or upon RBPMS manipulation levels. This observation
might be explained by the expected differences between in vivo and in vitro SMC
cultures, for instance tissue dedifferentiation led to 5660 differential expressed genes
whereas approximately only half of that was regulated in the PAC1 cells (2774). Aorta
dedifferentiation also promoted far more alternative splicing changes (1714 events)
than PAC1 cells (635). Therefore, although retaining differentiated properties that
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allow to interrogate SMC dedifferentiation in culture (Rothman et al., 1992), the PAC1
cell line has its limitations.
Thus, consistent with the hypothesis that RBPMS is a master regulator of AS in
SMCs, a functionally coherent set of genes important for SMC function was affected by
RBPMS mediated splicing. Although the consequences of some of the splicing isoforms
promoted by RBPMS are better understood, the roles of many other regulated ASEs
remain to be characterized.
4.4 Final conclusions
In summary, this chapter aimed to uncover the global changes in AS upon RBPMS
knockdown and overexpression using a high-throughput RNAseq approach. Profiling
of the transcriptome of PAC1 cells upon manipulation of RBPMS levels allowed the
discovery of numerous RBPMS-regulated ASEs. RBPMS affected all five categories
of AS by activating and repressing splicing. Moreover, RBPMS controlled splicing
of 20% of the events regulated during the PAC1 dedifferentiation (50% of RBPMS
knockdown ASEs) and RBPMS levels are sufficient to explain these splicing changes
during this transition. Surprisingly, RBPMS overexpression was also capable of fully
recapitulating some SM tissue splicing patterns which are not seen in the cultured PAC1
cell line. Thus, RBPMS not only promoted the differentiated PAC1 SMC pattern but
also established a further differentiated profile typical of a SM tissue state. Consistent
with the master regulator hypothesis, RBPMS targeted a functionally related subset
of mRNAs involved in SMC functions, for instance cytoskeleton, GTPase activity
and cell adhesion. These are all functions important for the SMC switching from a
contractile differentiated to a more motile and proliferative state. Moreover, the PPI
network of RBPMS targets also revealed a cluster of genes involved in the secretory
pathway, a feature critical for the more proliferative SMCs that are more synthetically
active. Therefore, these data established RBPMS as a splicing regulator in VSMCs,
promoting the differentiated AS program in these cells as expected from a master
splicing regulator.
In conclusion, this chapter has the following points as the main findings:
1. RBPMS knockdown and overexpression of RBPMS-A alter AS of PAC1 cells.
2. RBPMS affected all AS types, with no preference towards any category.
3. RBPMS was able to repress and activate splicing, displaying some bias towards
repression in the case of RBPMS-A overexpression.
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4. RBPMS effects on AS outnumber mRNA abundance changes, with little overlap
between genes regulated by both processes.
5. RNAseq analysis by rMATS detected AS changes with high confidence as experi-
mentally validated by RT-PCR.
6. RNAseq allowed the profiling of the differentiated and proliferative PAC1 cell
transcriptomes, providing insights on the mRNA changes (abundance and AS)
during the phenotypic switching of this SMC cell line.
7. RBPMS promotes the SMC splicing pattern; accounting for 20% of all the AS
changes observed during PAC1 cells dedifferentiation.
8. RBPMS-A overexpression reproduced the adult aorta tissue splicing pattern (e.g.
Cald1, Fermt2 and Tsc2 ), not usually observed in the PAC1 cell line.
9. RBPMS affected splicing of transcripts involved in SMC functions as indicated
by the GO analysis.
10. RBPMS could potentially disrupt a PPI network associated with the SMC
transition from a contractile to a motile phenotype by rearrangement of the
cytoskeleton components.
11. RBPMS targets are enriched for SM super-enhancer associated genes, reinforcing
their importance to the SMC biology.
In addition to that, this chapter also led to other questions listed below:
• Does RBPMS regulation of the SMC splicing lead to phenotypic changes?
• Does RBPMS regulation of the cytoskeleton genes affect SMC contractility or
motility?
• Does RBPMS repress the exon NM or activate exon SM in Actn1 splic-
ing?
• Does RBPMS directly regulate splicing of these targets?
• Are the conserved CACs important for RBPMS regulation of the SMC
splicing?
• What is the mechanism behind RBPMS regulation of splicing?
• How do the isoforms display different activities in splicing?
The questions in bold were addressed in the following chapters of this study.

Chapter 5
RBPMS: a direct regulator of
alternative splicing
5.1 Introduction
5.1.1 RBPs in the regulation of AS
5.1.1.1 Direct regulation of AS
AS is primarily regulated by the combination of cis-elements embedded in the pre-
mRNA sequence and trans-factors comprised of RBPs (reviewed in (Fu and Ares, 2014)).
The regulatory sequences act as splicing enhancers or silencers depending on the context
that they are found. This reflects in the position-dependent principles that underlie
the regulation of AS by RBPs, a feature outlined by several biochemical and molecular
studies and better understood now with more global approaches (Witten and Ule,
2011). Generally, splicing regulatory RBPs are able to repress splicing upon interaction
with exonic and upstream intronic regions and to activate inclusion upon binding to
sites in the downstream intron (Fu and Ares, 2014). Therefore, these common set of
rules followed by different RBPs indicate shared mechanisms for regulating the splicing
apparatus. Eventually, further studies of other RBPs and RNA splicing maps will shed
more light on the global principles of the position-based splicing and identify other
specific mechanisms that differ from those proposed so far.
5.1.1.2 Indirect regulation of AS
Aside from the direct regulation of AS, RBPs are known to regulate indirect targets as a
result of cross-regulation of other splicing regulators or via protein-protein interactions
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that allow RNA interaction (Fu and Ares, 2014; Jangi and Sharp, 2014). The former
is achieved by the regulation of AS-NMD events within RBPs or by production of
protein isoforms that are either nonfunctional or dominant-negative (Jangi and Sharp,
2014). A well characterized example of cross-regulation between post-transcriptional
factors is the PTBP1/PTBP2 switch in neuronal cells. PTBP1 regulates an event in
PTBP2 that when skipped triggers NMD (Boutz et al., 2007a,b; Makeyev et al., 2007;
Spellman et al., 2007). However, during neuronal differentiation, downregulation of
PTBP1 by miR-124 relieves its repressive activity upon PTBP2 allowing expression
of PTBP2 in these cells (Makeyev et al., 2007). Nowadays, the advances in global
transcriptome approaches such as RNAseq and iCLIP (Individual-nucleotide resolution
Cross-Linking and ImmunoPrecipitation) allow distinguishing directly regulated targets
and uncovering events that are actually part of a cascade of secondary splicing changes
due to direct regulation of splicing factors (Wollerton et al., 2004). For instance, by
applying these two approaches in parallel, Rbfox2 was shown to affect the gene expres-
sion of a network of RBPs via AS-NMD subsequently causing indirect splicing changes
(Jangi et al., 2014). Moreover, other RBPs are expected to be regulated in a similar
manner, since genes encoding splicing factors are enriched for AS-NMD events (Jangi
and Sharp, 2014). Finally, RBPs are likely to establish protein-protein interactions and
whether homotypic or heterotypic they all could affect the splicing outcome (Witten
and Ule, 2011). AS decisions can be modulated by the different conformational changes
in the pre-mRNA depending on the RBPs bound to it. Alternatively, larger complexes
comprising different RBPs can expand the targets of an RBP by allowing binding to
motifs that are specific to other components of the complex. Indeed, the latter has
been shown to be the case for RBFOX proteins which take part in a large assembly of
splicing regulators (LASR) involving several hnRNPs and other RBPs. Interestingly,
RBFOX was able to affect splicing using LASR component hnRNP M binding sites
(Damianov et al., 2016).
Therefore, RBPs are critical regulators of AS, affecting splicing in a direct and
indirect manner. In addition, the combinatorial nature of AS regulation is also
important for the establishment of tissue-specific programs (Baralle and Giudice, 2017;
Jangi and Sharp, 2014).
5.1.2 RNA binding by the RBPMS RRM domain
PAR-CLIP combined with structural analysis of RBPMS uncovered its RNA binding
features (Farazi et al., 2014; Sagnol et al., 2014; Teplova et al., 2016). RBPMS binding
to RNA was observed in several studies, but it was only in Farazi et al. (2014) that
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RBPMS global RNA targets were determined in HEK293, leading to the identification
of its binding motif as tandem CAC trinucleotides separated by variable spacer length
(1-10 nt). This recognition element has also been shown to be the preferred binding
site of the RBPMS ortholog proteins, CPO and MEC-8 in C. elegans and Drosophila
respectively (Soufari and Mackereth, 2017). PAR-CLIP defined RBPMS-binding sites
were distributed among 3′-UTR, intron, exons and repetitive regions. More than
half of the binding sites were found in the former two locations (Farazi et al., 2014).
Moreover, the crystal structure of human RBPMS RRM (residues 14-111), both free and
bound to UCACU RNA molecules, allowed further characterization of RBPMS residues
involved in RNA binding (Teplova et al., 2016). Briefly, RBPMS RRM comprises of
four-stranded anti-parallel β-sheets packed against a pair of α-helices, thus assuming
the classical RRM fold. Conserved aromatic amino acids, Phe27 and Phe65, were
key residues in the establishment of the intermolecular interaction. Other residues
involved in the RNA binding are highlighted in Figure 5.1. Consistent with the pair of
CACs identified by PAR-CLIP as the RBPMS RRM recognition element, structural
studies revealed RBPMS dimerisation properties (Teplova et al., 2016). Dimerisation
was achieved by residues within the RRM domain and it was critical to RBPMS RNA
binding. RBPMS dimeric nature is further discussed in Chapter 7. Furthermore,
analysis of RNA binding mutants addressed the requirement of a functional RRM
for RBPMS localization to stress granules in HEK293 cells (Teplova et al., 2016). In
parallel to RBPMS structure, another study resolved RBPMS2 structure underlying
similar features between the paralogs (Sagnol et al., 2014).
Taken together the fact that RBPs can directly and indirectly affect splicing as well
as being aware of the features underlying RBPMS binding to RNA, work described in
this chapter set to unravel whether the splicing changes observed upon manipulation
of RBPMS levels in PAC1 cells result from direct binding of RBPMS. To address this,
bioinformatic and biochemical approaches were applied.
5.2 Results
5.2.1 RBPMS regulates ASEs enriched for tandem CAC mo-
tifs separated by variable spacer length
To address whether the ASEs identified in the PAC1 RNAseq were directly regulated
by RBPMS, motif enrichment analyses were carried out by Dr. Aishwarya Jacobs
using the Matt toolkit (Gohr and Irimia, 2018). Analyses were performed using
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Fig. 5.1 Structure of RBPMS bound to CAC RNA molecule Crystal structure
of RBPMS (gray) bound to a CAC RNA molecule (blue and green representing C
and A nucleotides respectively). The residues involved in the RNA binding are
labeled and highlighted in green. Image was generated using PyMol (v2.3.0) and the
deposited structure of RBPMS RRM–RNA complex from the Research Collaboratory
for Structural Bioinformatics PDB (accession code 5DET).
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RBPMS binding motif (Farazi et al., 2014) and cassette exons regulated during PAC1
dedifferentiation, RBPMS knockdown and overexpression. Exonic and adjacent intronic
regions were analyzed for enrichment revealing a distribution pattern similar to the
position-dependent activity of other RBPs (Fu and Ares, 2014). Pairs of CACs
separated by 1-12 nt (CACN1-12CAC) were significantly enriched upstream (∼100 nt)
and within exons repressed by RBPMS whereas exons activated showed enrichment
in the downstream intron (Figure 5.2 and summarized in 5.3). The clearer position
patterns in the RBPMS-map generated using the RBPMS-A overexpression dataset
are explained by the total number of events found regulated in this experiment and
consequently the number of events used in the motif enrichment analysis (2965 versus
99). Moreover, consistent with its role in AS during SMC switching, CACN1-12CAC
enrichment was also identified around exons regulated during PAC1 dedifferentiation
(Figure 5.2). Exons more included in the differentiated state displayed downstream
enrichment and in those more included in the proliferative state, CAC motifs were
found within and upstream of the regulated exon (Figure 5.2). Furthermore, significant
depletion of RBPMS binding sites was also detected upstream and within exons
repressed by RBPMS-A overexpression (Figure 5.2 and 5.3).
Therefore, RBPMS is likely to directly regulate AS of its targets since enrichment
for its optimal recognition element was found around regulated exons. In addition, it
is possible that binding to repressive areas is dominant over activation as indicated by
the depletion of CACs in repressive locations for exons that are activated by RBPMS
overexpression.
5.2.2 RBPMS regulation of splicing relies on the recognition
of CAC motifs
To further validate the importance of RBPMS cis-elements in the regulated exons,
HEK293 cells were co-transfected with minigene reporters and RBPMS expression
vectors (Figure 5.4). Minigenes were representative of RBPMS-activated and RBPMS-
repressed ASEs, Flnb and Tpm1 respectively. Both regulated exons presented potential
RBPMS motifs in the expected locations, downstream for activation and upstream
for repression (Figure 5.5 and 3.11). Regulation of endogenous ASEs by RBPMS
overexpression in HEK293 was previously established and described in Chapter 3. In
addition to the fact that RBPMS was sufficient to switch to the differentiated SMC
splicing pattern, RBPMS overexpression in HEK293 also highlighted some differential
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Fig. 5.2 RBPMS displays positional dependent splicing activity. RBPMS
motif maps in regulated cassette exons from PAC1 dedifferentiation (D Ctr - P Ctr),
top, RBPMS knockdown (D KD - D Ctr), middle, and RBPMS overexpression
(P OE - P Ctr), bottom. A pair of CACs separated by 1 to 12 nucleotides was
used as RBPMS binding site. Motif enrichment as well as depletion is shown for
upregulated or differentiated exons (green), downregulated or proliferative exons (blue)
and unregulated exons (gray). Motif maps were generated using the Matt toolkit.
Statistical significance calculated by the Matt toolkit is shown by the line width.
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Fig. 5.3 RBPMS motif enrichment in PAC1 dedifferentiation and RBPMS
experiments. Summary of RBPMS motif enrichment in the differentially spliced
cassette exons from all the PAC1 experiments. PAC1 dedifferentiation (D Ctr - P
Ctr), RBPMS knockdown (D Ctr - D KD), RBPMS overexpression (P OE - P Ctr). A
pair of CACs separated by 1 to 12 nucleotides was chosen as RBPMS motif. Values
in black represent fold enrichment and in red fold depletion. Top and bottom (green
and blue respectively) of the panel represent upregulated and downregulated cassette
exons. Statistical significance calculated by the Matt toolkit is shown as * p < 0.05, **
p < 0.01 and *** p < 0.001. Note: RBPMS knockdown comparison was inverted to
represent RBPMS repressed and activated events.
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activity between isoforms. Therefore, regulation of the minigenes was tested upon both
RBPMS-A and RBPMS-B isoforms and also its paralog, RBPMS2.
In a minigene context, Flnb exon H1 was included at a level similar to the endogenous
regulation in HEK293 cells (∼7%, Figure 3.13), whereas RBPMS-A and RBPMS2
strongly promoted inclusion of exon H1 (greater that 74% inclusion), being sufficient to
switch AS isoform to the long Flnb transcript (Figure 5.4). Despite showing significant
changes upon RBPMS-B expression, activation was observed to a lower extent (∼half
of the other proteins) (Figure 5.4). Yet RBPMS-B protein expression levels were higher
than the other proteins (Figure 5.4 - western blots). Likewise, Tpm1 minigene showed
basal inclusion level close to 100% (Figure 5.4) comparable to the endogenous levels in
HEK293 cells (Figure 3.13), in which exon 3 was nearly completely included. Once
more, RBPMS-A was sufficient to cause a near complete switch to exon 3 exclusion
(Figure 5.4). RBPMS 2 was the second more active protein causing skipping of 47%
of exon 3 (Figure 5.4). Lastly, RBPMS-B was the least active protein, three fold less
active than RBPMS-A (Figure 5.4), even though it was expressed at a similar level
to RBPMS-A as shown by the western blots. Thus, both minigene reporters could
reproduce the endogenous AS response to RBPMS-A overexpression, showing a similar
isoform dependent activity, in which RBPMS-B has the lowest activity.
To uncover the cis-elements involved in the RBPMS-mediated splicing, CAC motifs
downstream of Flnb and upstream of Tpm1 alternative exons were mutated to CCC
in the minigene reporters. This point mutation was shown to be sufficient to impair
RBPMS binding (Farazi et al., 2014). The response to RBPMS was then assessed by
overexpression of the most active isoform in HEK293 cells. Mutation of the individual
clusters of CAC motifs downstream of exon H1 (12 motifs divided into three clusters -
5.6A and B) did not affect the basal splicing of Flnb exon H1 in HEK293 cells, yet it
revealed the importance of the second and third clusters for activation by RBPMS-
A (PSI< 16%) (Figure 5.6C). Additionally, consistent with that, the minigene with
all of the CACs mutated was completely unresponsive to RBPMS-A overexpression
(Figure 5.6E). Fredderick Richards, a Part III student working under my day to day
supervision in the laboratory, generated a Tpm1 minigene reporter in which all nine
CAC motifs upstream of Tpm1 exon 3 were mutated to CCC (Figure 5.7A). CAC
mutations in the Tpm1 minigene reporter did not impair the basal exon inclusion
observed in HEK293 cells, ∼100% inclusion of exon 3 (Figure 5.7A). However, mutation
completely abrogated RBPMS repression of Tpm1 exon 3 (PSIex3= 96.6). Moreover,
intermediate effects were obtained with individual and combined clusters (Appendix
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Fig. 5.4 RBPMS regulates splicing of Flnb and Tpm1 minigenes. Flnb exon
H1, left, and Tpm1 exon 3 minigene reporters, right, co-transfected with RBPMS
in HEK293 cells. Schematics of the minigenes are shown at the top. RT-PCRs for
the splicing patterns. PSI values are shown as mean ± sd from n=3. For Flnb, both
long and short isoforms were accounted for the final inclusion levels (PSIH1). Isoform
schematics on the side identify the PCR product. Differentiated exon is shown in
green and proliferative exon in blue. Western blot against GFP to verify Venus tagged
RBPMS levels. GAPDH was used as a loading control. Statistical significance from
Student’s t-test is shown as * p < 0.05, ** p < 0.01 and *** p < 0.001.
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Fig. 5.5 Conserved CAC motifs downstream of Flnb exon H1. Conserved CAC
motifs downstream of Flnb exon H1 are highlighted in blue. Intronic sequences shown
are located 120 and 328 nt downstream of Flnb exon H1. Basewise conservation track
and multiple alignment were generated by PhyloP and Multiz Alignments in the UCSC
genome browser. Chr coordinates: chr15:18,780,016-18,780,147 and chr15:18,779,810-
18,779,941.
- Figure A.3). Thus, CAC motifs adjacent to Flnb exon H1 and Tpm1 exon 3 are
required for activation and repression by RBPMS.
In the same manner, regulation of Actn1 exons NM and SM were further investigated
by transiently transfecting minigene reporters in HEK293 cells. Although rat Actn1
minigene and endogenous ACTN1 pairs of mutually exclusive exons were shown in
Chapter 3 to be regulated by RBPMS in PAC1 and HEK293 cells respectively, the
effects of overexpressed RBPMS could involve repression or activation of either the
NM or SM exon respectively (Figure 3.12B). However, due to the conserved CAC
motifs upstream of exon NM (Figure 3.11B and 5.8), it was hypothesized that RBPMS
promoted the SM pattern by repressing exon NM. To test this, first HEK293 cells
were co-transfected with the Actn1 reporter containing both exons (Figure 5.9). As
expected, exon NM was preferentially included in the HEK293 cells (PSI= 100%)
and a complete switch towards the SM differentiated pattern promoted by RBPMS-A
and RBPMS2 expression, but not RBPMS-B (Figure 5.9). Then, minigene reporters
containing only one of the Actn1 mutually exclusive exons (Southby et al., 1999) were
tested upon RBPMS overexpression (Figure 5.9).
The Actn1 reporter containing only the NM exon reproduced the complete switch
upon RBPMS-A and 2 expression (PSI= 0.0%) but not B (PSI= 73.8%) (Figure
5.9). This suggests that RBPMS acts on Actn1 AS by inhibiting inclusion of the NM
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Fig. 5.6 CAC motifs downstream of Flnb exon H1 are required for RBPMS
activation. A Schematic of the rat Flnb exon H1 minigene reporter. Potential RBPMS
binding sites downstream of exon H1 are highlighted. B Schematic of the Flnb mCAC
mutant minigenes (CAC to CCC). C RT-PCRs from HEK293 transient transfection
with RBPMS-A and the different Flnb single mCAC mutants. Experiment from n=1.
D Western blot for GFP to verify overexpression of Venus tagged RBPMS-A. E RT-
PCRs from HEK293 transient transfection with RBPMS-A and the Flnb minigene
reporter in which all the CACs were mutated. Values shown correspond to PSI ± sd
(n= 3). F Western blot for GFP to verify overexpression of Venus tagged RBPMS-A.
In C and F, reporter only and Venus controls were analyzed in parallel. Flnb isoforms
schematics on the left indicate the PCR products. Statistical significance was verified
by Student’s t test and is shown as * p < 0.05, ** p < 0.01 and *** p < 0.001. In D
and F, GAPDH was used a loading control.
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Fig. 5.7 CAC motifs upstream of Tpm1 exon 3 are required for RBPMS
repression. A Schematic of Tpm1 exon 3 minigene with upstream CAC clusters
highlighted. B RT-PCRs from HEK293 transiently transfected with RBPMS-A and
the Tpm1 minigene reporter wild-type (wt) and mCAC in which all the CACs were
mutated. Values shown correspond to PSI ± sd (n= 3). Statistical significance was
verified by Student’s t test and is shown as * p < 0.05, ** p < 0.01 and *** p < 0.001.
Bottom, western blot against GFP to verify overexpression of Venus tagged RBPMS-A.
GAPDH was used as a loading control. Protein size markers are indicated on the right.
exon. Nevertheless, the minigene containing only exon SM only produced the SM
included transcript in HEK293 cells despite the absence of an effector. In that way the
possibility that RBPMS also directly promotes inclusion of the exon SM could not be
fully excluded. Thus, these data further confirm the requirement of nearby CACs for
repression of the Actn1 NM exon by RBPMS and further mutations of these sites will
shed light on the importance of each clusters.
Thus, by repressing the NM exons of the two mutually exclusive events, Tpm1 and
Actn1, RBPMS promotes the SMC pattern in these two events. Moreover, RBPMS
is also able to switch Flnb splicing to the SMC pattern by activation of the exon H1.
In all of these events regulation by RBPMS was mediated by adjacent CAC motifs.
Finally, consistent with previous experiments carried out in this study, RBPMS-B was
the least active protein.
5.2.3 RBPMS directly binds to Flnb and Tpm1 RNAs via
CAC motifs
To confirm that the previously mutated CACs in the minigene reporters were actual
RBPMS binding sites, in vitro binding assays were performed using in vitro transcribed
5.2 Results 129
NMCAC1 CAC2 CAC3
CAC4cacacacaccaccttccac
caccctccccacccccctcac
caccac
CACTCCGGCAC
Actn1 exon NM minigene
NM
Fig. 5.8 Actn1 contains CAC motifs within and upstream of exon NM.
Schematic of the rat Actn1 minigene reporter containing only exon NM with CAC
clusters highlighted.
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Fig. 5.9 RBPMS represses the NM exon of Actn1. HEK293 cell co-transfected
with RBPMS isoforms and rat Actn1 minigenes containing the pair of mutually
exclusive exons (Actn1 ) or either one of them (Actn1 exon NM or SM). Schematics of
the minigenes are found at the top. RT-PCR products are identified by schematics on
the left. PSI values shown are mean ± sd (n= 3). Statistical significance was verified
by Student’s t test and is shown as * p < 0.05, ** p < 0.01 and *** p < 0.001. Bottom,
western blot against GFP to verify overexpression of Venus tagged RBPMS. GAPDH
was used as a loading control. Protein size markers are indicated on the right.
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RNAs and recombinant RBPMS-A and RBPMS-B proteins. Recombinant proteins
were obtained as detailed in Chapter 2. Briefly, recombinant proteins containing a
T7 and a 3xFLAG N-terminal tags and a His6 tail were expressed in E. coli, followed
by purification through two column systems. Isoform B was purified by a single
histidine-affinity chromatography step. Recombinant proteins were visualized in a
polyacrylamide gel and sequence verified by western blot (Figure 5.10). Additionally,
MALDI-TOF mass mapping analysis of both recombinant proteins, further validated
their identity and also eliminated any post-translational modification (Figure 5.10).
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Fig. 5.10 Rat RBPMS-A and RBPMS-B recombinant proteins. Left, quality
of RBPMS recombinant proteins were verified in polyacrylamide gel stained with
coomassie. Recombinant protein was loaded into the gel in a 1:2 serial dilution (2 -
0.25 µM). Specificity of the amino acid sequence of recombinant RBPMS proteins was
also verified by western blot using RBPMS and FLAG antibodies. Size markers are
indicated on the left. Right, RBPMS recombinant protein was verified by MALDI
mass spectrometry analysis and is shown for RBPMS-A and RBPMS-B. The two peaks
represent double and single charged RBPMS.
RBPMS binding to rat Flnb and Tpm1 CAC clusters was verified by using both
electrophoretic mobility shift assay (EMSA) and UV-crosslinking (Figure 5.11 and 5.12).
RBPMS-A and B isoforms bound to Flnb with similar apparent affinities (Kd ∼0.5
µM) (Figure 5.11). On the other hand, no binding was observed to the CAC mutant
RNAs (Flnb mCAC) (Figure 5.11). Moreover, binding to the wt but not to the mutant
Flnb RNA was also reproduced by UV-crosslinking, although in this assay, RBPMS-A
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showed greater intensity over RBPMS-B (Figure 5.11). For Tpm1, both RBPMS
isoforms bound to the wt RNA similarly to the binding observed for Flnb (Figure 5.12).
Although CAC mutations reduced the formation of the bound complex, they were not
sufficient to completely abrogate RBPMS binding (Figure 5.12). UV-crosslinking for
Tpm1 RNAs was very inefficient, although a faint band was observed for the wt but
not for the mutant RNAs (Figure 5.12). These data corroborate the fact that RBPMS
regulates splicing by directly binding to CAC elements downstream of activated exons
(Flnb) and upstream of repressed exons (Tpm1 ).
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Fig. 5.11 RBPMS binds to Flnb RNAs via CAC motifs. EMSA (top) and
UV-crosslink (bottom) using recombinant RBPMS-A and RBPMS-B and in vitro
transcribed Flnb RNA, wild-type and mCAC, corresponding to the intronic region
containing CAC clusters downstream of exon H1. in vitro binding experiments were
performed using recombinant protein in a serial dilution (1:4; 2 to 0.125 µM).
5.2.4 RBPMS binding mutant is not able to regulate splicing
Finally, to further confirm the direct regulation of splicing by RBPMS, an RNA binding
mutant version of RBPMS-A isoform was transiently transfected in HEK293 cells and
splicing changes assessed (Figure 5.13). The mutation of the lysine in the position 100
to a glutamic acid was previously reported to disrupt RBPMS binding to RNA and
therefore it was chosen for this study (Farazi et al., 2014). Consistent with all the
data presented so far, RBPMS wt was able to repress the NM exon from the mutually
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Fig. 5.12 RBPMS bind to Tpm1 RNAs via CAC motifs. EMSA (top) and
UV-crosslink (bottom) using recombinant RBPMS-A and B and in vitro transcribed
Tpm1 RNA, wild-type and mCAC, corresponding to the intronic region containing
CAC clusters upstream of exon 3. in vitro binding experiments were performed using
recombinant protein in a serial dilution (1:4; 2 to 0.125 µM).
exclusive events in the rat Tpm1 minigene reporter and endogenous ACTN1 as well
as activate splicing of endogenous FLNB and MPRIP cassette exons (Figure 5.13).
In contrast, the RNA binding mutant, which was expressed as similar protein levels
than the wt RBPMS-A, showed no splicing activity upon any of the four ASEs tested
(Figure 5.13). Once again these data show that RBPMS regulation of splicing, either
activation or repression, relies on direct binding to its RNA targets, with regulation
being lost upon disruption of the protein-RNA interaction.
Therefore, RBPMS is able to regulate splicing of its pre-mRNA targets by directly
binding to CAC sites present upstream or downstream of repressed and activated exons,
as shown by the impaired splicing upon disruption of either the cis-elements in the
minigene reporters or of the RNA binding capacity of RBPMS.
5.3 Discussion
RBPMS: a direct regulator of alternative splicing
RBPMS in vitro binding assays revealed that both isoforms could bind to Flnb and
Tpm1 RNAs and mutation of CAC motifs directly impacted binding of RBPMS (Figure
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Fig. 5.13 RBPMS binding mutant is not able to regulate splicing. RBPMS-A
binding mutant (K100E from Farazi et al. (2014)) was tested for regulation of rat
Tpm1 minigene reporter and endogenous ACTN1, FLNB and MPRIP splicing in
HEK293 cells. Wild-type RBPMS-A and RBPMS-B were tested alongside as well
as the reporter only and Venus controls. Schematic of RBPMS-A protein domain
arrangement, RRM amino acid sequence is found below it. Residues involved in RNA
binding are highlighted in green. RT-PCR products are identified by schematics on the
left. PSI values shown are mean ± sd (n= 3). Statistical significance was verified by
Student’s t test and is shown as * p < 0.05, ** p < 0.01 and *** p < 0.001. Western
blot against GFP to verify overexpression of Venus tagged RBPMS. GAPDH was used
as a loading control. Protein size markers are indicated on the right.
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5.11 and 5.12). The requirement of RNA binding was further confirmed in vivo by the
overexpression of an RNA binding mutant RBPMS-A, which was not able to promote
splicing changes as the wild-type (Figure 5.13). Consistent with that, a functional
RRM has previously been shown to be necessary for RBPMS localization to stress
granules in HEK293 cells (Farazi et al., 2014). Other studies have also reported similar
results (Gerber et al., 2002; Hörnberg et al., 2013; Kaufman et al., 2018), however
because the RBPMS mutant used had the full RRM deleted, it is not possible to
untangle whether the loss of function resulted from impairing RBPMS RNA binding
or dimerisation. Thus, the data presented here support RBPMS as a direct regulator
of AS in SMC.
The findings, however, are contrary to the results from Farazi et al. (2014), in which
no major role for RBPMS in mRNA splicing was found after RBPMS manipulation in
HEK293 cells and following transcriptional profiling. These opposite results are likely
to arise from the combination of the inefficient UV crosslinking in vitro and elimination
of ASE that although detected in the RNAseq did not display CLIP tags. In vitro
crosslinking experiments carried out for RBPMS and RNA targets (Flnb and Tpm1 )
were very inefficient, yet band shift experiments showed formation of RBPMS-RNA
complexes (Figure 5.11 and 5.12). Therefore, targets like Actn1 and Flnb that are
regulated in HEK293 cells might not have presented PAR-CLIP tags in Farazi et al.
(2014) due to the limitations of the crosslinking approach. Although the PAR-CLIP
was carried out with 4-thioU which is supposed to be more efficient. Nevertheless, the
use of minigene constructs for these splicing events (Tpm1, Actn1 and Flnb) proved
functional binding of RBPMS. For the future, CLIP should be applied to investigate
global RNA targets of RBPMS in more relevant biological system. For instance, PAC1
cells or embryonic stem cell derived VSMCs (ES-VSMCs) (Cheung et al., 2014) in
which more target transcripts would be expressed at high levels.
Interestingly, RBPMS-B lower activity in splicing could not be explained by impaired
binding as indicated by the EMSAs (Figure 5.11). Therefore, it is possible that RBPMS
repressive function is mediated by RBPMS-A C-terminus residues (20 last amino acids)
via specific protein-protein interaction. Further structural and functional analysis
attempting to resolve the differential activity are described in Chapter 7.
On the other hand, the direct binding of RBPMS to a few of its AS targets does
not completely eliminate the possibility of indirect ASEs among the events identified
regulated upon manipulation of RBPMS levels. In fact, it is likely that RBPMS
regulates other splicing factors that could then trigger a cascade of secondary AS
changes, as suggested for a master splicing regulator (Jangi and Sharp, 2014). Thus,
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this possibility is addressed in the following chapter.
Tpm1 alternative splicing regulation by RBPMS
RBPMS repressed inclusion of Tpm1 exon 3 by using upstream CAC motifs. Despite
using a minigene reporter containing exon 3 only, this ASE in the Tpm1 gene consists
of a pair of mutually exclusive exons, exon 2 and 3. Exon 2 is selected in SMCs and
exon 3 in skeletal muscle, heart and brain (Wieczorek et al., 1988). Consequently,
splicing of Tpm1 exon 2 and 3 has been used as a differentiation marker in SMC AS
studies (Gooding and Smith, 2008; Llorian et al., 2016; Rothman et al., 1992). In
spite of that, the functional consequences of this ASE to the protein and cell biology
remain unknown. Moreover, regulation of Tpm1 exon 3 was previously studied in the
laboratory and showed to be under control of MBNL1 and PTB (Gooding et al., 2013).
On the other hand, neither of these proteins, MBNL1 and PTB, were sufficient to
cause the switch in mRNA isoforms observed in RBPMS overexpression in HEK293.
Thus, it is likely that these proteins co-operate to establish the SMC pattern of Tpm1
splicing.
Flnb alternative splicing regulation by RBPMS
RBPMS promoted the activation of the Flnb exon H1 via binding to downstream
CAC motifs. Flnb is an actin binding and adhesion protein and its exon H1 encodes
the H1 hinge domain (van der Flier et al., 2002). Moreover, splice variants of FLNB
differentially modulate the organization of actin cytoskeleton and binding to integrins
with direct effects on myogenesis of C2C12 cells (van der Flier et al., 2002). More
recently, the same exon of Flnb was described under regulation of another splicing
RBP, QKI, during epithelial-mesenchymal transition (EMT) (Li et al., 2018). RBPMS
and QKI antagonistic control of Flnb exon H1 could potentially be a common feature
of the regulation of the SMC AS program, since QKI has been observed to promote the
proliferative phenotype (Llorian et al., 2016; van der Veer et al., 2013).This potential
interplay between RBPs was further explored in the following chapter.
Actn1 alternative splicing regulation by RBPMS
Regulation of Actn1 splicing was previously investigated in this laboratory. It
contains a pair of mutually exclusive exons, which are tissue specifically selected: a non-
smooth muscle, NM, and a smooth muscle, SM exon (Waites et al., 1992). Additionally,
the skipping of both exons is also observed in small proportions in SMCs (Gromak
et al., 2003). The NM exon encodes a functional Ca2+-binding EF hand domain which
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is then more present in non-SMCs. On the other hand, the ACTN1-differentiated
isoform lacks this full domain due to the inclusion of exon SM instead. The impairment
of Ca2+-binding allows stabilization of the ACTN1 containing structures in contractile
cells (Waites et al., 1992). Overexpression of RBPMS in HEK293, particularly isoform
A, promoted a complete switch towards the exon NM skipping in the minigene reporters
containing both exons and exon NM only, consistent with an RBPMS repressor activity
upon exon NM. Although previously described to be regulated by PTBP1 and CELF
proteins, none of these proteins were able to produce such a strong effect on Actn1
splicing (Gromak et al., 2003; Southby et al., 1999). Interestingly, synergistic and
antagonistic interactions between CELF and PTB proteins regulated Actn1 splicing,
in which CELF protein family members activated SM exon and also repressed exon
NM by displacement of PTBP1, a repressor of exon SM (Gromak et al., 2003).
Therefore, taken the fact that RBPMS and other RBPs (e.g. MBNL1, PTB and
QKI) regulates common targets, further investigations focusing on the synergistic and
antagonistic interactions between families of regulators could shed some light on the
control of the differentiated SMC AS program.
5.4 Final conclusions
This chapter aimed to determine whether RBPMS could directly affect splicing. The
strong enrichment of tandem CAC motifs with RBPMS regulated exons (Figure 5.2 and
5.3), the functional binding of RBPMS to Flnb and Tpm1 (Figure 5.11), the distinct
positional signatures of splicing activation and repression mediated by RBPMS (Figure
5.2 and 5.3) and the loss of splicing function by the RNA binding mutant (Figure 5.13)
support RBPMS as a direct regulator of splicing in differentiated SMC.
In conclusion, the main findings of this chapter are:
1. RBPMS-regulated exons display strong enrichment of tandem CACs motifs.
2. RBPMS-map revealed distinct positional signatures for splicing activation and
repression by RBPMS.
3. EMSA and UV-crosslinking confirmed binding of RBPMS to Flnb and Tpm1
RNAs.
4. RBPMS represses splicing via binding to upstream CAC motifs whereas activation
requires downstream motifs.
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5. CAC motifs show compensatory effects demanding mutation of several sites for
disruption of RBPMS regulation.
6. RBPMS represses the NM exon from the pair of mutually exclusive exons in the
Actn1 transcripts.
7. RBPMS RNA binding mutant is not able to regulate splicing.
8. RBPMS isoforms exhibit differential activity; RBPMS-B less active.
In addition, this chapter also led to other questions listed below:
• What is the specific mechanism behind RBPMS regulation of splicing?
• How can the isoforms display different splicing activity if both RBPMS-A
and RBPMS-B can bind RNA targets in vitro?
• What are the synergistic and antagonistic interactions between RBPMS
and other RBPs in the regulation of common pre-mRNA targets (e.g.
Tpm1, Actn1 and Flnb)?
The next chapters in this study provide some insights into these questions.

Chapter 6
RBPMS: a regulator of regulators
6.1 Introduction
6.1.1 Contribution of splicing to establishment of robust tran-
scriptomes
Studies of the regulation of transcriptomes and their role in cell homeostasis and
differentiation have focused on transcriptional programs as the main player in the
establishment of tissue transcriptomes. However, RNA sequencing technologies have
advanced in the past decades and provided evidence for the contribution of post-
transcriptional processes, especially AS, in the regulation of tissue transcriptomes. AS
is able to regulate a network of highly interconnected events, providing stability to
the system without losing its ability to respond to external stimuli (Jangi and Sharp,
2014).
AS reshapes the cell transcriptome by generation of alternative protein isoforms
and down-regulation of transcripts via coordination of AS-NMD (nonsense-mediated
mRNA decay). The combination of these processes can then form different regulatory
units such as negative and positive feedback loops (Figure 6.1). Furthermore, cross-
regulation (Figure 6.2) as well as integration of these individual regulatory motifs
into splicing cascades (Figure 6.2) provide mechanisms required for building robust
networks in biological systems (Jangi and Sharp, 2014). The different regulatory units
of the splicing network are further discussed below.
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6.1.1.1 Negative feedback of RBPs
AS coupled with NMD regulates the steady-state of many genes including many RBPs.
These RBPs can then be engaged in negative autoregulation through regulation of
the splicing of exons containing in-frame premature stop codons within their own
transcript. Thus RBPs reduce their own expression levels by targeting their own
transcripts to NMD (Figure 6.1). In fact, many splicing factors show enrichment for
conserved AS-NMD events, revealing a common mechanism of gene expression control
of RBPs (Jangi and Sharp, 2014; Wollerton et al., 2004). RBPs that display negative
autoregulation comprise for example the splicing regulators SR and hNRNP proteins
(Lareau et al., 2007; Ni et al., 2007). SR proteins usually promote poison exon inclusion
whereas some hnRNPs promote frameshift exon skipping e.g. PTBP1.
6.1.1.2 Positive feedback of RBPs
In contrast to negative feedback, RBP direct positive autoregulation via productive
splicing is very unusual. Interaction between two distinct splicing factors could provide
the mechanisms for positive regulation (Figure 6.1). Double-negative feedback loops
combine two RBPs that negatively cross-regulate each other, generating mutually
exclusive expression of these factors. Positive feedback generally produces bistability in
which two distinct steady states can be achieved (Jangi and Sharp, 2014). Nevertheless,
to date, AS-NMD positive feedback loop like described above has mainly been reported
to operate in insects (see section 6.1.2) (Pervouchine et al., 2018; Salz, 2011).
Another mode for establishing positive feedback is by coupling splicing and tran-
scription factors (Jangi and Sharp, 2014). For instance, during development, OCT4,
SRSF2 and MBD2 form a composite positive feedback loop, in which OCT4 drives
expression of the splicing factor SRSF2 which affects splicing of MBD2 towards an
isoform that promotes OCT4 expression (Lu et al., 2014).
6.1.1.3 RBP cross-regulation
Steady-states of RBPs under autoregulatory negative feedback are susceptible to addi-
tional post-transcriptional regulatory inputs (Jangi and Sharp, 2014). This secondary
modulation is responsible for defining the final expression level of the RBP across
different cell types. One mechanism involved in this process is cross-regulation between
RBPs, such as inhibition of an RBP negative autoregulatory poison exon upon binding
of a second RBP (Figure 6.2) (Jangi and Sharp, 2014). In this manner, a more robust
and tunable expression pattern of RBPs is ensured.
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Positive feedback
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Fig. 6.1 Regulatory units in splicing networks. Top, autoregulatory negative
feedback of RBPs mediated by regulation of NMD targeted exons. Regulation of
poison exons (red hexagon indicates premature termination codon, PTC) within its
own transcript leads to reduction of its own protein levels, maintaining a steady-state
level of expression, e.g. SRSF genes. Nonetheless, exon skipping can also lead to frame-
shifting and subsequent downregulation of transcripts e.g. PTBP1 (Wollerton et al.,
2004). Bottom, positive feedback via double-negative feedback loop. This results
from mutually exclusive expression of two RBPs due to their negative cross-regulation.
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Thereby it is expected that cross-regulation between RBPs leads to secondary
splicing changes within the splicing network of an specific RBP (Figure 6.3). Although
the network of a splicing factor primarily consists of its direct targets, indirect events
are also identified due to regulation of secondary RBPs levels through AS-NMD. Thus,
the initial signal from the first RBP can be amplified by the triggering of a cascade
of indirect splicing events (Jangi and Sharp, 2014). Such regulation was observed
during neuronal differentiation in which RBFOX2 upregulates PTBP2 by hindering
the autoregulatory AS-NMD suppression of Ptbp2 (Jangi and Sharp, 2014).
Cross-regulation autoregulatory
RBPSTOP
STOP
RBP
RBPRBP
RBP
Fig. 6.2 RBP autoregulatory feedback cross-regulation. Autoregulatory nega-
tive feedback loops can be controlled by other RBPs. Thus, a higher expression level
of the auto-regulated RBP can be achieved by a secondary RBP that inhibits the
negative regulation.
Therefore a better understanding of these regulatory networks is critical to gain
more insights into how splicing changes can determine cell fate.
6.1.2 Master regulators regulate other splicing regulators
RBPs acting as master regulators of splicing are proposed to be positioned at the top
of a splicing cascade, triggering direct changes and also indirect events by regulation of
secondary splicing factors (Jangi and Sharp, 2014). In this manner, master splicing
regulators would be able to build a robust network with a critical role in cell fate
determination.
Despite the fact that master RBPs are likely to be downstream of larger tran-
scriptional programs, as indicated by the approach of using super-enhancers for their
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Cross-regulation splicing cascade
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RBP A and B targets
Fig. 6.3 Cross-regulation establishes robust splicing networks by splicing
cascades. RBPs are able to amplify their splicing networks by combining direct
regulated targets to cross-regulated events that trigger a cascade of secondary events.
Thus, this integrated system amplifies the original signal and fine-tunes the RBP
splicing network.
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identification, transcription factors can also be found under the control of splicing fac-
tors (Jangi and Sharp, 2014). A very well characterized interplay of transcriptional and
post-transcriptional factors is the sex determination in Drosophila (Salz, 2011). In the
fruit-fly, the splicing repressor Sex Lethal (Sxl) is a key RBP in the sex-determination
pathway by activating the female isoform of the RBP Transformer (Tra) and repressing
the male-specific lethal 2 (Msl2) transcript. Moreover, female-specific isoforms of the
transcription factors Dsx and Fru are produced by the female-Tra isoform (Salz, 2011).
Thus, Sxl is a master splicing regulator that is required and even sufficient in the
determination of cell identity in Drosophila.
Therefore, master regulators can activate a robust splicing network by integrating
direct and indirect splicing changes in cooperation with alteration of gene expression
which arises from AS-NMD as well as regulation of transcription factors (Jangi and
Sharp, 2014). Understanding this co-regulation between master regulators and other
RBPs is critical for uncovering their roles in determining tissue specific splicing programs.
Secondly, the contribution of other RBP functions, e.g. mRNA stability and localization,
also need to be addressed to resolve the additional role of various post-transcriptional
regulatory mechanisms in the establishing of cell-specific transcriptomes.
Thus, taken the fact that master regulators can indirectly affect splicing and
gene expression by modulation of other RBPs and transcription factors (Jangi and
Sharp, 2014), this chapter set to identify and characterize any other splicing factor
under RBPMS regulation. Moreover, we also investigated if RBPMS targets other
post-transcriptional and transcriptional factors.
6.2 Results
6.2.1 Regulators regulated by RBPMS
To identify the protein classes targeted by RBPMS, functional classification of genes
differentially spliced upon manipulation of RBPMS levels in PAC1 cells was carried out
using PANTHER (v14.1) (Figure 6.4 and 6.5). In addition to the enriched functions
previously discussed (cytoskeletal, cell adhesion and ECM proteins), both datasets
showed regulation of transcription factors and nucleic acid binding proteins, including
RBPs (Figure 6.4 and 6.5). RBPMS knockdown affected seven RBPs, nine DNA
binding proteins and twelve transcription factors (Figure 6.4) whereas those numbers
were much larger in the overexpression experiment 91, 46 and 118 respectively (Figure
6.5).
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Fig. 6.4 RBPMS knockdown affects splicing of genes coding for a range of
protein classes. Functional classification of RBPMS knockdown splicing targets
according to their protein class using PANTHER (v14.1). Subclassification of nucleic
acid binding category is also shown. Number indicates the absolute number of genes
in the category. ASE analyzed are all the significant RBPMS knockdown regulated
events with |∆PSI| > 10%.
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Fig. 6.5 RBPMS overexpression affects splicing of genes coding for a range
of protein classes. Functional classification of RBPMS overexpression splicing targets
according to their protein class using PANTHER (v14.1). Subclassification of nucleic
acid binding category is also shown. Number indicates the absolute number of genes
in the category. ASE analyzed are all the significant RBPMS overexpression regulated
events with |∆PSI| > 10%.
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To get a more reliable and specific result, a second approach to investigate whether
RBPMS controlled other regulators was applied using two curated lists of transcription
factors and RBPs (Gerstberger et al., 2014; Lambert et al., 2018). These functional
subset of genes found differentially spliced upon RBPMS knockdown and overexpression
are shown in Table 6.1 and Table 6.2. In fact, in these analyses the lists of ASEs
regulated by RBPMS used were the functional one comprising cassette exons com-
monly regulated between RBPMS knockdown and PAC1 dedifferentiation or RBPMS
overexpression and aorta tissue dedifferentiation (see Material and Methods Chapter).
Five post-transcriptional regulators were found regulated by RBPMS knockdown, with
four of which were also regulated by RBPMS-A overexpression (Table 6.1). On the
other hand, RBPMS-A overexpression affected a more extended list of regulators,
including transcription factors (Table 6.2). In total it affected 20 genes with some of
those containing multiple exons targeted by RBPMS, resulting in a list of 31 cassette
exons differentially spliced (Table 6.2). Four genes were regulated in both experiments:
Lrrfip1, Mbnl1, Pstk and Rbm26. However, for Rbm26 the ASEs regulated in RBPMS
knockdown and overexpression were different. BecauseMbnl1 was the most well studied
RBP among the identified regulators, its splicing regulation by RBPMS was first chosen
to be further characterized.
Table 6.1 Transcriptional (TF) and post-transcriptional (PT) regulators differentially
spliced by RBPMS knockdown
RBPMS knockdown
Gene Chr Strand Exon Start Exon End ∆PSI Factor type
Eif5a 10 - 56530568 56530662 17.0 PT
Lrrfip1 9 + 98243215 98243287 -22.6 PT
Mbnl1 2 + 150864085 150864121 37.4 PT
Pstk 1 + 201952551 201952846 -17.6 PT
Rbm26 15 - 89296794 89296866 -14.5 PT
Therefore, this paved the way for potential secondary targets of RBPMS by reg-
ulation of other post-transcriptional regulators. Consistent with the hypothesis of
this study, regulation of regulators is a suggested feature of master splicing regulators
(Jangi and Sharp, 2014).
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Table 6.2 Transcriptional (TF) and post-transcriptional (PT) regulators differentially
spliced by RBPMS overexpression
RBPMS overexpression
Gene Chr Strand Exon Start Exon End ∆PSI Factor type
Akap17a 12 - 18530563 18530726 -44.3 PT
Akap17a 12 - 18529849 18530726 -34.9 PT
Ddit3 7 + 70582844 70582892 -33.2 TF
Dzip1 15 - 104170509 104170555 -21.4 TF
E2f5 2 - 88354476 88354612 -20.3 TF
Lrrfip1 9 + 98233128 98233206 23.0 PT
Lrrfip1 9 + 98243215 98243287 10.6 PT
Lsm14b 3 + 175415535 175415613 -72.6 PT
Lsm14b 3 + 175412593 175412710 -30.4 PT
Mbnl1 2 + 150864085 150864121 -43.5 PT
Mbnl1 2 + 150864801 150864896 -42.0 PT
Mbnl2 15 + 105772308 105772403 -40.7 TF/PT
Mrps18b 20 + 3348548 3348615 -42.6 PT
Mrps18b 20 + 3346556 3346625 -35.4 PT
Mrps18b 20 + 3346164 3346258 -19.2 PT
Mrrf 3 + 15475320 15475476 -13.9 PT
Mterf1 4 + 27366889 27367017 -23.6 TF
Mterf1 4 + 27367248 27367294 28.4 TF
Mybl1 5 + 9310670 9310850 28.4 TF
Myef2 3 - 117363827 117363878 -25.5 PT
Myef2 3 - 117362732 117362804 -20.0 PT
Papd7 1 + 36428872 36429031 -10.7 PT
Pprc1 1 + 265822338 265823056 -10.6 PT
Pprc1 1 + 265815951 265816044 -15.4 PT
Pprc1 1 + 265821381 265821511 -11.8 PT
Pstk 1 + 201952551 201952846 29.7 PT
Rbm26 15 - 89295925 89295997 -59.1 PT
Sp140 9 + 92657393 92657432 -19.4 TF
Stat1 9 - 54327359 54327491 -29.9 TF
Stat1 9 - 54327424 54327491 -34.6 TF
Tdrd7 5 + 61591965 61592183 -21.7 PT
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6.2.2 RBPMS regulates splicing of Mbnl1, another splicing
regulator
Muscleblind proteins have been implicated in regulation of AS of pre-mRNAs in health
and disease (reviewed in Fernandez-Costa et al. (2011)), also being involved in other
post-transcriptional processes such as mRNA localization (Wang et al., 2012), stability
(Masuda et al., 2012) and alternative polyadenylation (Batra et al., 2014). Moreover,
MBNL1 isoforms and paralogs have been shown to differ in their splicing activity
and localization (Kino et al., 2015; Sznajder et al., 2016; Tabaglio et al., 2018; Tran
et al., 2011). Therefore, regulation of MBNL1 isoforms by RBPMS could lead to broad
downstream effects, including further secondary ASE in the SMCs.
Mbnl1 AS exons regulated by RBPMS were visualized by sashimi plots from
RNAseq (Figure 6.6). Both RBPMS knockdown and overexpression in PAC1 cells
indicated RBPMS as a repressor of the Mbnl1 alternative exons referred to here as
exons 7 and 8 and also specified by their sizes 36 and 95 nt respectively (Figure 6.6).
Consistent with the RNAseq, the switch in RNA isoform was also significant in the
RT-PCR validation (Figure 6.6). RBPMS knockdown promoted inclusion of 52.3%
of exon 7 and 65.2% of exon 8, with an inclusion level difference of 33.6 and 16.6%
between RBPMS knockdown and control (Figure 6.6). RBPMS-A overexpression also
resulted in a clear switch as evident in the RNA-Seq data (Figure 6.6), and subsequently
validated by C. Gooding (Appendix - Figure A.4). Furthermore, the change in the
Mbnl1 RNA isoforms was sufficient to alter the protein levels as seen in the western
blot (Figure 6.6). However, not all the isoforms were identified at the protein level.
Two main bands could be identified regulated by RBPMS in the western blots ∼35
and ∼43 kDa. Based on the expected size of the peptides encoded by exons 7 and 8,
inclusion of each of these exons should result in a 1.3 or a 3.4 kDa shift respectively.
Additionally, inclusion of both exons produces a larger MBNL1 isoform, ∼4.3 kDa
protein shift. Thus, the two bands are likely to represent exon 8 only included isoform
(MBNL8) and both exons excluded isoform (MBNL∆7-8). The exact identity of the
bands is hindered by additional splicing events in Mbnl1 transcripts. Interestingly,
RBPMS-A overexpression in PAC1 cells also regulated a Mbnl1 paralog, Mbnl2, in
which an alternative exon equivalent to exon 8 (95 nt) was found to be repressed upon
RBPMS-A overexpression (Figure 6.7 and Appendix - Figure A.4). On the other hand,
Mbnl2 exon 7 was completely skipped in all the conditions (Appendix - Figure A.4).
Thus, activity of both MBNL1 and 2 is likely to be decreased coordinately, a feature
also observed in SM tissues in which alternative exons are more skipped.
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Fig. 6.6 RBPMS regulates Mbnl1 alternative splicing. Left, sashimi plot of
Mbnl1 exons differentially spliced by RBPMS. The numbers on the top of the arches
represent the number of exon-exon junction reads. PSIex7 and PSIex8 indicate the mean
of the inclusion of exon 6 (36 bp) and 7 (95 bp) as calculated by rMATS. Schematic of
the mRNA isoforms produced are found at the bottom as well as the chromosomal
coordinates. Right top, RT-PCR validation of Mbnl1 exon 7 and 8 by RBPMS
knockdown in PAC1 cells. PSI values shown are mean ± sd (n= 3). Statistical
significance was verified by Student’s t test and is shown as * p < 0.05, ** p < 0.01 and
*** p < 0.001. Right bottom, western blot against MBNL1 with protein isoforms
labeled on the left. TUBULIN was used as a loading control. Protein size markers are
indicated on the right.
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Fig. 6.7 RBPMS regulates Mbnl2 alternative splicing. Sashimi plot of Mbnl2
exons differentially spliced by RBPMS. The numbers on the top of the arches represent
the number of exon-exon junction reads. PSIex7 and PSIex8 indicate the mean of the
inclusion of exon 6 (36 bp) and 7 (95 bp) as calculated by rMATS. Schematic of
the mRNA isoforms produced are found at the bottom as well as the chromosomal
coordinates.
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Exclusion of exon 7 and 8 of Mbnl1 have previously been shown to affect MBNL1
localization and dimerisation, subsequently decreasing its splicing activity (Sznajder
et al., 2016; Tabaglio et al., 2018). Thereby, it could be possible that some of RBPMS-
regulated ASEs are in fact MBNL1 direct targets. To test this, C. Gooding performed
MBNL1 and 2 knockdown while overexpressing RBPMS-A in proliferative PAC1 cells.
In that manner, it was possible to distinguish ASE regulated by RBPMS, whose
changes were also dependent on MBNL1. Indeed, Ncor2 A5SS, previously identified
by Sznajder et al. (2016) as an ASE that was less responsive to the shorter MBNL1
isoforms, was identified as an indirect target of RBPMS. Ncor2 A5SS splicing was
unresponsive to RBPMS overexpression when combined to MBNL1 and 2 knockdown
(Appendix - Figure A.5). Nevertheless, Ncor2 A5SS was detected to be significantly
regulated by RBPMS-A overexpression by rMATS analysis, ∆PSI = 13%. In summary,
RBPMS promotes shorter isoforms of MBNL1 and 2 that have previously been shown
to be less active for some target ASEs (e.g. Ncor2 ).
6.2.3 RBPMS regulates splicing of Lsm14b, another post-
transcriptional regulator
Next, we set to further characterize other potential post-transcriptional regulators
affected by RBPMS. A promising candidate was Lsm14b, an RBP involved in the
cytoplasmic control of mRNA stability and translation (Brandmann et al., 2018).
Lsm14b alternative exon 6, which encodes for its only predicted NLS - RPPRRR,
showed a very high inclusion level difference of 70% between the PAC1 cells control and
RBPMS-A overexpression in the RNAseq analysis by rMATS (Table 6.2). Interestingly,
Lsm14b is another gene whose splicing is regulated during aorta dedifferentiation
but not in PAC1 cells as indicated in the Figure 6.8. In PAC1 cells, RBPMS-A
overexpression recapitulated the tissue differentiated splicing pattern by decreasing the
levels of inclusion of the Lsm14b exon to 11% (Figure 6.8). C. Gooding then confirmed
the switch in isoforms at the RNA and protein levels by RT-PCR and western blot
of the inducible RBPMS-A lentiviral populations (Appendix - Figure A.6). Despite
not being significant in the RNAseq splicing analysis, RT-PCR analysis of Lsm14b
AS upon RBPMS knockdown in PAC1 cells revealed a significant difference in the
inclusion level of this cassette exon, 12% more included in knockdown samples (Figure
6.8). Furthermore, a more dramatic change was observed at the protein levels as
indicated in the western blot (Figure 6.8). In fact, inclusion of the in-frame 29 amino
acid peptide encoded by Lsm14b exon 6 is expected to produce a 3.1 kDa shift in
6.2 Results 153
protein size (Figure 6.8). Finally, apart from its cytoplasmic roles, Lsm14b can also
shuttle to the nucleus in which its function is still unclear (Brandmann et al., 2018).
Thus, RBPMS mediated AS of Lsm14b could affect its localization and consequently
also its mRNA turn over function.
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Fig. 6.8 Lsm14b a post-transcriptional regulator regulated by RBPMS. Left,
sashimi plot of Lsm14b cassette exon differentially spliced upon RBPMS overexpression
in PAC1 cells. Plots are shown for aorta dedifferentiation (tissue (T) and cultured
primary SMC passage 9 (P9)), RBPMS knockdown and overexpression. The numbers
on the top of the arches represent the number of exon-exon junction reads. PSI indicate
the mean of the inclusion levels calculated by rMATS. Chromosomal coordinates and
splicing isoforms are shown at the bottom. Right, schematic of Lsm14b splicing event.
Amino acid encoded by the alternatively spliced exon is shown and the predicted NLS
highlighted in bold font. RT-PCR validation in RBPMS knockdown. PCR products are
indicated on the left. PSI values shown are mean ± sd (n= 3). Statistical significance
was verified by Student’s t test and is shown as * p < 0.05, ** p < 0.01 and *** p <
0.001. Western blot against LSM14B. GAPDH was used as a loading control. Protein
size markers are shown on the right.
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6.2.4 RBPMS regulates splicing of Myocd, a critical SMC
transcriptional factor
Detailed inspection of transcription factors affected by RBPMS knockdown and overex-
pression in PAC1 cells only highlighted minor splicing isoforms in genes whose function
in SMC biology are not clear (Table 6.2). Moreover, those changes were only observed
in the overexpression dataset. Therefore, being aware of the SMCs and cardiac cells
master transcriptional regulator, Myocd, we focused on any potential ASE in its gene
that could be regulated by RBPMS. In fact, Myocd is found expressed as two major
protein isoforms that arise from regulation of its alternative exon 2a (Creemers et al.,
2006; van der Veer et al., 2013). In cardiac cells and proliferative SMCs, a full length
MYOCD protein is produced by skipping of exon 2a (Creemers et al., 2006; van der
Veer et al., 2013). On the other hand, in differentiated SMCs, exon 2a is mainly
included, introducing an in-frame stop codon that then leads to the expression of an
N-terminal truncated MYOCD isoform by alternative translation initiation from a
downstream AUG codon in exon 4 (Creemers et al., 2006; van der Veer et al., 2013).
Thereby, the SMC isoform lacks the N-terminal MEF2 interacting domain, enabling
activation of SMC-specific promoters (Creemers et al., 2006; van der Veer et al., 2013)
(Figure 6.9). Indeed, supporting a potential role of RBPMS in the regulation of this
key SMC transcription factor, two conserved clusters of CACs were identified ∼200
nt downstream of Myocd exon 2a (Figure 6.10). The location of these binding sites
suggested an activation role for RBPMS, in agreement with the promotion of the
differentiated SMC specific isoform.
6.2.4.1 RBPMS promotes the inclusion of the Myocd SMC differentiated
exon
Although rMATS analysis did not identify significant changes in the inclusion of Myocd
exon 2a, manual inspection of RNAseq datasets, and subsequent RT-PCR analysis,
revealed that Myocd exon 2a was more included in differentiated than proliferative
PAC1 cells (Figure 6.11). Moreover, RBPMS knockdown decreased inclusion of exon
2a (Figure 6.11). Indeed, the inclusion levels calculated from the RNAseq manual
inspection was in good agreement with the RT-PCR observed PSI (70.8% and 64.9%
for differentiated PAC1 and 37.7% and 44.3% for RBPMS knockdown). In order to
better understand exon 2a regulation, a minigene reporter containing Myocd exon
2a and its flanking intronic regions was created (Figure 6.11). PAC1 cells were then
transfected with the minigene reporter, showing a basal inclusion level of ∼ 30%, in
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Fig. 6.9 Myocd exon 2a splicing in VSMC. Illustration of Myocd exon 2a ASE
in SM and cardiac cells. MYOCD full length containing the MEF domain is produced
by exclusion of exon 2a in cardiac and proliferative cells (blue). On the other hand,
inclusion of exon 2a in SMCs, inserts a premature stop codon, leading to the translation
of a downstream AUG codon, which codes for a shorter isoform that lacks the MEF
domain (green). The absence of the MEF2 interacting domain subsequently affects the
subset of genes activated by MYOCD.
the reporter only and Venus co-transfected controls (Figure 6.11). Expression of either
RBPMS-A or B significantly promoted inclusion of Myocd exon 2a in the PAC1 cells
to ∼70% (Figure 6.11). Thus, RBPMS knockdown and overexpression in PAC1 cells
regulated inclusion of Myocd exon 2a.
6.2.4.2 RBPMS regulates Myocd exon 2a via binding to downstream
CACs
Further investigation of the regulation of Myocd exon 2a by RBPMS was then achieved
by transfecting HEK293 cells with CAC mutated minigenes reporters (Figure 6.12A-B).
First, the wild-type minigene was tested in HEK293 and, as expected, exon 2a was
not included in these non-smooth muscle cells (Figure 6.12C). However, transient
overexpression of rat RBPMS-A and RBPMS-B promoted the inclusion of exon 2a,
increasing the PSI to ∼75% and 37% respectively (Figure 6.12C). Secondly, to address
the importance of the downstream CAC motifs, each cluster of CAC was mutated
to CCC and tested in HEK293 cells with co-transfection of RBPMS-A expression
vector (Figure 6.12C). Cluster 1 mutation (mCAC1) had minor effects on RBPMS-A
response, 67% exon 2a inclusion, yet activation by RBPMS-B was more affected by
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Fig. 6.10 Conserved CAC trinucleotides downstream of Myocd exon 2a.
Conserved CAC motifs downstream of Myocd exon 2a are highlighted in blue. 3′ end
of Myocd exon 2a is indicated by the purple box. Basewise conservation track and
multiple alignment were generated by PhyloP and Multiz Alignments in the UCSC
genome browser. Chr coordinates from rn6 : top panel, chr10:51,733,829-51,733,977,
and, lower panel, chr10:51,733,695-51,733,843
this cluster, reducing the inclusion level of exon 2a to 8.6%. Mutation of the second
cluster (mCAC2) affected regulation by both isoforms, decreasing the inclusion by ∼2
fold. But, it was the combined mutant (mCAC) that had the strongest effect in the
regulation by RBPMS, making the Myocd exon 2a reporter completely unresponsive
to RBPMS expression (Figure 6.12C).
RBPMS binding to Myocd RNA was investigated by in vitro binding assays using
both EMSA and UV-crosslinking. To confirm binding to the CAC clusters, assays were
performed with wild-type (wt) and CAC mutants (mCAC) using in vitro transcribed
RNAs (Figure 6.12D). In EMSA, both RBPMS isoforms bound to the wild-type RNA
at similar apparent affinities (0.125µM < Kd < 0.5µM) (Figure 6.12D). Myocd mCAC1
and mCAC2 were associated with more modest (Kd = ∼0.5µM) and drastic effects
(Kd = ∼2.0µM) respectively. Additionally, mutation of both CAC clusters (mCAC
reporter) completely impaired binding by RBPMS. UV-crosslinking of Myocd RNA
substrates and recombinant RBPMS was found to be very inefficient, with very faint
signal observed only for the wild-type and to a less degree to the mCAC1 (Figure
6.12D lower panel). Therefore, consistent with the splicing experiments, the in vitro
binding assays indicate that RBPMS binds to the CAC motifs downstream of Myocd
exon 2a, with these sites being critical for its splicing regulation. Moreover, individual
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Fig. 6.11 RBPMS promotes the splicing of the differentiatedMyocd isoform
in PAC1 cells. Left, Sashimi plot of Myocd cassette exon differentially spliced upon
RBPMS overexpression in PAC1 cells. Numbers on top of the arches represent the
number of exon-exon junction reads. PSI indicate the mean of the inclusion levels
calculated by rMATS. Chromosomal coordinates and splicing isoforms are shown at
the bottom. Right top, RT-PCR validation of the SMC pattern of Myocd exon
2a in the PAC1 dedifferentiation and RBPMS knockdown in PAC1 cells. Right
bottom, schematic of the rat Myocd exon 2a minigene. Splicing of the Myocd exon
2a minigene reporter in PAC1 cells upon transient transfection of RBPMS-A and
RBPMS-B. Reporter only and Venus controls were tested alongside. Western blot
against GFP and, GAPDH was used as a loading control. Protein size markers are
shown on the right. PCR products are indicated on the left. PSI values shown are
mean ± sd (n= 3). Statistical significance was verified by Student’s t test and is shown
as * p < 0.05, ** p < 0.01 and *** p < 0.001.
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mutation of each CAC cluster, mCAC1 and mCAC2, despite reducing the intensity of
the binding (Figure 6.12), did not provide evidence of an intermediate size complex.
Given that each cluster has sufficient CAC motifs to bind at least one dimer this
suggests that RBPMS might be binding to RNA as a higher order oligomer than just
a dimer.
6.2.4.3 Insertion of previously defined RBPMS site rescues RBPMS reg-
ulation of mCAC Myocd
In an attempt to rescue RBPMS activation of Myocd exon 2a, a sequence from the
UBE2V1 UTR, previously defined by PAR-CLIP to bind to RBPMS-A, was introduced
into the Myocd mCAC reporter (Farazi et al., 2014). The sequence containing three
CAC motifs separated by 1 and 3 nt was inserted into both locations of the mutated
Myocd CAC clusters (Figure 6.13). Regulation of exon 2a was then tested in HEK293
cells. In agreement with the last experiment, Myocd double mutant was not able to
promote inclusion of exon 2a in response to RBPMS-A or B. Nevertheless, insertion of
RBPMS sites from Ube2v1 significantly restored activation of exon 2a by RBPMS-A
(PSI = 31.7%), with minor effects upon RBPMS-B overexpression (PSI= 6.8%), despite
similar levels of protein expression of RBPMS isoforms shown by the western blots
(Figure 6.13). Moreover, the RBPMS sites from Ube2v1 did not affect the basal level
of inclusion of exon 2a in HEK293 cells as indicated by the reporter only and Venus
controls (Figure 6.13). This is consistent with the expected Myocd splicing pattern in a
non-smooth muscle cell. Thus, exchanging the CAC motifs with a predefined RBPMS
site in the Myocd minigene reporter reproduces the regulation by RBPMS-A, yet the
reason behind the isoform specific rescue remains unclear.
6.2.5 RBPMS and QKI play antagonistic roles in VSMC
QKI is another RBP that has been established as important in the SMC dedifferentiation
process, regulating the proliferative phenotype, the state in which it is found highly
expressed (Figure 3.5) (Llorian et al., 2016; van der Veer et al., 2013). Moreover, QKI
was also reported to be able to control the SMC dedifferentiated state by controlling
splicing of Myocd exon 2a (van der Veer et al., 2013). QKI binds to the 5′ end of
the exon 2a repressing its inclusion in proliferative SMCs (van der Veer et al., 2013).
Therefore, RBPMS and QKI could potentially play antagonistic roles in the regulation
of the SMC AS during the phenotypic switch of these cells. To test the functional
antagonism in the regulation of exon 2a, HEK293 cells were co-transfected with Myocd
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Fig. 6.12 RBPMS regulates splicing of Myocd exon 2a via downstream
CACs. A Schematic of the Myocd exon 2a minigene with downstream clusters of
CACs highlighted. B Schematic of the Myocd minigene mutant reporters. C RT-PCRs
to verify the splicing patterns of Myocd exon 2a reporters (wild-type and mutants) upon
RBPMS-A and RBPMS-B overexpression in HEK293 cells. Reporter only and Venus
controls were tested in parallel. PCR products are indicated on the left. PSI values
shown are mean ± sd (n= 3). Statistical significance was verified by Student’s t test
and is shown as * p < 0.05, ** p < 0.01 and *** p < 0.001. Protein expression levels are
shown in the western blot probing for GFP and GAPDH as a loading control. Protein
size markers are shown on the right. D in vitro binding of RBPMS-A and RBPMS-B to
Myocd exon 2a CAC clusters was tested by EMSA, top, and UV-crosslinking, bottom.
in vitro transcribed wild-type and CAC mutant radiolabelled RNAs were used. Binding
by recombinant RBPMS was tested in a serial dilution (1:4) in a range of 0.125 to 2
µM.
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Fig. 6.13 Inclusion of exon 2a in mCAC Myocd reporter can be rescued
by insertion of a defined RBPMS site. Top, a previously defined RBPMS
binding sequence from UBE2V1 (Farazi et al., 2014) was inserted into the mCAC
Myocd minigene and its splicing tested upon RBPMS overexpression in HEK293 cells.
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Bottom, western blot probing for GFP and GAPDH as a loading control. Asterisk on
the side of the gel indicates the GFP by-product from the minigene splicing.
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reporter and both RBPs, RBPMS and QKI (Figure6.14). RBPMS-A and RBPMS-B
promoted inclusion of Myocd exon 2a (88.4% and 67.7%), whereas expression of QKI
repressed its inclusion (PSI= 0.0%). When co-expressing the two RBPs, QKI even at
low concentrations strongly antagonized activation by RBPMS-A and RBPMS-B (PSI<
10%), repressing exon 2a below the basal level observed in HEK293 cells as indicated
by the Venus control (PSI= 17.5%). Thus, these data show that Myocd exon 2a is
under the control of RBPMS in the differentiated SMC and of QKI in the proliferative
SMCs, with QKI being the dominant regulator in this antagonistic regulation.
Interestingly, Flnb exon H1, which I found to be activated by RBPMS (Chapters
3-5), was recently shown to also be regulated by QKI during the epithelial mesenchymal
transition (Li et al., 2018). Similar to regulation of Myocd, QKI repressed inclusion
of exon H1, but in this case, as revealed by eCLIP (enhanced CLIP), repression was
mediated by unusual binding of QKI downstream of the regulated exon, which is
usually associated with activation (Li et al., 2018). To test for functional antagonism in
Flnb as well, endogenous splicing of exon H1 was verified in the previous co-transfection
with RBPMS and QKI and Myocd reporter (Figure 6.14). Consistent with the Myocd
results, QKI expression decreased inclusion of exon H1 by RBPMS isoforms from 50.6%
to 22.8% for RBPMS-A and from 56.5% to 11.6% for RBPMS-B. Nevertheless, the
reduction was not as drastic as the one observed in the regulation of Myocd exon
2a. Thus, splicing of Flnb exon H1 is also under control of RBPMS and QKI with
no clear dominant regulator in this splicing event. In addition to that, QKI motifs
were found enriched in RBPMS splicing targets as shown in Figure6.15. QKI binding
sites (ACTAACAA), were mainly distributed around exons more included by RBPMS.
Together, these data suggest a potential co-regulation of the SMC splicing by these
two RBPs.
6.3 Discussion
6.3.1 RBPMS regulates activity of other regulators via splic-
ing
In addition to regulation of various mRNAs involved in cytoskeleton and cell ad-
hesion, RBPMS also mediated alternative splicing changes in transcriptional and
post-transcriptional regulators. By regulating MBNL, LSM14B and MYOCD, RBPMS
has the potential for more widespread actions (Figures 6.6, 6.8 and 6.12).
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First, RBPMS affected ASEs in MBNL proteins that have direct effects on their
splicing regulatory activities (Sznajder et al., 2016; Tabaglio et al., 2018; Tran et al.,
2011). Despite the limitation of the short-term overexpression experiment for the
detection of secondary AS changes, a modest change in Ncor2 A5SS seems to reflect
an RBPMS-induced switch to less active MBNL isoforms (Appendix - Figure A.5,
validated by Clare Gooding in the laboratory). Implications of RBPMS-mediated
splicing of Mbnl1 and Mbnl2 are summarized in Figure 6.16.
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Fig. 6.16 RBPMS promotes the production of less active Mbnl1 isoforms.
Schematic of RBPMS indirect regulation of Ncor2 splicing via control of MBNL1
isoforms.
RBPMS also affected another RBP involved in non-splicing functions, Lsm14b.
The regulated Lsm14b event could potentially modulate mRNA stability, or an as yet
uncharacterized LSM14B role in the nucleus (Kırlı et al., 2015). Potential implications
of RBPMS-mediated splicing of Lsm14b is summarized in Figure 6.16
Lastly, RBPMS also directly targeted a critical SMC transcription factor, Myocd.
Interestingly, a similar regulation has been attributed to the myogenic AS master
regulator RBM24 (Jangi and Sharp, 2014), which is important for stabilization of
the transcription factor Myogenin mRNAs by binding to its 3′UTR (Jin et al., 2010).
RBPMS direct activation of Myocd exon 2a drives production of a more potent isoform
of the VSMC transcription factor which is associated with more differentiated SMCs
(van der Veer et al., 2013).
Additional effects upon transcription could also be conferred by RBPMS activation
of the Flnb H1 exon. Inclusion of the exon H1 produces a more nuclear FLNB isoform
which antagonizes the transcription factor FOXC1 in epithelial cells (Li et al., 2018).
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Fig. 6.17 Potential consequence of Lsm14b alternative splicing by RBPMS.
Schematic of the impairment of LSM14B nuclear shuttling and function in mRNA
turnover by RBPMS regulation of Lsm14b exon 6 which contains the only predicted
nuclear localization signal (shown in blue).
Indeed, FOXC1 and FOXC2 are expressed at higher levels in adult arteries than any
other human tissue (Lonsdale et al., 2013). Thus, RBPMS activation of this ASE
primarily affect SMCs by altering the cytoskeleton architecture but it could also lead
to additional effects upon transcription via regulation of FOXC1. In agreement with a
role in SMC biology, FOXC1 and FOXC2 are critical for the early remodeling of blood
vessels (Kume et al., 2001).
In Jangi and Sharp (2014), it was suggested that master regulators could regulate
other splicing factors via AS-NMD. However, instead of regulating splicing events
controlling the abundance of other regulators, RBPMS regulated post-transcription and
transcription factors by production of isoforms with differential activity, similarly to the
dominant negative isoform generated by RBFOX proteins (Damianov and Black, 2010).
Additionally, RBPMS-mediated splicing of Lsm14b outlines another manner by which
RBP functions can be controlled, which is by altering their subcellular localization. A
well characterized example of that is the one represented by the QKI protein isoforms
(Fagg et al., 2017). All of these processes comprise different mechanisms beyond
AS-NMD that assist in the establishment of robust and cell-specific transcriptomes.
Another interesting possibility is that RBPMS might affect other RNA processes
such as miRNA biogenesis. Recent studies have already uncovered the role of a number
of splicing factors in the miRNA processing (Michlewski and Cáceres, 2019). In fact,
RBPMS could potentially regulate the SMC miRNAs, miR143-145 (Boettger et al.,
2009; Cordes et al., 2009), as suggested by the presence of CAC motifs in their precursor
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miRNA. Thus, control of miRNAs could consist of an extra layer of regulation of the
SMC transcriptome and biology by RBPMS.
6.3.2 RBPMS oligomeric state
Band shift assays using recombinant RBPMS-A and B proteins and in vitro transcribed
Myocd RNA substrates with individual CAC clusters mutated (mCAC1 and mCAC2),
in addition to the reduction of binding, also revealed an interesting feature regarding the
size of the complex RNA-RBPMS formed (Figure 6.12). Each cluster contains enough
motifs to accommodate at least one dimer (potential four binding sites). Therefore,
smaller intermediate complexes were expected to be formed upon mutation of each
CAC cluster Myocd. Nevertheless, RBPMS-RNA complexes of the same size of the wt
RNA were observed for both isoforms. Furthermore, previous EMSA assays with Flnb
and Tpm1 also formed large complexes that required optimization of gel conditions
to allow complexes to enter the gel. Thus, it is likely that RBPMS binds to RNA in
higher order assembly, a property that might be common to both isoforms as well as to
repressive and activated RNAs. Consistent with our data, Farazi et al. (2014) reported
a molecular weight higher than a monomer for recombinant RBPMS full-length when
investigating the oligomeric state of RBPMS in the absence of RNA by gel filtration. In
fact, RBPMS oligomeric state could not be resolved due to the fact that the full-length
FLAG-HA-tagged protein elution volume exceeded the resolution limit of the gel-
filtration column (Farazi et al., 2014). However, N-terminal and C-terminal truncated
RBPMS, as well as the combined deletion mutant, resolved to a size corresponding to a
tetramer. Thereby, this assembly of larger assemblies is probably driven by additional
sequences to the RRM domain of RBPMS and may be affected by the different isoforms.
RBPMS structural and functional studies are presented in Chapter 7.
6.3.3 RBPMS and QKI in the establishment of differentiated
and proliferative SMC programs
Cell-specific splicing programs usually result from the combination of multiple regulatory
RBPs. QKI, PTBP1 and SRSF1 are all RBPs identified to promote the proliferative
SMC phenotype (Llorian et al., 2016; van der Veer et al., 2013; Xie et al., 2017).
In here, RBPMS and QKI antagonistically regulated at least two targets (Myocd
and Flnb) (Figure 6.14). Another potential ASE co-regulated by these two RBPs is
the penultimate exon of Smtn, which is repressed by RBPMS but activated by QKI
(Llorian et al., 2016). In agreement with that, QKI motif enrichment analysis pointed
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out significant association of QKI binding sites in RBPMS regulated exons (Figure
6.15). Thus, it is likely that RBPMS and QKI target a common set of ASEs but
act with opposing roles, regulating the differentiated and proliferative SMC splicing
programs. Indeed, the expression of the two RBPs are reciprocally regulated during
SMC dedifferentiation, indicating that the switch-like changes observed in many ASE
could be a consequence of their antagonistic activity.
Therefore, consistent with its designation as a master splicing regulator, RBPMS
regulated other post-transcriptional regulators and directly promoted VSMC-specific
splicing of the transcription factor Myocd by activating exon 2a inclusion, which
differentiates SMC and cardiac isoforms and promotes the contractile VSMC phenotype.
Moreover, identification of QKI co-regulated ASEs provided insights into potential
interplay between the two RBPs in the establishment of contractile or synthetic SMC
splicing programs.
6.4 Final conclusions
In conclusion, this chapter aimed to determine whether among the direct targets
of RBPMS there were events controlling other RBPs leading to secondary splicing
changes as well as other post-transcriptional processes. In addition, splicing regulation
of transcriptional factors was also addressed. Inspection of RBPMS regulated events
led to the identification of Mbnl1 and 2, Lsm14b and Myocd as targets that could
drive to secondary effects in mRNA splicing, stability and gene expression. Therefore,
compatible with its role as a master splicing regulator, RBPMS potentially increases the
robustness of its splicing network in SMC by integrating other RBPs and transcription
factors. Furthermore, QKI was shown to strongly antagonize the splicing of at least
two RBPMS targets, Myocd and Flnb, suggesting an interplay between these two RBPs
in SMC dedifferentiation.
In summary, the main findings of this chapter are:
1. RBPMS regulates splicing of Mbnl1 and 2 generating less active isoforms that
lead to secondary splicing changes.
2. RBPMS affected Lsm14b by repressing its exon 6 which encodes a predicted
NLS.
3. RBPMS directly controlled the critical SMC transcription factor Myocd via
binding to downstream CAC motifs.
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4. Insertion of an RBPMS-defined site rescued inclusion of Myocd exon 2a by
RBPMS-A.
5. RBPMS and QKI proteins antagonistically regulated Myocd exon 2a and Flnb
exon H1.
In addition to that, this chapter also led to other questions listed below:
• Which targets are directly regulated by RBPMS?
• Are there other indirect targets among RBPMS regulated splicing events?
• Does Mbnl isoform switch control other ASEs?
• Does Lsm14b exon 6 affect its subcellular localization? If it does, what is the role of
LSM14B in the nucleus as well as which transcript it targets?
• Does regulation of Myocd exon 2a by RBPMS lead to phenotypic changes in the
SMCs?
• Do further cis-element features determine differential binding by RBPMS isoforms?
• Do RBPMS and QKI form a general antagonistic mechanism for establishment of
switch-like splicing?
• Do other RBPs compete or cooperate in the regulation of RBPMS targets?
These questions are further discussed as potential future studies in the final chapter
of this thesis.
Chapter 7
RBPMS: anatomy of a regulator
7.1 Introduction
7.1.1 RBPMS domains and structure
The RBPMS protein family comprises RBPs that contain a single RRM (Farazi et al.,
2014). Conversely to RBPMS, most other RRM-containing proteins usually show this
motif repeated in tandem or together with other RNA-binding domains (Daubner et al.,
2013; Lunde et al., 2007). Nevertheless, Rbfox proteins (RBFOX1, RBFOX2, RBFOX3)
also contain a single RRM which binds RNA and do not dimerize (Auweter et al., 2006),
yet QKI proteins, also single RNA-binding domain, KH, containing RBPs, are found
forming homodimers (Beuck et al., 2012). In fact, the structure of both human RBPMS
and RBPMS2 RRMs have been solved revealing their RNA binding and dimerization
interface (Sagnol et al., 2016; Teplova et al., 2016). The structures provided insights
into RBPMS recognition of RNA at the molecular level as discussed in Chapter 5
(Sagnol et al., 2016; Teplova et al., 2016). Furthermore, RBPMS RRM has been shown
to drive its symmetrical dimerization in the free state, with CAC motifs specifically
bound by each monomer (Farazi et al., 2014) (Figure 7.1). RBPMS dimeric state is
consistent with its PAR-CLIP identified RNA recognition element comprising tandem
CAC motifs separated by variable spacer length (Farazi et al., 2014). The human
structure-defined RRM of RBPMS spans from residue 20 to 111 corresponding to the
N-terminus of the RBP. In brief, RBPMS homodimerization interface is formed by
electrostatic and hydrophobic interactions, with Asp34, Lys36, Arg38, Glu39 and Asp87
acting as key residues. The RRM residues involved in establishing the intermolecular
interactions are highlighted in Figure 7.1. Apart from the RRM, no further predicted
structured domains are found in the RBPMS sequence. In fact, the C-terminus of
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RBPMS consists of an intrinsically disordered proline rich region that could potentially
lead to further RNA or protein interactions. Moreover, despite its predominant nuclear
localization in PAC1 cells, no evident NLS could be identified in RBPMS sequence.
Lastly, RBPMS is found expressed as two main isoforms, RBPMS-A and RBPMS-B,
as a result of an alternative 3′ end exon. Hence, RBPMS isoforms only differ in their
C-terminal tails, in which RBPMS-A codes for a 20 amino acid sequence whereas
RBPMS-B contains a slightly longer tail formed by 43 residues.
Fig. 7.1 Structure of human RBPMS dimer bound to CAC RNA molecule
Left, crystal structure of the RBPMS homodimer (gray and black) bound to two CAC
RNA molecules (blue and green representing C and A respectively). Right, dimeriza-
tion interface with the residues involved in the dimerization labeled and highlighted
in orange. Images were generated using PyMol (v2.3.0) and the deposited struc-
ture of RBPMS RRM–RNA complex from the Research Collaboratory for Structural
Bioinformatics PDB (accession code 5DET).
Therefore, even though only a single RRM is present in RBPMS, its dimerization
confers a modular arrangement typical of other RBPs (Lunde et al., 2007). Consequently,
RBPMS dimerization promotes cooperative interaction strengthening the protein-RNA
binding affinity as indicated by structural-functional analysis of dimer mutants (Farazi
et al., 2014). Dimerisation is also known to allow RBPs to engage in simultaneous
protein-protein and protein-RNA interactions (Lunde et al., 2007). Consistent with
that, impairment of RBPMS2 dimerization resulted in the loss of the interaction with
EEF2 (Sagnol et al., 2014) and reduction of the ESRP1-RBPMS2 interaction (Sagnol
et al., 2016).
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7.1.2 C terminal disorded domains
Despite the increasing amount of evidence highlighting the importance of RBP’s
disordered regions (Calabretta and Richard, 2015), structural studies regarding these
protein segments are still limited due to the technical challenges imposed by these
regions. Thus, although the structure of RBPMS has been solved, the implications of its
C-terminus in the function and interactions of the protein remains unclear. Nevertheless,
functional studies with C-terminus deleted mutants have revealed its importance to
RBPMS functions. In contrast with the structural work, deletion of RBPMS C-
terminus (100-197) disrupted both RNA binding and dimerization in Xenopus oocytes
as indicated by in vivo poly(A) binding assays and immunoprecipitation (Gerber
et al., 2002). Deletion of the conserved C-terminal domain while maintaining the RRM
domain of RBPMS2 also altered its subcellular localization in zebrafish somatic blastula
cells (Kaufman et al., 2018) and in Xenopus retinal ganglion cells (RGC) (Hörnberg
et al., 2013). Moreover, RBPMS C-terminus was required for full stimulation of TGF-
β/Smad-regulated transcription and sufficient to interact with cFos in HEK293T cells
(Fu et al., 2015; Sun et al., 2006). Therefore, further studies focusing on RBPMS
C-terminus could reveal interesting features of the disordered regions in this RBP, e.g.
short linear motifs involved in protein-protein interactions.
7.1.3 Post-translational modification in RBPs
Protein post-translational modification (PTM) is a process in which different functional
groups are covalently added to the polypeptide sequence, such as phosphate (PO43-),
methyl (CH3), acetyl (C2H3O), ubiquitin (small protein) and glycans (polysaccharides)
(Lovci et al., 2016). The highly dynamic and largely reversible nature of PTMs provides
the cell with a mechanism to finely regulate its protein network (Deribe et al., 2010).
In terms of function, PTMs can affect translocation, secretion, function and elimination
of the modified protein, leading to effects in almost all cellular processes, including
survival, proliferation, differentiation and migration (Deribe et al., 2010; Lovci et al.,
2016). Interestingly, many RBPs could have their RNA-binding activity regulated
by PTMs as indicated by the strong enrichment of modification sites within RBPs
(Castello et al., 2016; Hentze et al., 2018). This could consequently affect the dynamics
of these RBPs.
PTMs are triggered in response to several extra and intracellular signals in a manner
that PTM control of regulatory RBPs allows post-transcriptional processes to respond
to stimuli (Hentze et al., 2018; Lovci et al., 2016). For instance, AS response to distinct
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extracellular signals like EGF (Epidermal growth factor), Wnt, insulin, cytokines and
heat stress act through regulation of splicing factors (Lovci et al., 2016). A splicing
regulator affected by PTM via signaling is HNRNPL (Vu et al., 2013). The PI3K/AKT
pathway leads to phosphorylation of HNRNPL S52 which then increases its splicing
activity by out-competing HNRNPU binding (Vu et al., 2013).
In fact, during VSMC phenotypic switch, cells are exposed to several signal inputs
from adhesion receptors, extracellular matrix and growth factors (Frismantiene et al.,
2018). Thereby, protein PTM assumes a critical role in the downstream signaling
pathway, modulating different targets which include RBPs (Lovci et al., 2016).
Thus, the work described in this chapter aimed at mapping RBPMS regions involved
in its splicing activity using structural-functional analysis. Additionally, motivated
by the importance of PTMs in the regulation of RBPs, we sought to uncover any
potential modulation of RBPMS splicing function via PTMs, such as phosphorylation
and ubiquitination.
7.2 Results
7.2.1 RBPMS dimerization is critical for its splicing regula-
tion
In order to understand the contribution of the dimerization to RBPMS splicing function,
two RBPMS-A dimer mutants were created by mutation of either individual residue R38
or combined with E39 (R38Q and R38E & E39A, dimer mutant 1 and 2 respectively)
(Figure 7.2A). These mutants were previously shown to impair dimerization and
localization to stress granules (Farazi et al., 2014). Transfection of HEK293 cells
with RBPMS wild-type and dimerization mutants was then carried out to assess
any functional consequence to the repression of Tpm1 minigene and ACTN1 and
activation of FLNB and MPRIP splicing (Figure 7.2B-D). All proteins were expressed
to comparable levels as indicated by western blot, allowing comparison of their activities.
Consistent with previous data in this study, RBPMS overexpression in HEK293 cells
promoted the SM splicing pattern with RBPMS isoform B showing less activity
in the repression events, Tpm1 and ACTN1. Conversely, both mutations affecting
dimerization of the most active isoform, RBPMS-A, completely abrogated its splicing
activity, both repression and activation as shown by the inclusion levels similar to
the basal level observed for the controls and by the splicing efficiency (Figure 7.2 B
and D). Splicing efficiency of the mutants was calculated by subtracting the Venus
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inclusion level from the inclusion levels of the different RBPMS constructs, then the
difference was normalized to the most active isoform (RBPMSA). The mean of the PSI
values were used to calculate the splicing efficiency. RBPMS binding mutant (K100E)
was transfected alongside, since mutation of residues involved in dimerization were
reported to decrease RBPMS RNA binding (Teplova et al., 2016). Both RNA binding
and dimer mutants showed similar results. Thus, RBPMS regulation of splicing not
only requires binding to the target RNAs but also relies on its dimerization.
7.2.2 RBPMS C terminus is necessary for its splicing function
In order to map the functional regions of RBPMS, several deletion mutants were
designed to cover both N and C termini (Figure7.3 A). Activity of the mutants in
the regulation of splicing was tested in HEK293 cells. Tpm1 minigene reporter and
endogenous ACTN1 were used as repressed events and Myocd minigene reporter and
endogenous FLNB as activation ASEs. For repression, only RBPMS ∆N mutant
showed activity comparable to wild-type RBPMS-A in both targets, promoting nearly
a complete switch in Tpm1 splicing (Figure7.3 B). Deletion of RBPMS C-terminus,
RBPMS ∆20, leaving all sequences in common to RBPMS-A and B, resulted in partial
activity as indicated by the inclusion levels observed for Tpm1 exon 3 and ACTN1 exon
NM, ∼50% and ∼86% respectively. This mutation is also equivalent to deletion of the
RBPMS-B 43 amino acid tail, and compared to full length RBPMS-B it has increased
activity (79.8% versus 53.2%). This suggests the existence of an inhibitory activity by
the RBPMS-B C-terminal tail. Moreover, deletion of just an additional 15 amino acids
(∆35) was sufficient to drive complete loss of repressor activity (Figure7.3B-C). For
activation, a similar pattern was observed, in which the N-terminus was dispensable
for its activity and the C-terminus critical for RBPMS regulation of Myocd and FLNB
splicing (Figure7.3 B-C). The full C-terminus deletion mutant, RBPMS∆C, showed
severe impairment of its activation (∼7.6% of RBPMS-A activity). However, both
RBPMS∆20 and ∆35 did not impair RBPMS activation to the same extent than
observed for repression. RBPMS∆35 still showed ∼60% and ∼91% activation activity
on FLNB and Myocd splicing respectively, whereas the same mutant displayed less
than ∼15% repressing activity on Tpm1 and ACTN1 splicing compared to RBPMS-A
(Figure7.3 C). Finally, RBPMS RRM itself, which is involved in the RNA binding
and dimerization of RBPMS, was not sufficient to either activate or repress splicing.
Therefore, these data provide insights into the regions that are involved in RBPMS
splicing in addition to the RRM, uncovering the importance of the C-terminal sequence.
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Fig. 7.2 Dimerization is critical for RBPMS-A splicing regulation. A Left,
amino acid sequence of RBPMS RNA Recognition Motif (RRM) with residues involved
in RNA binding and dimerization highlighted in green and yellow. Right, full length
RBPMS schematic with mutated residues indicated. B RT-PCRs to verify the splicing
patterns of rat Tpm1 exon 3 reporter and endogenous ACTN1, FLNB and MPRIP
upon overexpression of rat RBPMS-A and RBPMS-B wild-type and binding and
dimerization RBPMS-A mutants in HEK293 cells. Reporter only and Venus controls
were also included. PCR products are indicated on the left. PSI values shown are
mean ± sd (n= 3). Statistical significance was verified by Student’s t test and is shown
as * p < 0.05, ** p < 0.01 and *** p < 0.001. C Western blots probing for GFP and
GAPDH as a loading control. Protein size markers are shown on the right. D Bar plots
of the splicing efficiency of the different effectors normalized to RBPMS-A isoform
(dark gray). Means of the PSI values were used to calculate the splicing efficiency.
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Fig. 7.3 RBPMS C-terminus is required for splicing regulation. A Schematics
of the different RBPMS mutants tested. B Top, activity of RBPMS mutants upon
Tpm1 and Myocd minigene reporters and endogenous ACTN1 and FLNB in HEK293
cells were assessed by RT-PCR. Reporter only and Venus controls were analyzed in
parallel as well as wild-type RBPMS isoforms. PCR products are indicated on the left.
PSI values are mean ± sd (n= 3). Statistical significance was verified by Student’s t
test and is shown as * p < 0.05, ** p < 0.01 and *** p < 0.001. Bottom, western blots
probing for GFP and TUBULIN as a loading control. Protein size markers are shown
on the right. C Bar plots of the splicing efficiency of the different effectors normalized
to RBPMS-A isoform (dark gray bar). Means of the PSI values were used to calculate
the splicing efficiency.
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In addition to the N and C terminal mutations, Zoe Heckhausen, a summer student
under my day to day supervision in the laboratory, obtained RBPMS-A mutants
containing internal deletions in regions of RBPMS C-terminus (Figure 7.4). Internal
deletion regions were chosen by the level of conservation across different species (Figure
7.4). Residues 126 to 146 were deleted in RBPMS-A ∆1, 148 to 163 from RBPMS-
A ∆2 and a larger deletion, 126 to residue 163, in the case of RBPMS-A ∆1-2.
Regulation of Tpm1 exon 3 splicing by RBPMS-A mutants was verified in HEK293
cells transfections. The wild-type RBPMS showed the usual differential activity and
despite all the deletions, all RBPMS-A mutants showed no difference in their repressive
activity relative to RBPMS-A wt, splicing efficiency of ∼90% (Figure 7.4). Therefore,
RBPMS repressive activity is driven by further sequences embedded in its C-terminus
than the ones deleted in here.
7.2.3 Assessing RBPMS activity by artificial tethering
To further investigate the contribution of the location of the binding sites to the splicing
regulation as well as a starting point for further structure function analysis, artificial
MS2 tethering assays were carried out. This assay consists of recruiting RBPs to RNA
molecules via the interaction between the MS2 bacteriophage coat protein domain and
its specific stem-loop structure motif (Figure 7.5).
Firstly, full length wt RBPMS-A, RBPMS-B and, RBPMS-A binding mutant were
fused to the bacteriophage MS2 protein domain. Additionally, MS2-coat protein hairpin
binding sites were inserted downstream and upstream of the mCAC Myocd and Tpm1
minigene reporters respectively (Figure 7.6). Restoring of the activation of Myocd exon
2a and repression of Tpm1 exon 3 was then assessed by overexpression of MS2-tagged
RBPMS proteins in HEK293 cells (Figure 7.6). RBPMS recruitment to either CAC
locations downstream of Myocd exon 2a was sufficient to restore its inclusion (∼45%)
(Figure 7.6 top panel). Moreover, the RNA binding mutant, K100E, was also able to
activate splicing of exon 2a but to a lesser extent (∼20%) (Figure 7.6 top panel). For
Tpm1, individual hairpins in each cluster upstream of exon 3 resulted in very mild
effects, being the greatest repression achieved with the further CAC location, 25.5%
and 15.6% exclusion of exon 3 for RBPMS-A and RBPMS-B respectively (Figure 7.6
bottom panel). Insertion of the hairpins in both locations of Tpm1 caused a greater
level of skipping, approximately 50% and 40%, but still not as fully responsive as the
wild-type constructs when transfected with RBPMS-A. On the other hand, RBPMS-B
showed higher repressive activity than in the previous transfections. Interestingly,
recruitment of the binding mutant to the location did not affect the inclusion levels of
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Fig. 7.4 Internal deletions of RBPMS C-terminus do not affect its splic-
ing activity. Top RBPMS alignment and conservation across different species and
schematics of RBPMS-A internal deletions. Bottom Activity of RBPMS mutants
upon Tpm1 minigene reporter in HEK293 cells were assessed by RT-PCR. Reporter
only and Venus controls were analyzed in parallel as well as wild-type RBPMS isoforms.
PCR products are indicated on the left. PSI values are mean ± sd (n= 3). Statistical
significance was verified by Student’s t test and is shown as * p < 0.05, ** p < 0.01
and *** p < 0.001. Bottom, western blots probing for GFP and GAPDH as a loading
control. Protein size markers are shown on the right. C Bar plot of the splicing
efficiency of the different effectors normalized to RBPMS-A isoform (dark gray bar).
Means of the PSI values were used to calculate the splicing efficiency.
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Fig. 7.5 MS2 tethering assay. Tethered function technique allows elucidation of
the molecular roles of RBPs by artificial recruitment of these proteins to sites in
RNA molecules via the interaction between the bacteriophage MS2 domain and its
hairpin-binding motif.
exon 3. This suggests that perhaps the RNA binding capacity from RBPMS RRM is
still somehow required for its function, however this was not further investigated herein.
Moreover, another explanation could be that more RBPMS needs to be recruited
to repress splicing. Indeed Tpm1 exhibits several CAC motifs upstream of exon 3
(Figure 3.11) and insertion of further MS2 hairpins might be necessary for RBPMS
maximal repression. In summary, recruitment by artificial tethering recovered RBPMS
activation whereas only partial repression was rescued as indicated by Myocd exon 2a
inclusion and Tpm1 exon 3 skipping respectively.
To get more insights into RBPMS structure functions, Myocd mCAC minigene
reporter containing the MS2 hairpins was then further used to recruit MS2-tagged
RBPMS mutants. RBPMS-A and B with N-terminus and RRM deleted (RBPMS-
A112-197 and RBPMS-B112-220), RBPMS∆C and, RBPMS RRM were tested upon
their regulation of Myocd exon 2a inclusion by artificial recruitment (Figure 7.7).
Interestingly, the RBPMS∆C mutant and the RRM on its own were not sufficient to
promote inclusion of the exon 2a (PSIex2a= 0.0). Nevertheless, both RBPMS-A112-197
and RBPMS-B112-220 mutants retained more splicing activity than the other RBPMS
deletion-mutants (Figure 7.7), despite the lack of the RRM domain and their lower
protein expression levels compared to the other mutants (see western blotting). However,
their activity was still lesser than the wt proteins and RBPMS binding mutant. Thus,
these data further confirmed the requirement of the C-terminal sequences of RBPMS
for its mediated splicing. It will be interesting to assess whether this is a common
feature of RBPMS repression as well.
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Fig. 7.6 Regulation of mutated reporters are rescued by artificial tethering
assays. MS2 hairpins were inserted into the Myocd and Tpm1 minigene reporters as
shown in the schematics, top and bottom respectively. Their activities were then tested
for RBPMS-A and RBPMS-B and binding mutant (K100E) by RT-PCR. Reporter
only and MS2 controls were analyzed in parallel. PCR products are indicated on the
left. PSI values shown are mean ± sd (n= 3). Statistical significance was verified by
Student’s t test and is shown as * p < 0.05, ** p < 0.01 and *** p < 0.001. Western
blots probing for FLAG and GAPDH as a loading control. Protein size markers are
shown on the right.
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RBPMS deletion mutants and wt. B Activity of the mutants were then tested alongside
RBPMS-A and RBPMS-B and RNA-binding mutant (RBPMS-A K100E) by RT-PCR.
Reporter only and MS2 controls were analyzed in parallel. PCR products are indicated
on the left. PSI values shown are mean ± sd (n= 3). Statistical significance was
verified by Student’s t test and is shown as * p < 0.05, ** p < 0.01 and *** p <
0.001. Western blots probing for FLAG and GAPDH as a loading control. Protein size
markers are shown on the right.
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7.2.3.1 Properties of RBPMS isoforms C termini
To explore the importance of the C-terminal tail of each isoform, more mutational
functional studies were carried out focusing on RBPMS-A and RBPMS-B last 20
and 43 amino acids. RBPMS-B C-terminal tail was fused to RBPMS-A, creating
an RBPMS-AB mutant, and vice versa (Figure 7.8A). These constructs were then
co-transfected with Tpm1 minigene reporter and their splicing activity compared to
the wild-type RBPMS isoforms and the C-terminus truncated RBPMS, RBPMS ∆C
(Figure 7.8B-C). Interestingly, fusion of the C-terminal tail from the other isoform
was sufficient to override the original splicing activity. In other words, RBPMS-A
fused with RBPMS-B C-terminus lost its full repression of Tpm1 exon 3 (PSI= 59.9%),
whereas the RBPMS-B containing the RBPMS-A tail was then able to repress splicing
of exon 3 (PSIex3= 12.7%) (Figure 7.8B). Moreover, the C-terminus deletion remained
more active than RBPMS-B or AB indicating an inhibitory function of isoform B tail.
In summary, this showed that the full repressive capacity of RBPMS is determined by
the isoform C-terminal tail; the RBPMS-A tail enhances activity, while the RBPMS-B
tail reduces activity of the remainder of the protein.
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Fig. 7.8 Further C-terminus of RBPMS determines its splicing repression
capability. A Schematics of the RBPMS mutants. B Top, activity of RBPMS
mutants upon rat Tpm1 minigene reporter in HEK293 cells were assessed by RT-PCR.
Reporter only and Venus controls were analyzed in parallel as well as wild-type RBPMS
isoforms. PCR products are indicated on the left. PSI values are mean ± sd (n= 3).
Statistical significance was verified by Student’s t test and is shown as * p < 0.05, **
p < 0.01 and *** p < 0.001. Bottom, western blots probing for GFP and GAPDH
as a loading control. Protein size markers are shown on the right. C Bar plots of the
splicing efficiency of the different effectors normalized to RBPMS-A isoform (dark gray
bar). Means of the PSI values were used to calculate the splicing efficiency.
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7.2.3.2 RBPMS-B and its potential inhibitory role
A possible explanation for the RBPMS-B C-terminus-inhibition of its repressive activity
is that the C-terminal tails have different properties such as aggregation capabilities.
Aggregation of RBPs has been studied in pathologies mainly neurodegenerative diseases
(e.g. FUS and TARDBP in amyotrophic lateral sclerosis - ALS), but more recently it
was also implicated in the regulation of RBP splicing function, for instance RBFOX
self-aggregation through its tyrosine-rich domain (Conlon and Manley, 2017; Ying et al.,
2017). So, using a protein aggregation predictor, AGGRESCAN (Conchillo-Solé et al.,
2007), the differences in the "aggregation" propensity between the two major isoforms of
RBPMS were inspected (Figure 7.9A). Strikingly, RBPMS-B C-terminus, highlighted in
yellow, was predicted to be more prone to formation of aggregate structures as indicated
by the high HSA (hot spot area) value (Figure 7.9A). On the other hand, this feature
was not predicted for RBPMS-A. Thus, to address the importance of the aggregation,
the residues predicted to be involved in this property (LLQQIRFVSGNVFVTYQ)
were deleted from RBPMS-B C-terminus, RBPMS-B HSA. This mutant was then
tested upon regulation of the rat Tpm1 exon 3 minigene reporter. Remarkably, the
mutant RBPMS-B HSA, gained full repressive activity as indicated by the PSI= 34.2%
similar to the RBPMS-A PSI= 36.0% whereas RBPMS-B displayed a PSI= 87.7%
(Figure 7.9B and D). Therefore, these data show that the core region of the RBPMS-B
specific tail antagonizes the intrinsic activity of the protein. Whether this antagonism
is mediated by aggregation remains to be determined.
7.2.4 Post-translational modifications
To address any potential role of post-translation modification (PTM) in the regulation
of RBPMS splicing activity, RBPMS residues reported to be post-translationally
modified were identified using the PhosphoSitePlus database (Table 7.1) (Hornbeck
et al., 2015). The HTP (High Throughput Papers) index was then used to sort the
more meaningful PTMs, leading to the following modifications: ubiquitination of K109
and phosphorylation of residues T113 and T118 (Table 7.1). These modifications
were in residues lying in both RBPMS isoforms, adjacent to the RRM domain, and
therefore could potentially modulate both proteins. Furthermore, only ubiquitination
of K191 and methylation of R198 were specific to RBPMS isoform A and RBPMS-B
respectively (Table 7.1). The role of phosphorylation was first chosen to be further
characterized.
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Fig. 7.9 RBPMS isoform specific C-termini have different aggregation
propensity. A Plots of the aggregation-prone segments in RBPMS-A and RBPMS-
B, top and bottom, respectively. Aggregation prediction is indicated by the "hot
spot" area (HSA). Isoform specific C-terminal sequence is highlighted and residues
deleted from RBPMS-B are in bold font. Prediction was obtained from AGGRESCAN
(http://bioinf.uab.es/aggrescan). B Activity of RBPMS-B aggregation mutant upon
Tpm1 minigene reporter in HEK293 cells was assessed by RT-PCR. Reporter only
and Venus controls were analyzed in parallel as well as wild-type RBPMS isoforms.
PCR products are indicated on the left. PSI values are mean ± sd (n= 3). Statistical
significance was verified by Student’s t test and is shown as * p < 0.05, ** p < 0.01 and
*** p < 0.001. C Western blots probing for GFP and GAPDH as a loading control.
Protein size markers are shown on the right. D Bar plots of the splicing efficiency of
the different effectors normalized to RBPMS-A isoform (dark gray bar). Means of the
PSI values were used to calculate the splicing efficiency.
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Table 7.1 List of human RBPMS PTM from the PhosphoSitePlus database
Residue Sequence RBPMS HTP
RBPMS-A RBPMS-B
K6 MNNGGKAEkENtP ✓ ✓ 1
K9-ub NNGGKAEkENtPsEA ✓ ✓ 2
T12-p GKAEkENtPsEANLQ ✓ ✓ 2
S14-p AEkENtPsEANLQEE ✓ ✓ 5
T25-p LQEEEVRtLFVsGLP ✓ ✓ 1
S29-p EVRtLFVsGLPLDIK ✓ ✓ 1
K36 sGLPLDIKPRELYLL ✓ ✓ 2
K48 YLLFRPFKGYEGSLI ✓ ✓ 1
K60-ub SLIKLTSkQPVGFVS ✓ ✓ 6
K109-ub NTKMAKNkLVGtPNP ✓ ✓ 9
T113-p AKNkLVGtPNPstPL ✓ ✓ 8
S117-p LVGtPNPstPLPNTV ✓ ✓ 4
T118-p VGtPNPstPLPNTVP ✓ ✓ 9
S144-p VPALYPSsPEVWAPY ✓ ✓ 1
R198 CPLLQQIRFVSGNVF gap ✓ 5
K191 EATSQGWKSRQFC ✓ gap 1
7.2.4.1 RBPMS phosphorylation
Phosphorylation mutant versions of the most active RBPMS isoform, RBPMS-A,
were generated by mutating both threonine residues at positions 113 and 118 (Figure
7.10A). Threonine substitutions to alanine, RBPMS T/A, and glutamic acid, RBPMS
T/E, were used to mimic unphosphorylated and phosphorylated RBPMS respectively.
Mutants were tested upon transient transfection of HEK293 cells and splicing activity
verified for Tpm1 and Myocd minigenes as well as endogenous ACTN1 and FLNB,
covering repressed and activated targets (Figure 7.10 B-D). Strikingly, the T/E mutation
of RBPMS-A severely impaired its repressor activity as indicated by the significant
changes in the Tpm1 and ACTN1 splicing (Figure 7.10B). RBPMS T/E promoted less
repression of the NM exons in Tpm1 and ACTN1 (PSIex3=64.8% and PSINM= 55.4%).
On the other hand, alanine substitutions were associated with an opposite effect, by
slightly but significantly enhancing the repression of the same exons (PSIex3=7.8%
and PSINM= 33.1%). Furthermore, both mutants were expressed at protein levels
similar to the wt proteins, allowing attribution of the differential activity solely to the
Thr mutations (Figure 7.10 C). Conversely, the same mutations did not impair the
activation of FLNB exon H1 and caused minor effects to Myocd exon 2a (Figure 7.10 B).
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Additionally, RBPMS-A phospho-mutants still retained more activity than RBPMS-B
as shown by the parallel transfection of HEK293 cells with this isoform, even though
RBPMS-B was more expressed than the other proteins (Figure 7.10 C). These data
suggested that phosphorylation at these sites could be critical PTMs, mainly inhibiting
the repressive function of RBPMS-A as summarized in the efficiency plots (Figure 7.10
D).
Due to the fact that RBPMS-A phospho-mutations mainly impaired its repressive
function, minor or no effects were speculated for RBPMS-B, which shows only full
splicing activation. Surprisingly, RBPMS-B phosphomimetic was no longer able to
activate splicing of FLNB exon H1 (Figure 7.11 A). RBPMS-B T/E showed basal
levels of exon H1 inclusion, ∼8%, whereas the T/A mutant kept an activation level
similar to the wild-type (48.8%). Consistent with previous data, RBPMS-B had less
repressor activity upon Tpm1 and ACTN1 splicing and that was further reduced with
the substitution of the threonine residue to glutamate in the case of Tpm1 exon 3
(Figure 7.11 A). Thus, RBPMS isoforms show different effects upon phosphorylation
as indicated by these experiments using RBPMS-B phospho-mutants.
To understand the contribution of each of the threonine residues, individual mutants
were created: RBPMS-A T113E and T118E (Figure 7.10A). Mutation was also carried
out for S117, adjacent to the phosphorylated T118. Splicing of Tpm1 exon 3 minigene
reporter was assessed in HEK293 upon overexpression of the different mutants (Figure
7.12). Mutation of only one of the threonine residues uncovered T113 as the individual
site at which phosphomimetic mutation had the greatest effect, by reducing RBPMS-A
activity by ∼50% (Figure 7.12B). However, the phosphomimetic mutation at T118 did
not affect skipping of exon 3 by RBPMS as shown by the inclusion level similar to the
wild-type RBPMS-A (∼23%) (Figure 7.12A). Moreover, none of the single mutations
at the threonine sites were able to recapitulate the same loss of activity observed for
the double mutant, suggesting that phosphorylation at both residues is required for full
inhibition (Figure 7.12 B). Additional mutation at the S117 to either gluatamic acid or
aspartate further inhibited the skipping of exon 3, ∼5% compared to RBPMS-A T/E,
the difference being only significant for the TST/D mutant (Figure 7.12 A). Thus, the
phosphorylation motif in RBPMS involves both threonines at positions 113 and 118
and potentially the serine at position 117 (TxxxST). The sole contribution of serine
117 as well as the effects to RBPMS-B activation are yet to be investigated.
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Fig. 7.10 Phosphorylation affects RBPMS splicing activity. A Schematics of
RBPMS isoforms A and RBPMS-B with phosphorylated motifs highlighted. Mutants
are listed under it. B Activities of the mutants upon Tpm1 and Myocd minigene
reporter and endogenous ACTN1 and FLNB in HEK293 were assessed by RT-PCR.
Reporter only and Venus controls were analyzed in parallel as well as wild-type RBPMS-
A and RBPMS-B. PCR products are indicated on the left. PSI values shown are mean
± sd (n= 3). Statistical significance was verified by Student’s t test and is shown as
* p < 0.05, ** p < 0.01 and *** p < 0.001. C Western blots probing for GFP and
GAPDH as a loading control. Protein size markers are shown on the right. Lower band
in the GFP western blot is a by-product of the Myocd minigene reporter. D Bar plots
of the splicing efficiency of the different effectors normalized to RBPMS-A isoform
(dark gray bar). Means of the PSI values were used to calculate the splicing efficiency.
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Fig. 7.11 Phosphorylation differentially affects RBPMS isoforms. A Top,
activity of RBPMS-B phosphomimetics upon Tpm1 minigene reporter and endogenous
ACTN1 and FLNB in HEK293 were assessed by RT-PCR. Reporter only and Venus
controls were analyzed in parallel as well as wild-type RBPMS isoforms. RBPMS-A
mutants were also tested alongside. PCR products are indicated on the left. PSI values
are mean ± sd (n= 3). Statistical significance was verified by Student’s t test and is
shown as * p < 0.05, ** p < 0.01 and *** p < 0.001. Bottom, western blots probing
for GFP and GAPDH as a loading control. Protein size markers are shown on the
right. B Bar plots of the splicing efficiency of the different effectors normalized to
RBPMS-A isoform (dark gray bar). Means of the PSI values were used to calculate
the splicing efficiency.
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Fig. 7.12 Phosphorylation of both threonines, T113 and T118, is required
for maximum inhibition A Top, activity of RBPMS-A single mutants and serine
phosphomimetics upon Tpm1 minigene reporter in HEK293 cells were assessed by RT-
PCR. Reporter only and Venus controls were analyzed in parallel as well as wild-type
RBPMS-A. RBPMS-A T113E & T118E was also tested alongside. PCR products are
indicated on the left. PSI values are mean ± sd (n= 3). Statistical significance was
verified by Student’s t test and is shown as * p < 0.05, ** p < 0.01 and *** p < 0.001.
Bottom, western blots probing for GFP and GAPDH as a loading control. Protein size
markers are shown on the right. B Bar plots of the splicing efficiency of the different
effectors normalized to RBPMS-A isoform (dark gray bar). Means of the PSI values
were used to calculate the splicing efficiency.
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7.2.4.2 RBPMS ubiquitination
Another PTM strongly supported by experimental evidence was the ubiquitination of
the lysine 109, just upstream of the phosphorylated residues (Table 7.1). This residue
lies within the RRM domain and is involved in contacting RNA (Figure 7.2) (Farazi
et al., 2014). The proximity to the phosphorylation sites led to the hypothesis that
perhaps its ubiquitination is linked to the initial phosphorylation of these residues in
a similar manner to reported for IkappaB (DiDonato et al., 1996). Phosphorylation
of IkappaB at two serine residues triggers ubquitination of adjacent lysines that then
target it for proteasome degradation (DiDonato et al., 1996). To investigate a similar
regulation of RBPMS, lysine 109 to arginine amino acid substitution was carried out
in both RBPMS isoforms, wild-types and phosphomimetics (Figure 7.13A). From
all the RBPMS ubiquitination mutants, only the RBPMS-A K109R mutant showed
significant change in the inclusion level of exon 3 compared to wild-type, being exon
3 more skipped (88.3% exclusion) (Figure 7.13B-C). In addition to that, no increase
in the protein expression levels was observed for the ubiquitination mutants (Figure
7.13B, bottom). Actually, if there is any apparent change in expression, it is towards
a decrease upon phosphorylation and blockage of ubiquitination as indicated by the
levels of RBPMS KT mutants in the western blot (Figure 7.13B, bottom). Therefore
this experiment did not provide any evidence supporting a linkage between RBPMS
ubiquitination and its protein turnover. Furthermore, the K109R mutation did not
block the effect of the T/E mutations.
7.3 Discussion
7.3.1 RBPMS dimerization and its splicing activity
Consistent with studies associating RBPMS dimerization to its functions, disruption
of RBPMS dimerization strongly affected its splicing function (Figure 7.6). The same
mutant tested in this study was no longer able to localize to stress granules upon
oxidative stress (Farazi et al., 2014). Moreover, impairing RBPMS2 dimerization also
had deleterious effects to SMC dedifferentiation and interaction with ESRP2 (Sagnol
et al., 2016, 2014). Thus, dimerization might be involved in RBPMS functions by
also determining protein-protein interactions. Nevertheless, the primary cause of the
reported effects is most likely to be the reduction of RNA binding. Dimerization allows
effective cooperative binding to dual CACs, but the impairment of the dimer interface
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Fig. 7.13 RBPMS phosphorylation is not linked to ubiquitination. A
Schematics of RBPMS isoforms and location of lysine residues shown to be ubiq-
uitinated (pink). Mutants are listed below schematics. B Top, activity of RBPMS
ubiquitination resistant mutants upon Tpm1 minigene reporter in HEK293 cells were
assessed by RT-PCR. Reporter only and Venus controls were analyzed in parallel as
well as wild-type RBPMS isoforms. RBPMS-A and RBPMS-B T113E & T118E were
also tested alongside. PCR products are indicated on the left. PSI values are mean
± sd (n= 3). Statistical significance was verified by Student’s t test and is shown as
* p < 0.05, ** p < 0.01 and *** p < 0.001. Bottom, western blots probing for GFP
and GAPDH as a loading control. Protein size markers are shown on the right. C
Bar plots of the splicing efficiency of the different effectors normalized to RBPMS-A
isoform (dark gray bar). Means of the PSI values were used to calculate the splicing
efficiency.
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leads to significant decrease in RNA binding affinity. Indeed, Teplova et al. (2016)
showed a 4-fold drop in the affinity of dimer mutants.
7.3.2 RBPMS activation and repression mechanisms
Artificial tethering assays of RBPMS using MS2 coat protein further confirmed RBPMS
positional-dependent splicing activity and also suggested RBPMS-mediated repression
of Tpm1 exon 3 to be mechanistically distinct fromMyocd exon 2a activation. Upstream
binding of RBPMS was only able to repress splicing in the presence of a functional wt
RRM domain (Figure 7.10). At first sight this appear to be a surprising result, since
the basis of the MS2 approach is that you can replace the normal mode of RNA binding
by an artificial RNA-RBP interaction. Nonetheless, such difference between splicing
activation and repression upon tethering RBPs to downstream and upstream sites has
also been reported for RBFOX1 proteins (Sun et al., 2012; Ying et al., 2017). Despite
that, the exact mechanism for requirement of RNA binding for repression by this RBP
still has to be elucidated. It is possible that RBPMS needs to interact with other RNA
sequences in addition to the MS2 hairpin inserted in the minigene, in order to establish
repressive activity. A possible scenario is the requirement of further binding of RBPMS
on the pre-mRNA itself to loop out the exon to be excluded. An even more interesting
scenario would be one where RBPMS interacts with snRNAs in the spliceosome. Indeed,
RBPMS and U1A proteins share similarities in their intermolecular recognition of CAC
element in RNAs (Teplova et al., 2016). U1A is a component of the U1 snRNP, which
is involved in pre-mRNA splicing, and interacts with the stem-loop II of U1 snRNA
(Howe et al., 1994; Oubridge et al., 1994). U1 snRNA is critical in the recognition of
the 5′ splice site during early steps of the spliceosome assembly (Plaschka et al., 2019).
In fact, accessory RBPs have been reported to facilitate U1 snRNP recognition of the 5′
splice site promoting exon inclusion (Roca et al., 2013). Additionally, PTBP1 binding
to the CU-rich elements flanking the c-src N1 exon allows interaction with U1 snRNA,
more specifically with stem-loop IV, and this results in exon repression (Sharma et al.,
2011). Inhibition of splicing by PTBP1 was then shown to result from formation of
a repressed complex that cannot progress to an exon definition complex (Wongpalee
et al., 2016). Therefore, RBPMS could exhibit a similar mechanism of repression
by competing with U1A and disrupting interactions in the U1 snRNP bound at the
regulated 5′ splice site preventing formation of functional spliceosome. Consistent with
PTBP1 binding to elements flanking repressed exon, a few conserved CAC motifs are
also found downstream of Tpm1 exon 3 (Figure 3.11), whose importance to RBPMS
splicing is yet to be determined.
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7.3.3 RBPMS splicing activity beyond its RRM domain
Further structural-functional analysis disclosed RBPMS C-terminus as essential for its
splicing activity and MS2 tethering assays hinted that the C-terminus is potentially
sufficient to drive its splicing activation. However, stronger conclusion could not be
drawn as a result of problems with protein expression of the deletion mutants. In
addition to that, despite being sufficient for RNA binding and dimerization in vitro
(Sagnol et al., 2014; Teplova et al., 2016), the RRM domain alone could not mediate AS
changes. Nevertheless, previous studies have shown that the oligomeric state of RBPMS-
A and RNA binding affinity are also dependent on its C-terminal region (Farazi et al.,
2014). In agreement with its critical role in splicing, the C-terminal region downstream
of the RRM has been implicated in several functions of RBPMS/RBPMS2. Granular
localization in retinal ganglion cells (Hörnberg et al., 2013) and cFos interaction in
HEK293 cells (Fu et al., 2015). Interestingly, Xenopus RBPMS2 C-terminus, last 34
amino acids, was required for binding to Nanos1 RNA in vivo. Therefore future work
will address whether loss of splicing by C-terminus truncated RBPMS is due to a
decrease in RNA binding, dimerization and/or to intrinsic functions of this region.
Like other splicing regulators that display isoform differential activity (Partridge and
Carter, 2017; Tabaglio et al., 2018; Wollerton et al., 2001), RBPMS-A strongly activated
and repressed AS whereas RBPMS-B acted mainly as an activator. Surprisingly, both
isoforms were able to bind to activated and repressed RNAs with similar affinities
(Figure 5.11 and 5.12). Therefore, considering the fact that RBPMS isoforms differ
only in their C-terminal sequence, a potential explanation for RBPMS-A repressive
role is interactions mediated by the isoform specific region. However, RBPMS ∆20
was still able to cause repression (∼40%) suggesting that it is actually RBPMS-B
C-terminus that inhibits its splicing repressor role. Consistent with it, fusion of RBPMS
isoforms with each others C-terminal regions reproduced the repressive splicing effects
of the fused isoform C-terminus. This indicates that the further C-terminal regions
can potentially modulate RBPMS activity by enhancing or diminishing its repression.
Function conferred by disordered regions of an RBP is not an exclusive feature of
RBPMS and it has been described for several other splicing regulators (Calabretta
and Richard, 2015). For instance, RBFOX2 C-terminal domain was shown to recruit
LASR (Large Assembly of Splicing Regulators) and to be required for splicing (Ying
et al., 2017). This RBFOX2 study also revealed another property of this protein which
is the formation of higher order assemblies via its tyrosine-rich C-terminal domain
(CTD) (Ying et al., 2017). Actually, AS within regions encoding intrinsically disordered
segments of splicing regulatory proteins alters their own splicing regulatory activity
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and seems to be a recurring mechanism determining splicing regulation (Gueroussov
et al., 2017). Indeed, RBPMS isoforms showed distinct aggregation-prone peptides
as predicted by AGGRESCAN (Figure 7.9). Deletion of the peptides predicted as
potential hot-spots of amyloidal aggregation from RBPMS-B CTD conferred repressive
effects not observed with the wild-type RBPMS-B. Thereby, AS control of RBPMS
CTD could affect its splicing regulation through formation of multivalent assemblies.
The implication of these residues in RBPMS-B differential localization and formation
of intracellular inclusions in vivo remain to be addressed. Nevertheless, in preliminary
biophysical studies using recombinant protein, RBPMS was found to produce large
complexes (data not shown). Further work aiming to address the role of aggregation
in vivo and in vitro in RBPMS splicing will shed some light on its mechanism.
7.3.4 Regulation of RBPMS activity by phosphorylation
Master splicing regulators are likely to be tightly regulated by transcriptional, transla-
tional and post-translational signals in order to ensure splicing network only in response
to the right environmental cues (Jangi and Sharp, 2014). Considering the importance
of PTM to modulation of splicing networks by RBPs (Hentze et al., 2018; Jangi and
Sharp, 2014), potential PTM of RBPMS was also examined. Using RBPMS with
mutantions in Threonine 113 and 118, a role of phosphorylation in the regulation of
RBPMS splicing activity was disclosed in addition to its transcriptional control. PTMs
are known to modulate RBPs activity by altering their ability to bind target RNAs or
proteins as well as their subcellular localization (Naro and Sette, 2013). Actually, the
threonine residues found to be phosphorylated are located adjacent to RBPMS RRM
and can possibly affect RNA binding or dimerization. However, splicing activation
by RBPMS-A was not affected in the phosphomimetic mutant indicating that RNA
binding, dimerization and localization are unlikely to be impaired by phosphorylation.
Furthermore, PTMs have been pointed out as one of the factors in the control of the
phase separation and aggregation behavior of RBPs (Hofweber and Dormann, 2018).
Thereby, an intriguing connection between phosphorylation and aggregation is likely
to exist and can perhaps explain the differential splicing effects observed with the
phosphomimetic substitutions in RBPMS-A and RBPMS-B.
The kinase involved in RBPMS phosphorylation and the signal that triggers it
remain to be identified. Although kinase predictors suggested CDK4 as a potential
kinase in the phosphorylation of RBPMS, preliminary data using inhibitors did not
affect RBPMS-mediated AS (data not shown). Other possible kinases include ERK
and p38, members of the conserved signaling pathways that activate the mitogen-
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activated protein kinases (MAPKs) (Roux and Blenis, 2004; Venigalla and Turner, 2012).
Interestingly, RBPs have been suggested as a point of convergence of MAPK pathways
(Venigalla and Turner, 2012). Lastly, the glycogen synthase kinase-3, GSK3, has recently
been shown to phosphorylate multiple splicing factors, leading to indirect changes in AS
(Shinde et al., 2017). In fact, the GSK3 consensus motif, (pS/pT)XXX(S/T), resembles
RBPMS phosphorylation site (TPNPST). Thus it could potentially be the kinase
modulating RBPMS activity via its phosphorylation (Shinde et al., 2017). Therefore,
further studies are required to address the pathways driving RBPMS phosphorylation
in SMC and other cell types.
Finally, similar phosphorylation taking place in RBPMS2 has not yet been re-
ported (Hornbeck et al., 2015). In the paralog, despite the conservation of all the
residues, the Thr118 and Ser117 are inverted and the proline adjacent to the site
is missing (TPNPTSV). Moreover, in human RBPMS2 the second threonine is not
conserved. Thus, RBPMS phosphorylation could correspond to a specific mechanism
of its regulation that is not shared between paralogs.
Taken together, the data in this chapter uncovered several features of RBPMS
regulation of splicing. However, further studies focusing on RBPMS C-terminal tails
are required to better understand the isoform-specific differential activity and the
importance of each isoform to the cell biology. Additionally, investigations of the
mechanism behind RBPMS phosphorylation will be crucial for comprehending how
RBPMS is regulated in response to external signals and its following disruptions to
RBPMS splicing network.
7.4 Final conclusions
In summary, this chapter addressed some of the mechanisms underlying RBPMS
regulation of splicing. It provided insights into the importance of RBPMS dimerization
and its C-terminal region. Modulation of RBPMS by post-translational modifications
was also investigated, indicating a role for RBPMS phosphorylation. Lastly, RBPMS-
B CTD inhibition of its splicing repression could be associated with its potential
aggregation capacity. Therefore, these data pave the way for a better understanding
of how this SMC master regulator controls splicing and could potentially respond to
different cues from the environment.
In conclusion, the main findings of this chapter are:
1. RBPMS dimerization is required for its splicing activity.
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2. RBPMS C-terminus is essential for its activity, with RBPMS-A specific C-
terminus being necessary for maximal repression, whereas the RBPMS-B C-
terminus antagonizes the repressor activity.
3. Artificial recruitment of RBPMS to downstream and upstream sites of CAC
mutated Myocd and Tpm1 recovered splicing activation and repression.
4. MS2 tethered RBPMS RNA binding mutant could activate Myocd exon 2a but
not repress splicing of Tpm1 exon 3, suggesting that RNA binding is required for
repression.
5. MS2 tethered RBPMS-A and RBPMS-B C-termini hinted a potential splicing
function by these sequences.
6. RBPMS-B specific aggregation features might explain its reduced splicing repres-
sor activity.
7. Two Thr residues of RBPMS adjacent to its RRM domain can be phosphoryated.
8. T113 and T118 residues phosphomimetic mutants differentially modulate RBPMS
activity, inhibiting RBPMS-A splicing repression and RBPMS-B splicing activa-
tion.
9. Phosphorylation of both Thr residues is required for maximum inhibition of
RBPMS repression.
10. Effects of T113/118 phosphorylation are unlikely to involve subsequent ubiquiti-
nation of K109.
In addition to that, this chapter also led to other questions listed below:
• Why is RBPMS binding mutant tethered to MS2 protein not sufficient for splicing
repression?
• What is the kinase responsible for RBPMS phosphorylation?
• What is the signaling pathway that triggers RBPMS phosphorylation?
• How does phosphorylation inhibit RBPMS splicing activity?
• What is the mechanism behind RBPMS regulation of splicing?
• How does RBPMS-B C-terminus inhibit its repressive role?
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• Do RBPMS proteins form high molecular weight complexes?
• Do RBPMS isoforms display differential aggregation capacities?
• Can RBPMS C-terminus propensity to aggregate explain its lower splicing activity?
The next chapter explore some of these questions as potential future studies of
RBPMS.
Chapter 8
RBPMS: a master splicing
regulator of VSMC
8.1 General Discussion
8.1.1 Do super-enhancers point the way to tissue-specific reg-
ulators?
By using the approach suggested by Jangi and Sharp (2014), we focused on RBPs
whose expression is driven by super-enhancers in smooth-muscle tissues. In this
manner, RBPMS was identified as a critical splicing regulator of the VSMC AS
program. Therefore, this work vindicates Jangi and Sharp’s approach for identification
of tissue-specific splicing master regulators paving the way for the identification of
further regulators in other tissues. The usefulness of the super-enhancer approach is
highlighted by the mRNA-Seq data of rat aorta tissue and PAC1 dedifferentiation.
Using mRNA-Seq data only, 29 RBPs are found regulated during the phenotypic switch
in PAC1 cells (Figure 8.1) and an even larger number in aorta tissue 49 RBPs (Figure
8.2). On the other hand, by focusing on super-enhancers associated RBPs, only nine
candidates were suggested as potential regulators of the SMC program (Chapter 3).
Additionally, with RBPMS being among so many other regulated RBPs, perhaps it
would not have been chosen as the first candidate to be characterized if the super-
enhancer approach had not been used. Even though RBPMS could have been identified
by mRNA-Seq data, the method applied in this study then allowed investigating a
smaller subset of RBPs, facilitating the identification of RBPMS. Additionally, when
we started this study, we did not have mRNA-Seq data for rat aorta and/or PAC1
dedifferentiation. In that way this approach may help in situations in which mRNA-
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Seq data is not available for the system of interest. Nevertheless, with the recent
growing availability of mRNA-Seq data for a range of tissues, a more global and
systematic bioinformatic approach could perhaps be used to identify other possible
tissue AS master regulators. For instance, using super-enhancer database (Hnisz
et al., 2013; Khan and Zhang, 2016) coupled with GTEX RNA-Seq data (Lonsdale
et al., 2013), and an RNA-binding protein database (Ray et al., 2009), it may be
possible to find whether motifs enriched around different tissue-specific regulated exon
correspond to binding motifs of RBPs associated with super-enhancers in the same
tissue. Thus, integrating those datasets via computational analysis may provide a more
comprehensive understanding of the specific post-transcriptional regulatory components
in distinct physiological contexts.
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Fig. 8.1 RBPs upregulated in rat differentiated PAC1 cells. RBPs upregulated
in rat differentiated PAC1 cells (Dif) compared to the proliferative PAC1 cells (Pro).
RBPs showing fold change > 1.5, TPM > 10 and padj < 0.05 are indicated with green
labels.
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8.1.2 How much of a master regulator is RBPMS?
RBPMS met many, but not all of the criteria of a master regulator suggested by Jangi
and Sharp (2014):
1. it has a wide dynamic range of expression between tissues and differentiation
states of SMCs (Chapter 3).
2. changes in RBPMS activity appear to be solely responsible for 20% of the AS
changes between differentiated and proliferative PAC1 cells (Chapter 4);
3. RBPMS target splicing events that are enriched in functionally coherent groups
of genes affecting cell-substrate adhesion and the actin cytoskeleton, which are
important for SMC cell phenotype-specific function (Chapter 3-4);
4. it regulates splicing and activity of other post-transcriptional regulators in SMCs
(Chapter 6), and
5. it regulates splicing and activity of the key SMC transcription factor MYOCD
(Chapter 6).
One of the first criteria suggested by Jangi and Sharp (2014) is that master
regulators play a role in establishing and maintaining cell identity. However, the
biological function of the RBPMS-regulated splicing network to the phenotype of SMCs
remains to be addressed. As a splicing regulator, RBPMS is only able to regulate
transcripts actively transcribed, and so it is unlikely to be sufficient to establish a
differentiated SMC phenotype. Nevertheless, consistent with a role of RBPMS in
maintaining a mature SMC differentiated state, RBPMS promoted tissue-like AS
patterns, for example in Cald, Fermt2 and Tns1 (Chapter 4). In fact, the CALD1
isoform produced by RBPMS is a well known marker of SMCs. Thus, even though
RBPMS was not enough to upregulate the total transcript levels of SMC markers,
it was able to increase SMC-specific isoforms detected at protein levels (Chapter 4).
Moreover, RBPMS was responsible for the regulation of a quarter of the AS changes
taking place during PAC1 cell dedifferentiation. This is a very impressive number of
ASEs solely dependent on RBPMS expression, yet the minimum fraction of splicing
events that has to be regulated in a particular condition to qualify the RBP as a master
regulator is disputable (Jangi and Sharp, 2014). This quantitative feature could be
highlighted in the future by such bioinformatic studies suggested above.
Another feature that RBPMS failed to meet was the lack of AS-NMD events
(Chapter 3). In fact, AS regulation of RBPMS can result in non-productive isoforms
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that then control its expression levels. Possibly, the presence of regulatory exons
is critical in terminally differentiated cells but not in cell-types that retain pheno-
typic plasticity such as SMCs. The ability of these cells to interconvert between a
contractile-differentiated state and a proliferative-dedifferentiated state is required for
their physiological functions (Frismantiene et al., 2018). Therefore, perhaps in SMCs
these AS-NMD events may consist of the motifs of a bistable double-negative regulation
in order to allow master regulators of different phenotypes. Interestingly, QKI which is
a regulator of the proliferative phenotype of SMCs might be able to regulate RBPMS
expression by affecting production of non-functional and/or NMD targeted transcripts
as indicated by the presence of QKI motifs around RBPMS critical exons.
Thus, even though RBPMS did not completely fulfill the criteria of a master
regulator as determined by Jangi and Sharp (2014), the features identified in this work
provide enough evidence for a role of RBPMS as a major splicing regulator of VSMCs.
Future studies will aim to address the remaining characteristics of a master regulator
not yet uncovered for RBPMS in this work.
8.1.3 Are changes promoted by RBPMS-A overexpression
artefactual?
Insights about RBPMS regulation of SMC splicing were gained by the RBPMS-A
overexpression dataset (Chapter 4), but a lot of the overexpression targets are likely to
be artefactual. RBPMS-A overexpression led to a strong 70-fold increase in transcript
levels and RBPMS-A absolute levels were also incompatible with physiological levels
observed in aorta tissue (Chapter 4). Thus, despite being very informative, conclusions
drawn from the overexpression dataset require caution. For instance, a lot of genes
regulated at the mRNA abundance or the skewed number of ASEs towards less inclusion
by RBPMS overexpression were not observed upon RBPMS knockdown. Therefore,
due to the fact that the knockdown approach consists of a more physiological approach,
it nicely complements the overexpression experiment and reinforces the real effects of
manipulation of RBPMS levels.
8.1.4 Does RBPMS phosphorylation take place in vivo?
Phosphorylation of two threonine residues of RBPMS regulated its splicing activity as
indicated by mutations that mimicked phosphorylation (Chapter 7). However, a major
remaining question is whether these post-translation modifications indeed happen in
the cell. These modifications were reported by proteomic studies (Hornbeck et al., 2015)
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but were not validated in this study. Nevertheless, treatment of protein lysates from
PAC1 cells with phosphatases caused a protein size shift in RBPMS when visualized
in a polyacrylamide gel, indicating that RBPMS is potentially phosphorylated in
these cells (experiment carried out by C. Gooding in the laboratory). Yet this does
not provide direct evidence for the specific modification of the Thr 113 and/or 118.
Moreover, the molecular mechanism behind inhibition of RBPMS splicing by these
modifications is not clear. Due to the proximity of these residues to the RRM, it
is likely that they disrupt RNA-binding, but that should affect both repression and
activation, and not either one. Altered localization or dimerization also cannot explain
inhibition of a specific activity while maintaining the other. Future approaches to be
applied to better understand the role of phosphorylation in the regulation of RBPMS
as well as the conditions in which it occurs are discussed below.
8.1.5 Does RBPMS liquid phase separate?
In view of the fact that the recombinant RBPMS seems to assemble into something
much larger than just a dimer (Chapter 5-6), one could wonder if this relates to its
activity in the cell. Indeed, RBFOX proteins have been shown to assemble into large
complexes (Damianov et al., 2016; Ying et al., 2017) and the potential similarities with
RBPMS were raised in Chapter 7 (see Discussion section). Despite RBP aggregation
being associated with pathological conditions in the past, a very topical subject in
the field of RBPs is the physiological roles of these "aggregates" (Polymenidou, 2018).
In fact, actual aggregates are insoluble aberrant assemblies and more fibrous-like
structures whereas these recently characterized "aggregates" consist of dynamic and
reversible assemblies. Therefore these physiological "aggregates" have been more
correctly termed as higher-order assemblies (Polymenidou, 2018). The dynamic nature
of these assemblies allows them to exhibit a phase transition behavior (Polymenidou,
2018). This liquid-liquid phase separation promotes compartmentalization of functions
in membrane-less organelles-like structures (RNP granules) (Lin et al., 2015). In the
cytoplasm, self-assembly is involved in the formation of cytoplasmic stress granules
and transport granules whereas in the nucleus it is believed that the self-assembly
concentrates factors in the nucleolus and the Cajal body (Lin et al., 2015; Polymenidou,
2018). The self-assembly property can be conferred by intrinsically disordered regions
of RBPs and recently shown to regulate splicing by RBFOX (Ying et al., 2017).
The splicing capability of the tyrosine repetitive sequence in the disordered region of
RBFOX was associated with its ability to self-assemble and localize within the nucleus.
Thus, the intriguing formation of large complexes by RBPMS recombinant protein
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and the presence of aggregation features in its C-terminal disordered domain hint that
higher-order assemblies might be a feature of RBPMS splicing regulation. Indeed,
self-assembly could be relevant to the observation that RBPMS is associated with
stress granules in the cytoplasm (Farazi et al., 2014).
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8.2 Conclusion
This study provided clear evidence that RBPMS acts as a master splicing regulator of
VSMCs. It also vindicated Jangi and Sharp’s suggested approach for the identification
of tissue-specific master splicing regulators. By focusing on RBP genes associated with
SM super-enhancers, RBPMS was identified as a key regulator of the differentiated
SMC AS program. RBPMS was predominantly nuclear and found expressed in the rat
pulmonary artery PAC1 cells in two major isoforms: RBPMS-A and RBPMS-B, which
vary in their extreme C-termini. Initial experiments with SMC minigene reporters
(Tpm1 and Actn1 ) supported the role of RBPMS in AS of differentiated PAC1 cells.
Based on these results, mRNA-Seq was carried out for RBPMS knockdown and
RBPMS-A overexpression in differentiated and dedifferentiated PAC1 cells respectively.
RBPMS promoted numerous differentiated splicing patterns, solely regulating 20%
of the AS changes during PAC1 phenotypic switching. Additionally, RBPMS-A
overexpression was sufficient to promote fully differentiated SMC tissue-like AS patterns,
as exemplified by Fermt2, Cald1 and Tsc2. RBPMS targeted a network of proteins
involved in the actin cytoskeleton, focal adhesions and the secretory pathway: all
critical machineries in the interconversion between the contractile differentiated and the
motile-synthetically active dedifferentiated SMC states. Super-enhancer association of
RBPMS targets further reinforced the importance of these genes to the SMC biology.
Bioinformatic tools and biochemical assays confirmed RBPMS direct regulation
of splicing. Similarly to other AS regulators, RBPMS splicing activity was position-
dependent; sites upstream and within exon associated with repressed exons whereas
downstream sites with activated exons as indicated by RBPMS splicing maps. Moreover,
in vivo transfections with wild-type and CAC mutant minigene reporters as well as
RBPMS RNA-binding mutant and lastly in vitro binding assays (EMSA and UV-
crosslinking) consistently supported RBPMS direct regulation of SMC splicing via
CAC motifs. Nevertheless, RBPMS could also lead to secondary effects on splicing
and transcription by controlling splicing and activity of other regulators of AS (Mbnl1,
Mbnl2 ), mRNA stability (Lsm14b) as well as a key SMC transcription factor (Myocd).
Notably, RBPMS promoted production of a MYOCD isoform that more potently
activates the contractile phenotype, acting antagonistically with QKI which is more
highly expressed in proliferative cells.
In addition to that, a few features underlining RBPMS splicing activity were
provided in this work by applying structure-function studies. RBPMS dimerization was
essential for its activity, although RBPMS RRM was not sufficient to promote splicing
changes. Moreover, RBPMS N-terminus was dispensable for its activity whereas the
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C-terminus was required for its function. Surprisingly, a core section of the RBPMS-B
C-terminus antagonized the repressor activity, potentially explaining the lower activity
of RBPMS-B compared to RBPMS-A, particularly for splicing repression. Moreover,
two Thr residues (position 113 and 118) of RBPMS adjacent to its RRM domain could
be phosphorylated. Phosphomimetic mutants differentially modulated RBPMS activity,
inhibiting splicing repression by RBPMS-A and splicing activation by RBPMS-B.
In summary, this study provides the strongest evidence to date for a molecular
function of RBPMS as a splicing regulator, matching many of the expected criteria of
a master regulator of AS in differentiated VSMCs: a high dynamic range of expression
during SMC dedifferentiation; regulation of a coherent set of targets important for SMC
function; and regulation of other post-transcriptional and transcriptional regulators.
Finally, RBPMS splicing activity was further characterized in this study uncovering
some specific mechanisms of its AS regulation and differential activity of RBPMS
isoforms. The main findings of this work are listed and summarized in the following
model (Figure 8.3).
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Fig. 8.3 Summary of the main findings of this study that corroborate RBPMS as a
smooth muscle master splicing regulator.
Highlights
• Super-enhancer association to identify master splicing regulators
• RBPMS is an alternative splicing regulator
• Differential activity of RBPMS isoforms
• RBPMS targets mRNAs important for SMC function (Figure 8.4)
• RBPMS splicing activity requires additional sequences to its RRM
• RBPMS splicing cascade involves other regulators (MBNL and MYOCD)
• RBPMS phosphorylation modulates its splicing activity
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8.3 Future directions
Identification of RBPMS as a splicing regulator of VSMCs led to further questions
reported throughout this work. Although some of these have been addressed in here,
some questions remain to be answered in future studies (Figure 8.5).
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Fig. 8.5 Schematic of the future directions for better understanding of RBPMS.
RBPMS regulated splicing in controlling SMC phenotype
Despite the regulation of hundreds of ASEs, of which some have well-characterized
functions, manipulation of RBPMS levels, either by depletion or overexpression, did not
lead to any apparent phenotype in the PAC1 cells. Due to the involvement of the genes
regulated by RBPMS in cytoskeleton and focal adhesion functions, a few phenotypic
screenings focusing on those functions were carried out but no striking alterations in
the arrangement of actin fibers or size of the focal adhesion were observed. Moreover,
migratory capacities were not altered upon RBPMS knockdown or overexpression.
Nonetheless, these experiments need to be repeated and further analyzed into more
details to unravel any phenotype. Additionally, the cultured PAC1 system might not
consist of the most appropriate model and despite the fact that PAC1 cells retain
some of the differentiation features of SMC, other models representative of the more
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differentiated state could be explored such as primary cells or even generation of a
transgenic animal model to get insights into function of RBPMS in VSMCs.
SMCs also show a great deal of diversity (Fisher, 2010), even within single blood
vessels (Cheung et al., 2012). Therefore, an interesting scenario could arise from the
association of RBPMS with more differentiated cells, a feature already highlighted in a
single cell RNA-Seq in which Rbpms was identified as part of a transcriptome signature
of contractile mouse aorta SMCs cells (Dobnikar et al., 2018). Moreover, diversity is
also found in the splicing of tonic and phasic SMCs (Shukla and Fisher, 2008). Thus,
even though RBPMS was identified regulating the VSMC splicing program, other
RBPs might act as master regulators of some of these specialized SMC types.
Finally, the role RBPMS in SMC phenotypic switching could also be investigated in
disease conditions, when the SMC interconversion is dysregulated (Bennett et al., 2016;
Frismantiene et al., 2018). Indeed, RBPMS levels have been shown to decrease in the
carotid ligated mouse vessels (unpublished data from Dr. Aishwarya Jacob), indicating
a potential role of RBPMS in the maintenance of healthy vascular tissues. Additionally,
the carotid injury model could be used in the future to look at AS changes during
phenotypic modulation in vivo. Another interesting possibility that could associate
RBPMS with cardiovascular diseases is that disease associated SNPs could create or
remove CAC motifs that then dysregulate RBPMS-regulated ASEs.
RBPMS isoform differential activity
Experiments carried out in here revealed that RBPMS activity was regulated via
generation of different isoforms via AS of its own transcript. However, mRNAseq was
only carried out for PAC1 cells overexpressing RBPMS-A. Taken the differential splicing
activity of RBPMS isoforms, it would be interesting to also investigate the global
targets of RBPMS-B. This would provide a better dataset of common and distinct
events regulated by RBPMS isoforms. Moreover, it could reveal further biological
implications of different levels of expression of the isoforms in SMCs. In that way,
approaches for manipulation of individual isoforms by either CRISPR-Cas9 or ASO
could be carried out in SMCs.
In fact, regulation of the alternative 3′ end exon which determines the two major
RBPMS isoforms should also be investigated. Inclusion of RBPMS exon 7 as opposed
to exon 8 leads to expression of RBPMS-B, which is the least active isoform. Thus,
insights could be gained by the study of the aspects of these exons affecting this critical
splicing decision in RBPMS. In addition to that, RBPMS exon 6 skipping produced
several non-functional isoforms which could consist of a negative feedback loop in
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the regulation of RBPMS levels. Interestingly, clusters of RBPMS optimal binding
sites (CAC motifs) could be identified downstream of exon 6, indicating a potential
auto-regulatory mechanism.
Mechanism of splicing regulation by RBPMS
In order to address the different properties of RBPMS-A and RBPMS-B determining
their repressive activity, additional biophysical studies have been carried out in the
laboratory, especially focusing on their capability to form large assemblies (data not
shown). Proteomic studies by co-immunoprecipitations and mass spectrometry should
be aimed to uncover any potential protein-protein interaction with co-regulatory
proteins and/or target core splicing factors that could explain RBPMS splicing function
and differential activity. Interestingly, STRING generated RBPMS interactome shows
interactions with other RBPs involved in mRNA splicing, e.g. RBFOX2, QKI and
ESRP1 (Figure 8.6). Epithelial Splicing Regulatory Protein 1 (ESRP1) was identified
to interact with RBPMS2 via immunoprecipitation in chicken DF1 fibroblast cell line
(Sagnol et al., 2016). While interactions with other RBPs were identified in large scale
studies and have not been analyzed in detail.
Fig. 8.6 Human RBPMS interactome RBPMS protein partners interactome in
humans generated using STRING (v 11.0) and using experiments as the only source of
interactions. Network edges mean confidence where line thickness indicate strength of
data support
Another methodology to be applied in the characterization of RBPMS splicing
activity is MS2 artificial tethering. In this study (Chapter 7), initial experiments were
8.3 Future directions 211
carried out establishing MS2 assays in repressed and activated exons (Tpm1 exon 3
and Myocd exon 2a). Even though only RBPMS full length and RBPMS-A binding
mutant were tested in the assays shown here, a library of several RBPMS truncated
mutants fused to an MS2 domain has been generated to be used in the identification of
RBPMS “effector” regions. These mutants could unravel regions required for RBPMS
splicing in addition to RNA-binding and dimerization conferred by the RRM. Thus,
MS2-tethering will test whether recruited effector domains are sufficient to mediate
regulation. Lastly, MS2-tethering studies will be applied to investigate the role of the
isoform specific CTDs.
Interestingly, nuclear extracts from HEK293 overexpressing RBPMS-A were suffi-
cient to repress Tpm1 exon 3 in an in vitro splicing assay (Appendix - Figure A.7 and
A.8, data from Fredderick Richards, Part III student). Therefore, by further applying
this method, more information about RBPMS splicing mechanism could be gained
in the future. Additionally, taken that both isoforms, A and B, were able to bind to
Tpm1 RNA, in vitro splicing assays could also highlight the different steps of splicing in
which RBPMS-B fails to promote Tpm1 repression. Eventually, regulatory complexes
could be assembled on Tpm1 transcripts with exon 3 and flanking regulatory elements
in nuclear extracts with and without RBPMS. The high resolution structure of these
macromolecular complexes could then be assessed by CryoEM to provide rich insights
into RBPMS mechanism of action.
RBPMS splicing cascade: indirect targets
RBPMS regulated other post-transcriptional factors involved in mRNA splicing,
like Mbnl1 and Mbnl2, and in other processes such as mRNA stability by regulation
of Lsm14b. Consequently, RBPMS was associated with indirect splicing changes by
the switch of MBNL isoforms, e.g. Ncor2 A5SS. Therefore, in order to distinguish
direct and secondary targets of RBPMS in a more high-throughput manner, iCLIP
experiments could be preformed in the SMCs. RBPMS iCLIP experiments would allow
elucidation of the RNA-RBPMS interactions taking place in these cells and could also
be used to address if there is any difference in the global binding between RBPMS
isoforms. These datasets could further vindicate RBPMS regulation of splicing by
direct binding to pre-mRNAs in vivo and shed light onto indirect splicing events.
RBPMS also controlled splicing of a SM transcription factor, Myocd. Although no
changes in SMC markers were observed upon manipulation of RBPMS levels, regulation
of such a transcription-factor is expected to modulate expression of differentiation
markers, leading to greater contractility. The lack of MYOCD activation of SMC genes
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could be explained by the limitations imposed by the transient nature of RBPMS
knockdown and overexpression in PAC1 cells. So in the future, RBPMS knockout
by CRISPR-Cas9 and sustained RBPMS overexpression could provide better insights
into the regulation of the differentiation state upon RBPMS splicing control of Myocd
transcripts among other targets.
Modulation of RBPMS activity by post-translational modification
Investigation of the regulation of RBPMS by PTMs revealed phosphorylation
as a major regulator of its activity. However, neither the signaling pathway nor
the kinase/phosphatase involved in RBPMS phosphorylation were found out in this
study. Thereby they will be the aim of future experiments. These studies could
uncover potential environmental cues that are involved in the activation or inhibition of
RBPMS-mediated splicing. Moreover, the full understanding of the interplay between
the kinase, RBPMS and its RNA targets may provide novel insights into the dynamic
reshaping of SMC transcriptome by RBPMS.
To understand how phosphorylation regulates RBPMS activity, proteomic studies
could also include T113/118 phospho-site mutants. Protein interactions disrupted
or acquired by these phosphorylated residues could potentially be identified. Finally,
phosphorylation could allosterically control RBPMS activity due to the proximity of
the Thr to RBPMS RRM domain. Thereby, structural studies could also be explored
to resolve the mechanism behind RBPMS phosphorylation.
Cytoplasmic roles of RBPMS
In this work, the focus was given to the nuclear role of RBPMS in post-transcriptional
processes, specifically in alternative splicing. However, most attention has been paid
to RBPMS cytoplasmic roles in the studies investigating RBPMS. In fact RBPMS has
been implicated in several other mRNA processes by these studies (Farazi et al., 2014;
Furukawa et al., 2015; Hörnberg et al., 2013; Rambout et al., 2016; Sagnol et al., 2016).
Therefore, there is a lot of scope for RBPMS functions in mRNA stability, localization
and translation, whose importance in SMCs is yet to be determined.
Transcriptional control of RBPMS
In this study, RBPMS was found acting as a master regulator of VSMCs, reshaping
the transcriptome of these cells. Yet Rbpms is still under transcriptional control.
In addition to Rbpms association with SMC super-enhancers, only one single study
attempted addressing RBPMS transcriptional control (Ye et al., 2018). The knowledge
8.3 Future directions 213
of the transcription factors driving Rbpms expression could contribute to the better
understanding of the strong downregulation of Rbpms levels during SMC dedifferentia-
tion. RBPMS levels could also be titrated in some conditions by non-coding RNAs
(ncRNAs). For instance, lncRNAs (long noncoding RNAs) containing repetitive CAC
sequences could sequester RBPMS and control its splicing activity, in a similar way to
PTBP1 and the lncRNA PNCTR (Yap et al., 2018). Thus, investigation of RBPMS
expression control and titration by ncRNAs would provide insights into its distinct
expression pattern and activity in different tissues and also elucidate its downregulation
in some disorders involving SMC phenotypic plasticity, like cardiovascular diseases.
SMC splicing code
Tissue-specific AS programs are likely to arise from the combinatorial effects of the
different trans-factors. In this study, we addressed the interplay between RBPMS and
QKI, a known regulator of the proliferative state, in the regulation of some common
AS targets (Myocd and Flnb). These factors were as expected antagonistic, but QKI
seemed to be the dominant regulator. Additionally, PTBP1 and MBNL are also known
to regulate Tpm1 and initial experiments by Fredderick Richards have also revealed
that these factors are necessary for full repression of Tpm1 exon 3 by RBPMS (data
not shown). Therefore, future studies will also aim to characterize the different input
signals from cooperative and antagonistic interactions between RBPMS, a master
regulator of the differentiated VSMCs, and regulators of the proliferative state, e.g.
QKI and PTBP1, in RBPMS splicing decisions.
In conclusion, future studies will aim to understand the mechanism of splicing
regulation by RBPMS, the role of the RBPMS regulated splicing program in controlling
different aspects of SMC phenotype and finally, the potential role of subversion of this
program in cardiovascular diseases.
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Fig. A.1 Doxycycline treatment of lentiviral control cell lines does not affect
AS. Validation of RBPMS regulated ASE in lentiviral control populations (P LV) upon
doxycycline treatment. A differentiated and proliferative cassette exon, Ptprf and
Piezo1 respectively, and a mutually exclusive exon Actn1 are shown. Values shown
are the mean ± sd of PSI (n = 3) of percentage of exon inclusion (PSI). Statistical
significance was calculated using Student’s t-test (* p < 0.05, ** p < 0.01 and *** p <
0.001). Experiment was carried out by Clare Gooding.
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Fig. A.2 RBPMS overexpression promotes smooth muscle CALD1 isoform
switch. Left, RT-PCR validation of Cald1 ASE (A5SS and SE) in the RBPMS
overexpression in proliferative PAC1 cells. Schematic of the Cald1 ASE and Cald1
isoforms amplified in the PCR are shown on the top and left, respectively. Right, the
switch in Cald1 isoform was shown at the protein level by western blot probing for
CALD1. The specificity of the isoform switch was also confirmed in Mus musculus
differentiated (D0) and proliferative (D7) SMC samples from aorta tissue. The larger
smooth muscle specific isoform of CALD1 is indicated by h-CALD1. Values shown
are mean ± sd (n = 3) of percentage of exon inclusion. Statistical significance was
calculated using Student’s t-test and is shown as * p < 0.05, ** p < 0.01 and *** p <
0.001. Experiment was carried out by Clare Gooding.
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Fig. A.3 Mapping RBPMS cis elements in the Tpm1 exon 3 splicing re-
porter. Top, potential RBPMS CAC motifs upstream of exon 3 are highlighted in the
schematic. Middle, combinations of different CAC mutations were tested for RBPMS
A overexpression in HEK293 cells. Schematics of the splicing isoforms identify the
PCR products and values shown are mean ± sd (n = 3) of PSI. In case of MXE the
Sm exon inclusion is shown. Statistical significance was calculated using Student’s
t-test (* p < 0.05, ** p < 0.01 and *** p < 0.001). Bottom, overexpression was
assessed by western blot probing for GFP and GAPDH as a loading control. * No
overexpression was detected in this lane although the PSI differs from the reporter
only PSI. Experiment was carried out by Fredderick Richards.
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Fig. A.4 RBPMS overexpression switches MBNL1 and 2 splicing isoforms.
Left, RT-PCR validation of Mbnl1 exons 7 and 8 and Mbnl2. Values shown are the
mean of the PSI ± sd (n = 3). PSI values are shown for each Mbnl1 exon (exon
7 – 36 bp and exon 8 – 95 bp) as PSIex7 and PSIex8. For Mbnl2, exon 7 isoforms
were not detected in the RT-PCRs. Schematics of the splicing isoforms identify the
PCR products. Right, western blots probing for MBNL1 and 2 with splicing isoforms
indicated on the right. TUBULIN was used as a loading control for the western blots.
Statistical significance was calculated using Student’s t-test (* p < 0.05, ** p < 0.01,
*** p < 0.001). Experiment was carried out by Clare Gooding.
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Fig. A.5 Ncor2 is a RBPMS indirect splicing target regulated via MBNL
isoform switch. Top, MBNL1 and 2 knockdown in inducible RBPMS A (P OE)
or in lentiviral control (P LV) PAC1 cells to assess the dependence of the MBNL1
isoform switch in the regulation of Ncor2 A5SS by RBPMS. Ncor2 A5SS splicing was
verified by RT-PCRs and the mean of the PSI ± sd (n = 3) are shown. PCR products
are indicated by the splicing schematics on the side. Bottom, western blots for
MBNL1 and 2 and FLAG to confirm MBNL knockdown and RBPMS A overexpression.
TUBULIN was used as a loading control for the western blots. Statistical significance
from Student’s t-test is shown as * p < 0.05, ** p < 0.01, *** p < 0.001. Experiment
was carried out by Clare Gooding.
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Fig. A.6 RT-PCR validation of Lsm14b in the RBPMS-A overexpression in proliferative
PAC1 cells. Left, schematic of the Lsm14b event at the top and schematic of its isoforms
at the left. Right, western blots probing for LSM14B with splicing isoforms indicated
on the right. GAPDH was used as a loading control. Statistical significance was
calculated using Student’s t-test (* p < 0.05, ** p < 0.01, *** p < 0.001). Experiment
was conducted by Clare Gooding.
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Fig. A.7 RBPMS represses the splicing of Tpm1 exon 3 in vitro. Left,
schematic representation of transcript TM234. Diagonal lines indicate alternative 2-4
or 3-4 splice pathways- expected intermediates and products of these pathways are
shown below. Right, denaturing gel resolving radiolabelled products following in vitro
splicing of TM234. Each reaction took place in a total volume of 10 µL. Nuclear
extract (NE) made up 60% of the total reactions. Lanes 3- 7 contain 20% HeLa NE
(final concentration 1.25 mg/mL) and a 40% cross-titration of NE from HEK293 cells
overexpressing GFP against those overexpressing RBPMS-GFP (final concentration 0.
45 mg/mL). The HeLa only reaction (lane 2) is made up with Buffer E. Lanes 8 and 9
contains 40% NE as indicated plus 20% buffer E. The identities of various products
are shown schematically to the right of the gel. Lariat products resolving above the
pre-mRNA cannot be distinguished without debranching and subsequent analysis of
their molecular weights. Experiment was conducted by Fredderick Richards and the
figure and respective legend is from his dissertation.
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Fig. A.8 RBPMS represses the splicing of Tpm1 exon 3 in vitro. Left,
schematic representation of transcript TM134∆122L. Diagonal lines indicate alternative
1-3-4 or 1-4 splice pathways- expected intermediates and products of these pathways
are shown below. The precise- 1-3-4 splicing pathway depends on whether the upstream
intron (1-3) or downstream intron (3-4) is removed first. Right In vitro splicing of
TM134∆122L Each reaction took place in a total volume of 10 µl. Nuclear extract
(NE) made up 60% of the total reaction. Lanes 3- 8 contain 20% HeLa NE (final
concentration 1.25 mg/ml) with titration of RBPMS-GFP NE titration from 15% to
0% as shown above each lane. This was titrated against GFP NE to a total volume
of 40% to retain an overall protein content equal to the TM234 splicing reactions (i.e.
0.45 mg/mL final). The HeLa only reaction (lane 2) was made up with buffer E. Lanes
9 and 10 contain 40% NE as indicated plus 20% Buffer E. The identities of various
products are shown schematically to the right of the gel. Lariat products resolving
above the pre-mRNA cannot be distinguished without debranching and subsequent
analysis of their molecular weights. Experiment was conducted by Fredderick Richards
and the figure and respective legend is from his dissertation.
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Table A1 Gene list of GO terms enriched in genes differentially spliced by RBPMS
knockdown
GO Term Description Genes
Cell Component
GO:0005856 Cytoskeleton SPATA7, LDB3, MYO9B , PDLIM5, ABI1, LRRFIP1,
MPRIP, PDLIM7, OSBPL10, MAST2, FUZ, PARD3,
PACSIN3, SYNE2, SGCA, FLNA, FLNB, ITGB1BP1,
NF2, SVIL, NSMF, MACF1, RAI14, SMTN
GO:0042995 Cell projection PKD1, PDLIM5, ACTN1, ABI1, SLC9A1, DAAM1,
LRRC16, CAMK2G, FUZ, ARHGEF6, MARK3, FLNA,
ITGB1BP1, SEMA6A, NF2, SVIL, NSMF, LDB3,
CAD, CDC42BP, DNM2, PDLIM7, PIAS3, PAFAH1B1,
DNM1, APP, SLC4A7, EIF5A, BBS2, FAT1,
PTPRF
GO:0030054 Cell junction CD99, PDLIM5, ACTN1, ABI, MPRIP, SLC9A1,
FLNA, FLNB, PPFIA1, CLSTN1, NF2, SVIL,
PPFIBP1, NSMF, MAP4K4, ARHGAP17, CDC42BPA,
DNM2, PDLIM7, SORBS1, PARD3, SGCA, SYNE2,
APP, ECT2, GJC1, FAT1, RAI1
GO:0120025 Plasma membrane bounded PKD1, PDLIM5, ACTN1, ABI1, SLC9A1, DAAM1,
cell projection LRRC16A, CAMK2G, ARHGEF6, MARK3, FLNA, ITGB1BP1,
SEMA6A, NF2, SVIL, NSMF, LDB3, CDC42BPA,
DNM2, PDLIM7, PIAS3, PAFAH1B1, DNM1, APP,
SLC4A7, EIF5A, BBS2, FAT1, PTPRF
GO:0005911 Cell-cell junction ACTN1, PDLIM5, ARHGAP17, CDC42BPA, PDLIM7, SLC9A1,
SORBS1, PARD3, SGCA, FLNA, ECT2, GJC1, FAT1
Molecular Function
GO:0008092 Cytoskeletal protein binding ACTN1, PDLIM5, ABI1, MPRIP, DAAM1, FLNA,
FLNB, CLSTN1, INF2, NF2, SVIL, MACF1,
MAP4K4, LDB3, MYO9B, DNM2, MAST2, SORBS1,
PACSIN3, FMNL3, PAFAH1B1, KLC1, STIM1, SYNE2,
DNM1, RAB11FIP5, SMTN
GO:0003779 Actin binding MYO9B, ACTN1, PDLIM5, MPRIP, DAAM1, SORBS1,
FMNL3, SYNE2, FLNA, FLNB, INF2, NF2,
SVIL, MACF1, SMTN
GO:0030695 GTPase regulator activity ARHGEF6, MYO9B, ARHGAP23, GAPVD1, ARHGAP17,
TBC1D1, ITGB1BP1, ARHGEF10L, AGFG2, EVI5L,
SLIT2, ECT2
GO:0017016 Ras GTPase binding MYO9B, GAPVD1, ARHGAP17, ARHGEF10L, DAAM1, EVI5L,
CAMK2Ga, ARHGEF6, FMNL3, TBC1D1, FLNA, SBF1,
RAB11FIP5, INF2, ECT2, ERBB2
GO:0060589 Nucleoside-triphosphatase MYO9B, GAPVD1, ARHGAP17, ARHGEF10L, EVI5L, SLIT2,
regulator activity ARHGEF6, ARHGAP23, FNIP2, TBC1D1, ITGB1BP1,
AGFG2, ECT2
Biological Process
GO:0030029 Actin filament-based process LDB3, MYO9B, CDC42BPA, ARHGEF10L, SLC9A1, PDLIM7,
DAAM1, SORBS1, FMNL3, PAFAH1B1, SYNE2, FLNA,
MYL6, FLNB, INF2, NF2, SMTN
GO:0044087 Regulation of cellular component PDLIM5, ARHGEF10L, SLC9A1, SLIT2, LRRC16A, FUZ,
biogenesis PHLDB1, MTMR3, FLNA, ITGB1BP1, PPFIA1, CLSTN1,
NF2, MACF1, CEP120, PIEZO1, MAP4K4, DNM2,
STAG2, EVI5L, SDCCAG3, FNIP2, SYNE2, APP,
PLD1, ECT2, MED25
GO:0051128 Regulation of cellular component PKD1, CBFA2T2, ITGA7, PDLIM5, FN1, ARHGEF10L,
organization SLC9A1, SLIT2, LRRC16A, FUZ, PHLDB1, MTMR3,
FLNA, ITGB1BP1, PPFIA1, CLSTN1, SEMA6A, LGALS1,
INF2, NF2, MAP2K7, NSMF, PIEZO1, CEP120, MACF1,
MAP4K4, WDR70, ARHGAP17, DNM2, STAG2, EVI5L,
PACSIN3, FMNL3, SDCCAG3, RHOT1, PAFAH1B1, SYNE2,
FNIP2, DNM1, APP, EIF5A, PLD1, ECT2, MED25,
ERBB2, PTPRF, CISH
GO:0010810 Regulation of cell-substrate adhesion FLNA, ITGB1BP1, FN1, DNM2, ABI3BP, NF2,
SLC9A1, LRRC16A, MACF1, MAP4K4
GO:0007010 Cytoskeleton organization LDB3, CDC42BPA, ARHGEF10L, PDLIM7, DAAM1, MAST2,
SORBS1, PARD3, PACSIN3, FMNL3, MARK3, PAFAH1B1,
SYNE2, FLNA, FLNB, SEMA6A, INF2, NF2,
SVIL, MACF1, CEP120, SMTN

